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Chapter 1 1
Chapter 1
General introduction
1.1 Aim and scope of the thesis
Thanks to the continuous progress made in recent years, medical imaging has become an
important tool in the diagnosis of various pathologies. In particular, magnetic resonance
imaging (MRI) permits to obtain images with a remarkably high resolution without the use of
ionizing radiation and is consequently widely applied for a broad range of conditions in all
parts of the body.
Contrast agents are used in MRI to improve tissue discrimination. Different categories of
contrast agents are clinically available, the most widely used being gadolinium chelates. One
can distinguish between extracellular gadolinium chelates such as Gd-DTPA, and
hepatobiliary gadolinium chelates such as Gd-BOPTA. The latter are able to enter
hepatocytes from where they are partially excreted into the bile to an extent dependent on the
contrast agent and animal species. Due to this property, hepatobiliary contrast agents are
particularly interesting for the MRI of the liver. Actually, a change in signal intensity can
result from a change in transport functions signaling the presence of impaired hepatocytes,
e.g. in the case of focal (like cancer) or diffuse (like cirrhosis) liver diseases. Although the
excretion mechanism into the bile is well known, the uptake mechanisms of hepatobiliary
contrast agents into hepatocytes are still not completely understood and several hypotheses
have been proposed. As a good knowledge of these transport mechanisms is required to allow
an efficient diagnosis by MRI of the functional state of the liver, more fundamental research
is needed and an efficient MRI compatible in vitro model would be an asset. 
So far, most data concerning these transport mechanisms have been obtained by MRI with
in vivo models or by a method of detection other than MRI with cellular or sub-cellular
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models. Actually, no in vitro model is currently available for the study and quantification of
contrast agents by MRI notably because high cellular densities are needed to allow detection,
and no metallic devices can be used inside the magnet room, which is incompatible with most
tissue or cell cultures that require controlled temperature and oxygenation. 
The aim of this thesis is thus to develop an MRI compatible in vitro cellular model to study
the transport of hepatobiliary contrast agents, in particular Gd-BOPTA, into hepatocytes
directly by MRI. A better understanding of this transport and especially of its modification in
case of hepatic disorder could permit in a second step to extrapolate this knowledge to
humans and to use the kinetics of hepatobiliary contrast agents as a tool for the diagnosis of
hepatic diseases. 
1.2 Outline
This general introduction is followed by two theoretical chapters (chapters 2 and 3). The
experimental work of this thesis is described in chapters 4 to 7 and finally, general
conclusions are drawn and perspectives for future work are presented in chapter 8. Chapters 2,
5 and 7 are intended for publications. 
Chapter 2 reviews the design, setup, validation and applications of the hepatocyte hollow
fiber bioreactor (HFB). Special attention is paid on the culture conditions necessary to ensure
a good cellular viability and functionality. This review also exposes the different tests that can
be performed to control these parameters. Finally, the different uses of hepatocyte HFB are
discussed, notably their use as a tool for the study of drug metabolism and transport. 
Chapter 3 gives an overview of medical imaging, explains the principles of MRI and
introduces the MRI contrast agents currently used, in particular for liver imaging. It intends to
give the basic theory necessary for a good comprehension of the work described in this thesis.
This chapter also reviews the present knowledge about the transporters known or suspected to
play a role in the transport of MRI contrast agents in hepatocytes.
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The isolation and preservation processes of rat hepatocytes are evaluated in chapter 4. A
method to keep hepatocytes viable and functional for several hours is needed, as the MRI
experiments cannot be performed immediately after hepatocyte isolation. The assessment of
cryopreservation and cold preservation in the University of Wisconsin solution is described.
Chapter 5 is concerned with the development and validation of the MRI compatible
hepatocyte HFB. A conventional HFB system, as described in chapter 2, is modified in order
to be compatible with the magnetic field. This newly developed hepatocyte HFB is validated
with an extracellular contrast agent, Gd-DTPA, and a hepatobiliary contrast agent,
Gd-BOPTA, to check whether this cellular model can reveal a reproducible difference
between the two types of contrast agents.
Three complementary studies performed to a) investigate the effect of contrast agent
concentration on the MR signal, b) study a possible improvement of the MR signal analysis
by the use of regions of interest or masks of the hollow fibers, and c) set up an additional in-
line test for the evaluation of the viability of hepatocytes in the HFB, are reported in
chapter 6.
Chapter 7 presents first the study of the expression of the receptors known or suspected to
play a role in the transport of Gd-BOPTA in hepatocytes by Western blotting. The
functionality of the transport mechanism assessed with an uptake study of Gd-BOPTA in
freshly isolated rat hepatocytes in suspension is then described. Finally, the use of the MRI
compatible hepatocyte HFB is extended to the study of the effect of Gd-BOPTA
concentration on its uptake. A compartmental pharmacokinetic model is developed to
describe the MRI data.
General conclusions on the work performed during this thesis are drawn and an outlook on
further research is given in chapter 8. There follows a summary in English and French, a
summary for the general public, and a list of the abbreviations currently used throughout this
document.
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Chapter 2
Hepatocyte hollow fiber bioreactors:
design, setup, validation, and applications
2.1 Introduction 
With its numerous different functions, the liver is one of the most important organs of the
body. First, it plays a role in glucide metabolism, converting galactose and fructose to glucose
which is particularly important for maintaining glycemia. Second, the liver is the main organ
for lipid metabolism, being the major site of -oxidation. It is also active in the metabolism of
proteins, including urea formation to eliminate ammonia which is toxic for the central nervous
system. Moreover, it has a secretory function, synthesizing bile acids for fat digestion and
most of the plasma proteins like clotting factors and albumin. Finally, the liver plays also a
key role in the metabolism of endogenous and exogenous substances in order to facilitate their
excretion. These functions are carried out by the hepatocytes, epithelial cells that represent
80% of the liver volume. The remainder is constituted of at least four other types of cells,
including endothelial cells, Kupffer cells, fat-storing cells and pit cells [1]. Methods routinely
used to cultivate isolated hepatocytes include suspensions, adhesion on plates and more
recently hollow fiber bioreactors (HFB).
HFB allow a dynamic three-dimensional mode of cell culture, which permits to restore a
tissue-like cell density and interactions between cells, simulating physiological conditions.
HFB have been used with different cell types to generate cell products like antibodies or
hormones [2] and as artificial organs like bioartificial livers (BAL), pancreas, kidneys, and
parathyroid glands [3]. In recent years, scientists have become increasingly interested in using
hepatocyte HFB as a BAL to detoxify the blood of patients with acute liver failure (ALF).
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The present chapter focuses on HFB as a liver model, i.e. containing primary hepatocytes
or hepatocyte derived cell lines. It gives an overview of the different steps taking place in the
setup of hepatocyte HFB and reviews notably drug metabolism studies performed with HFB.
The aim is to provide the basic knowledge necessary to develop a hepatocyte HFB and to
check its performance. First, generalities on HFB are exposed, including principles, transport
phenomena, designs and cell culture conditions. Then, the tests which can be performed to
assess the performance of the HFB, i.e. the viability and functionality of its cells, are
discussed. Finally, possible uses of hepatocyte HFB are described. When reviewing the drug
metabolism studies made with hepatocyte HFB, we have distinguished between metabolic
studies performed to check hepatocyte viability and functionality in the HFB, and the studies
pertaining to drug metabolism in the strict sense.
2.2 Principles and design of hepatocyte hollow fiber bioreactors 
2.2.1 Principles
A HFB consists of a network of hollow fibers (HF) bundled together within a transparent
plastic shell which defines two compartments, the extracapillary space (ECS) between the
fibers and the plastic shell, and the intracapillary space (ICS) inside the fibers (figure 2.1).
Although different kinds of HFB configurations exist, the principle of the perfusion system is
similar for all of them. The basic system first described by Knazec et al. [4] comprises a
culture medium reservoir, a pump, an oxygenation system and a HFB. It is a dynamic system
where culture medium is continually pumped from a reservoir, charged with oxygen and
carbon dioxide through silicone tubing, flows within the HF, diffuses radially through the
semi-permeable membrane into the ECS and turns back to the reservoir. Under standard
conditions, the entire system is placed in a 37°C CO2 incubator. 
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ECS ICS
O2/CO2 supply Peristaltic pump Medium reservoir
Hollow fiber bioreactor
O2 CO2
Figure 2.1: Schematic illustration of a hollow fiber bioreactor perfusion system. Culture medium is
continually pumped from a reservoir, charged with oxygen and carbon dioxide, flows within the
hollow fibers, diffuses radially through the semi-permeable membrane into the ECS and turns back to
the reservoir. ECS: extracapillary space, ICS: intracapillary space. 
Under these conditions the physiological environment is simulated and the HFB behaves
like an organ. Indeed, HF act as blood vessels, with a culture medium oxygenated by an
artificial lung (oxygenation system) replacing the blood, and the blood circulation is ensured
by an artificial heart (pump).
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2.2.2 Solute transport phenomena in hollow fiber bioreactors
Transport phenomena are of first importance since they affect directly cell viability and
functionality and thus, the performance of the bioreactor. Fluid circulating within the HF
brings oxygen and nutrients to cells and removes CO2 and other waste products. Transport
phenomena depend on the design of the HFB as on culture conditions. 
In a HFB, one can distinguish at least three regions (figure 2.2): the medium (or
blood/plasma in the case of BAL) compartment where culture medium (or blood/plasma)
flows, the membrane compartment, and the cell compartment where cells are located [5]. In
order to permit oxygen and nutrients to move from the culture medium to the cells, they must
be transported:
 From the medium bulk to the medium-membrane interface. This occurs generally
according to a diffusion-convection mechanism.
 Across the membrane wall. Mass transfer across semi-permeable membranes occurs by
diffusion and/or convection in response to existing trans-membrane concentration or
pressure gradients respectively. The porosity and the surface of the fibers, as well as the
thickness of the membrane are important parameters which influence transport. Increasing
pore size increases solute transport by both diffusion and convection, but also facilitates
transport of immunogenic proteins in the case of BAL. Hence, membrane porosity is an
important characteristic of HFB as it determines the size of the solutes able to cross the
membrane. 
 From the membrane surface through the cell mass. The presence of cells reduces solutes
mobility in the cell compartment. Collagen or other extracellular matrix proteins often
used to provide a substratum for cell attachment may also decrease solute mobility.
Nyberg et al. [6] estimated the diffusion coefficient of oxygen in a collagen-hepatocyte
gel being about 10% lower than that in water.
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Figure 2.2: Illustration of mass transport phenomena in hollow fiber bioreactors (HFB). Membrane
porosity is an important characteristic of HFB as it determines the size of the solutes able to cross the
membrane. 
In contrast to HFB, the transport in the liver is achieved primarily by convection along the
sinusoid with a short diffusion distance (< 5 m) across Disse space [7].
2.2.3 Designs of hollow fiber bioreactor 
There are various configurations of HFB used for cell culture (figure 2.3). We distinguish
here between single circuits where only the culture medium (or the blood/plasma in the case
of BAL) is perfused through the HFB, and multiple circuits where two or more fluxes are
present.
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Flow reductor
Filter
O2, CO2
O2
Figure 2.3: Current hepatocyte hollow fiber bioreactor (HFB) designs. In the single circuits, only the
culture medium or the blood/plasma in the case of bioartificial livers is perfused through the HFB,
while in multiple circuits two or more fluxes are present.
2.2.3.1 Single circuit systems
The simple mode (figure 2.3a) corresponds to the first model described by Knazek et
al. [4]. Cells are cultivated outside the HF, while culture medium is perfused inside. It is the
simplest and thus the most used system. In this model, the ECS pressure remains relatively
constant along the length of the HFB, which is not the case for the ICS pressure. At the tube
inlet, the ICS pressure is maintained above the ECS pressure. However, it decreases along the
length of the HFB and can drop below the ECS pressure. Thus, while the initial convective
trans-membrane flux is towards the ECS, it can be directed back into the ICS further down the
axis [8]. Therefore, cells near the downstream section of the HFB can be under
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nutrient-starvation conditions. This problem becomes more severe as the length of the HFB
increases [2]. In the case of cell suspensions, this phenomenon may cause cells to be pushed
and packed at the downstream end of the HFB [9].
To avoid the pressure drop along the HFB and thus the axial nutrient gradient, Rozga et
al. [10] imagined a variant of the simple model (figure 2.3b). In his system the shell port
downstream is open. Therefore, feed stream diffuses across the HF membrane and exits
through the shell-side port. Unlike in the simple model, the tube-side pressure is always
greater than the shell-side pressure but decreases linearly along the HFB. Thus, flow is always
into the shell and solute appearance is faster than in the simple model [8]. A filter is set at the
downstream side port to retain cells in the ECS.
Another single circuit has been described by Iwata et al. [11]. Compared to the simple
model, the compartments are reversed, i.e. cells are cultivated in the ICS while the medium is
perfused through the ECS (figure 2.3c). The advantage of this system is the short distance
between the cells and the HF membrane. Consequently, even hepatocytes in the central part of
the HF are well fed.
2.2.3.2 Multiple circuit systems 
Unlike simple circuits, multiple circuit systems comprise more than one flux. Nyberg et
al. [12-14] used a system where hepatocytes are entrapped in collagen gels inside the lumen
of the HF. The medium circulates within the HF, over the gel-entrapped hepatocytes
providing them with nutrients (figure 2.3d). A second flux, consisting of medium or
blood/plasma in the case of BAL, flows in the ECS. The advantages of this design are the
presence of a support for cell growth and the small diffusion distance for mass transfer of
nutrients and waste products.
Flendrig et al. [15] built a HFB which delivers gases and liquid nutrients separately to the
cells (figure 2.3e). It consists of a spirally wound non-woven polyester matrix which creates a
three-dimensional framework for hepatocyte immobilization and aggregation, and of
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integrated hydrophobic HF membranes for decentralized oxygen supply and CO2 removal.
Medium is perfused through the ECS and is therefore in direct contact with hepatocytes. 
Gerlach et al. [16] used a HFB made of three discrete capillary systems, each serving a
different purpose: one for plasma inflow, another for oxygenation and carbon dioxide
removal, and the third for plasma outflow (figure 2.3f). The advantage of this system is the
three-dimensional framework for decentralized cell perfusion with low metabolite gradients
and decentralized oxygenation and CO2 removal. Gerlach further improved the system by
adding a fourth capillary system containing sinusoidal endothelial cells for co-culture [17]. 
2.3 Setup of hepatocyte hollow fiber bioreactors
2.3.1 Hepatocyte culture in hollow fiber bioreactors
Hepatocytes are anchorage-dependent epithelial cells which require a surface for
attachment and proliferation. Recent advances in cell culture have evidenced the critical role
of the microenvironment on cell activities. In vivo, cell microenvironment mainly consists of
interactions between homotypic or heterotypic cells which affects the functional activity of
cells and the cell shape and polarity [18]. The main progresses recently made in hepatocyte
culture have been to define in vitro conditions which mimic in vivo situations. Schematically,
three major strategies can be used: 1) providing hepatocytes with one of the several
components that form the hepatic extracellular matrix (a complex mixture of collagens,
non-collagenous proteins and carbohydrates) 2) using cell-cell contacts between hepatocytes
3) restoring cell-cell communications of hepatocytes with other liver cell types in co-culture. 
In the case of HFB, several tools have been used to provide an attachment surface to the
hepatocytes, including HF surface coating, attachment to microcarriers, and gel embedding.
Figure 2.4 illustrates examples of hepatocyte culture in HFB. 
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a) Cell suspension /
        aggregates
b) Cell adhesion c) Gel embedding d) Microcarriers e) Microencapsulation
Figure 2.4: Hepatocyte culture in hollow fiber bioreactors (HFB). While the hepatocytes are simply
loaded in the HFB in the case of suspensions, an attachment surface is present in the case of cell
adhesion, gel embedding, microcarriers and microencapsulation.
2.3.1.1 Suspension of freshly isolated hepatocytes
Suspensions of freshly isolated hepatocytes (figure 2.4a) represent a quick, simple and
reproducible manner of preparing a HFB. Furthermore, they permit to incorporate a large
number of cells in a HFB, leading to an important cellular density. Suspensions have the
advantage of representing a homogenous hepatocyte population with a cellular activity and
function comparable to those present in vivo. Hepatocytes remain able to metabolize many
compounds by phase I and II enzymes [19]. 
However, since hepatocytes are anchorage-dependent cells, their viability and functionality
in suspension are limited to a few hours after their isolation, thus restricting extended
experiments [20]. Prolonged survey of hepatocytes is only possible if they are maintained in
culture attached to a support. Modification of the membrane architecture due to the isolation
process is another disadvantage of freshly isolated hepatocytes in suspension. Cells loose their
polarity, and structural and functional alterations can appear at the level of each
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hepatocyte [21]. This has to be taken into account when such preparations are used as models
of hepatic transport.
Nevertheless, an interesting aspect is that hepatocytes seem to spontaneously form
aggregates when cultured at high density in suspension in bioreactors [15,16], restoring
cell-cell interactions, leading to a better functionality and viability. Iwata et al. [11] prepared a
BAL system by simply inoculating a porcine hepatocyte suspension into the ICS, medium
being perfused through the ECS. They observed that hepatocytes formed aggregates
spontaneously during perfusion, and exhibited tight cell-cell contact characteristics. 
2.3.1.2 Adhesion on artificial membranes
As already discussed, the HF membrane separates cells from the perfusion medium. Its
second role is to provide an attachment surface to hepatocytes (figure 2.4b), which improves
their activity and viability. Hepatocytes are allowed to attach directly on the membrane or on
a coated surface [22,23]. Immobilization and growth depend on the nature of the membrane as
on the coating components. Substances often used to coat HF membranes include soluble
basement membrane extracts (Matrigel) [17], collagen (Vitrogen) [24] and fibronectin [25]. 
Membranes with different chemical and physical properties have been used. Qiang et
al. [26], compared growth and function of a human hepatoma cell line on six different
membranes. Four of them were cellulose-based membranes, Cuprophan, Hemophan,
Cellulose acetate, and Bioflux, two were synthetic polymers (SPAN and polysulphone).
Polysulphone, SPAN and Hemophan appeared to be ideal membranes for hepatoma cells
anchorage, while cells attached to cellulose acetate membrane to a lesser extend and failed to
attach to Cuprophan and Bioflux. The cellular integrity was largely dependent on its
attachment to the membrane, the best results being obtained with polysulphon. The intrinsic
structure of membranes contributes highly to the differential behavior of hepatocytes on
membranes. Although the precise mechanism of cellular attachment has not been elucidated,
the importance of an electrically polar surface is recognized. Hemophan and cellulose actetate
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are positively charged; polysulphone and SPAN are negatively charged. The unmodified
cellulose membranes, Cuprophan and Bioflux remain electrically neutral. These results
confirm that membranes that have hydrophilic groups on their surface enhance cell growth
and functionality. A disadvantage of this mode of culture in HFB is the low cellular density
achievable, as all hepatocytes have to be attached to the fiber membrane. 
2.3.1.3 Gel embedding
Gel embedding of hepatocytes is represented in figure 2.4c. The gel matrix increases the
surface area for cell support, yielding better cell viability and functionality. Hepatocytes can
be entrapped in a collagen gel and cultured in the ECS [27,28] or in the ICS [12-14] of the
bioreactor (figure 2.3d). Hepatocyte embedding in a collagen I gel at a concentration of about
0.2% is often used. A disadvantage of this design is that a steep concentration gradient of
nutrients and oxygen may occur through the gel depth, resulting in either cell starvation or
accumulation of toxic metabolites near the cells [5]. 
2.3.1.4 Microcarriers
Microcarriers (figure 2.4d) are artificial spherical bodies made from different materials
including dextran, polystyrene, biologically modified polyhydroxymethylmethacrylate
(poly-HEMA) or glass. Compared to membrane adhesion, microcarriers provide an increased
surface area available for hepatocyte adhesion, increasing the cell density achievable in the
HFB. Like HF membranes, microcarriers can be coated with different substances like
chitosan [29], collagen [10,30-33] or fibronectin [34].
Dixit et al. [25] developed microcarriers with biologically modified poly-HEMA which
yielded a higher hepatocyte immobilization than collagen-coated dextran microcarriers.
Moreover, newly developed multiporous cellulose microcarriers are able to contain cells in
their pores and may be more suitable than dextran microcarriers as a matrix for long-term,
high-density culture of isolated hepatocytes [35]. The biopolymer chitosan is a suitable
scaffold for the attachment of hepatocytes, because of its nontoxic and biocompatible nature
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and its structure similar to that of glycosaminoglycans which are components of the liver
extracellular matrix [36].
Furthermore, microcarriers are used to cryopreserve hepatocytes for the further preparation
of the HepatAssist BAL (see §2.5.2), as microcarrier-attached hepatocytes are known to retain
a good viability and functionality after thawing. Hepatocytes attached to collagen-coated
dextran microcarriers have also been intraperitoneally injected into rats to treat liver
insufficiency [37].  
2.3.1.5 Microencapsulation
An example of microencapsulation is shown in figure 2.4e. Hepatocytes entrapped within a
gel matrix of calcium alginate maintain their functionality in vitro [38-40], but difficulty has
been experienced in terms of the permeability through the gel matrix of high-molecular
weight substances such as secreted plasma proteins, although Tompkins et al. [41] showed
that transport limitations do not occur in alginate droplets. In the case of BAL, encapsulation
also permits to immunoisolate hepatocytes. As with microcarriers, hepatocytes retain their
functional activity and metabolic capacity after cryopreservation in alginate droplets [42].
2.3.1.6 Co-culture
Co-culture means that two or more cell types are cultured together, resulting in a cell
behavior and physiological responses which would not occur if the cell types were cultured
alone. In the case of hepatocytes, co-culture with fibroblasts [43], endothelial cells [44] or
with another epithelial cell type [45] improved hepatocytes functionality and life span in
culture.
This technique has been applied notably by Gerlach et al. [17] who used a bioreactor made
of four capillary systems, one being loaded with liver endothelial cells while the hepatocytes
were cultured in the ECS.
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2.3.2 Conditions of hollow fiber bioreactor culture 
2.3.2.1 Culture medium
Optimization of the culture medium composition contributes to the long term maintenance
of cell viability and functionality. Most authors use complete media containing amino acids
and vitamins in addition to salts. The most common complete medium for hepatocytes culture
is Williams’E medium [46], but media as Chee’s essential medium [24] and
Dubelcco’s [31,47] are also cited. Simple balanced salt solutions (BSS) can be used such as
Dubelcco’s phosphate buffer saline or Hank’s BSS. When performing metabolic studies, one
should be aware that the more constituents in the culture media the higher the risks of
interactions. Albumin or serum, growth factors and antibiotics are often included in the
medium. In the case of BAL, medium is replaced by the patients or animals plasma or blood,
although some authors keep in addition a culture medium stream flow to provide hepatocytes
with specific nutrients and to eliminate hepatocyte waste products. 
The presence of a carbonate buffer in the medium and 5% CO2 in the incubator atmosphere
ensures a pH around 7.4. If the CO2 concentration in the gas phase increases, HEPES can be
added to the medium to better stabilize the pH around 7.4. According to the human plasma
osmolality, media osmotic pressure is usually set at 290 mOsm/kg. Slightly hypotonic media
are sometimes used to compensate evaporation during long experiments. Upon exposure to
anisotonic conditions most cells, including hepatocytes, initially change their volume
according to the tonicity of the extracellular compartment [48]. In a second step, they are
capable to actively restore their volume despite continuous hypotonic or hypertonic challenge,
which is called regulatory volume decrease and regulatory volume increase, respectively. 
2.3.2.2 Oxygenation
Special attention must be paid to optimal oxygenation of cells, since oxygen plays a key
role in hepatocyte attachment and function [15]. Anoxia results in a gradual increase in
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plasma membrane permeability, leading to the initiation of cell death. The capacity to supply
the culture with oxygen is severely limited by the low solubility of oxygen in the medium
(0.2 mmol O2/liter at 37°C) and by the very high specific oxygen consumption rate of
hepatocytes [2]. For this reason, oxygen is used as the limiting substrate in models of
metabolite transport in HFB [49-51]. At high cell densities and low oxygen tensions, cells
may change from aerobic metabolism to anaerobic glycolysis [2]. Macdonald et al. [52]
determined in an MRI investigation that a diffusion distance between 200-500 m is
necessary to keep hepatocytes viable in a simple circuit bioreactor. 
The first HFB oxygenation system described by Knazec et al. [4] consisted of silicone
tubing through which O2 and CO2 (5% CO2 in air) diffuse readily from the incubator
atmosphere to the solution flowing inside the tubing. This oxygenation system is called
indirect oxygenation as it is placed in series in the HFB system, oxygenating the circulating
medium. On the other hand, the term of direct oxygenation is employed when the oxygenation
system is included directly in the bioreactor. The later is the method used by Gerlach et
al. [16,17,53] who found that during the first 24 hours of culture, hepatocytes in HFB reduced
the ammonia content in the medium in the same range with direct and indirect oxygenation
but that in longer term cultures the direct method resulted in enhanced cell metabolism. The
composition of the feeding gas also influences the oxygen consumption. It was shown that the
oxygen consumption rose with increasing oxygen tension [54].
2.3.2.3 Flow rate
High flow rates are often used to enhance in particular the amount of dissolved oxygen
delivered to hepatocytes. Actually, the rate of solute appearance in the ECS is a function of
the flow rate [8,10] and as oxygen is crucial for the maintenance of hepatocyte viability, its
diffusion is much more critical than diffusion of other nutrients [55]. However, high flow
rates are generally reluctantly selected because they increase hepatocyte shear stress and can
cause an axial concentration gradient of cellular viability in spatial distribution. 
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2.3.2.4 Cellular density
The optimal hepatocyte density is the maximal one which permits to supply each cell with
sufficient nutrients, including glucose and oxygen. It is reflected by the performances of the
hepatocyte HFB: increasing cell mass must not alter cell functionality and viability. The
optimal cellular density depends mainly on the HFB dimensions and on the mode of cell
culture chosen. Actually, for cell suspensions, a tightly packed fiber bundle will support a
high local density in the space between fibers, but the volume available for cells is reduced.
Conversely, a large fiber spacing will afford a large volume for cells at a lower local density.
Chresand et al. [50] proposed an equation to determine the maximal cell density achievable
with a definite HFB based on nutrients consumption, oxygen being the limiting substrate, and
on the HFB characteristics, i.e. the bioreactor and fiber dimensions, and the number of fibers.
Gerlach et al. [16] observed a different behavior of primary hepatocytes depending on their
density in the HFB. When hepatocytes are seeded at low density between the HF, they adhere
to the membrane surface and flatten. If they are seeded at high cellular densities, they attach
to the membrane surface and additionally form aggregates in the ECS.
2.4 Validation of hepatocyte hollow fiber bioreactors
The validation of a HFB after its setup by checking its ability to sustain a good cellular
viability and functionality is an important step, as the performances of the HFB directly
depend on these factors. Most cellular viability tests rely on direct coloration of cells with dye
(e.g. trypan blue, fluorescein). But such kind of tests cannot monitor cellular viability during
HFB experiments as HFB are closed systems, impeding cell sampling. Consequently, other
tests have to be used to quantify hepatocyte viability in HFB, as for example dosage of
enzymes released, or evaluation of complex synthetic and metabolic activities.
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For the validation procedure of HFB, we distinguish here between the evaluation of
oxygen consumption and dosage of endogenous substances (e.g. enzymes, proteins), and the
assessment of the metabolism of drugs and endogenous compounds.
2.4.1 Evaluation of the oxygen consumption and dosage of endogenous compounds
Oxygen consumption is currently used to assess cellular viability as it reflects the
biochemical state of the cellular population. The consumption of insulin, which is sometimes
added to the medium, is an indirect measure of hepatocytes growth as it stimulates
hepatocytes proliferation. Dosage of liver specific proteins (e.g. albumin, fibrinogen,
haptoglobin, creatinin, transferrin) reflects the synthetic capacity of hepatocytes associated
with the preservation of a transcriptional activity. 
Measurement of the specific release of intracellular enzymes (LDH, AST, ALT, GPT,
GLDH, GGT and transaminases) due to membrane leakage acts as a criterion of cellular
integrity. Some amino acids are sometimes dosed because they have long been suspected to
be involved in hepatic encephalopathy, although their exact role has not been defined
clearly [33].
2.4.2 Study of the metabolism of drugs and endogenous compounds
The term metabolism includes all the chemical reactions which modify molecules inside
the body. It consists of the degradation or formation of complex substances and the use of
nutrients to produce energy [56]. It includes also the modification of molecules to render them
more hydrophilic to facilitate their elimination mainly through the kidneys which affects
endogenous compounds and drugs. These reactions can be separated into phase I and phase II
reactions. Phase I reactions involve the creation or modification of functional groups in a
substrate molecule (i.e. oxidation, reduction and hydrolysis). Thus, phase I processes are often
designated as functionalization reactions. In contrast, phase II reactions involve the
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conjugation of an endogenous molecule or fragment to the substrate, yielding a metabolite
known as a conjugate. Thus, phase II processes are often called conjugation reactions [57]. 
Table 2.1 presents different substances currently studied in hepatocyte HFB, either for the
validation of the HFB or for the investigation of their metabolism.
2.4.2.1 Metabolic studies of endogenous compounds
The lactate/pyruvate ratio is an index of the functional state of cellular oxidation and
aerobic metabolism [15]. Like oxygen consumption, the glucose depletion in the medium is
an indicator of the biochemical state of the cells. The galactose elimination capacity has been
used in clinical diagnosis as an indication of functional liver cell mass. In fact, galactose has
first to enter cells by a carrier-mediated transport process, where it is then converted to
glucose almost exclusively in the liver by enzymes involving galactokinase and
uridyltransferase.
Ammonia elimination is a relevant metabolic reaction for BAL performance test as
ammonia is one of the neurotoxic species related to hepatic encephalopathy [58]. Ammonia is
detoxified by ureagenesis showing that hepatocytes retain the enzymes of the urea cycle. For
in vitro tests, ammoniac elimination and urea synthesis are evaluated after administration of
NH4Cl. In the case of BAL tested with animals or humans, ammonia is naturally present in
the blood as it results from the proteins degradation. 
Bilirubin uptake, conjugation and excretion is a complex hepatic function [59]. Free
bilirubin is conjugated with glucuronic acid by the hepatic enzyme uridine diphosphate-
glucuronyltransferase, making it water soluble and thus excretable into the bile as the mono-
and diglucuronide. It is an endogenous marker of phase II reactions. Finally, cytidine
deamination to uridine by the enzyme cytidine deaminase indicates the functionality of
cytosine arabinoside metabolism [22].
Table 2.1: Metabolic reaction, marker and analytical method of substances currently studied in hepatocyte
hollow fiber bioreactors. 
Reaction Marker Analytical method Reference
Endogenous compounds
Ammonia Ureagenesis Ammonia HPLC/UV [12,60]
Ureagenesis
Ureagenesis
Urea 
Urea 
UV
HPLC/UV
[15,22,61]
[12]
Bilirubin Glucuronidation Mono- and di-
glucuronide
HPLC/UV [30]
Cytidine Deamination 14C-uridine Radioactivity [22]
Galactose Conversion to glucose Galactose UV [15,17,62]
Glucose Glycolysis and gluconeogenesis Glucose Test strips [15]
Exogenous compounds
Diazepam Oxidation 
Oxidation
Diazepam
Diazepam
HPLC/UV
Gaz-liquid
chromatography
[24,54]
[22]
Hydroxylation Temazepam HPLC/UV [24,54]
N-Demethylation Nordiazepam HPLC/UV  [24,54]
Hydroxylation+N-demethylation Oxazepam HPLC/UV [24,54]
Lidocaine Oxidation 
Oxidation 
Oxidation 
Oxidation 
Lidocaine
Lidocaine
Lidocaine
Lidocaine
GC
HPLC/UV 
Immunoassays
Fluorescence
polarization
[29]
[11,12,15]
[17,63]
[64]
N-Dealkylation
N-Dealkylation
N-Dealkylation
MEGX
MEGX
MEGX
HPLC/UV
Immunoassays
Fluorescence
polarization
[11,12,15]
[17,63,65]
[64]
N-Dealkylation GX HPLC/UV [12,15]
Amide hydrolysis Xylidine HPLC/UV [15]
Hydroxylation 3-OH-Lidocaine HPLC/UV [12,65]
N-Dealkylation + hydroxylation 3-OH-MEGX HPLC/UV [12]
Midazolam Oxidation Midazolam Immunoassays [17]
Cyclosporine Hydroxylation First-generation
monohydroxylation
products
HPLC/UV [10]
N-Demethylation First-generation
N-demethylation
products
HPLC/UV [10]
19-nortestosterone Conjugation 19-Nortestosterone GC/MS [10]
Isomerisation
Isomerisation
19-Noreticholanolone
19-Norepiandrosterone
GC/MS
GC/MS
[10]
PSP Glucuronidation PSP-glucuronide UV [24]
19-nortestosterone Glucuronidation 19-Nortestosterone
glucuronide
GC/MS [10]
4-MU Conjugation 4-MU HPLC/UV [12]
Glucuronidation MUG HPLC/UV [12]
Sulfation MUS HPLC/UV [12]
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MEGX: monoethylglycinexylidide, GX: glycinexylidide, PSP: phenolsulfonphthalein, 4-MU: 4-methylumbelliferone,
MUG: 4-methylumbelliferone glucuronide, MUS: 4-methylumbelliferone sulfate
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2.4.2.2 Metabolic studies of drugs
Diazepam, an anxiolytic drug, and lidocaine, a local anesthetic and antiarrhythmic drug,
are the most frequently used substrates to evaluate the metabolic function of hepatocytes.
Their total metabolic activity reflects the status of the P450 pathway, indicating that
hepatocytes have the capacity for oxidation and/or reduction of drugs. They can be considered
as phase I markers. The scheme of diazepam metabolism is represented in figure 2.5.
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Figure 2.5: Oxidation of diazepam by cytochrome P450 to temazepam, nordiazepam and oxazepam.
Cyclosporine, an immunosuppressive agent, and midazolam, an anxiolytic compound, are
also used as phase I markers. Although being a parent compound of the endogenous substance
testosterone, 19-nortestosterone has been classified as a xenobiotic since it serves as an
anabolic drug. Glucuroconjugation of 19-nortestosterone and 4-methylombelliferone, a
spasmolytic and choleretic drug, are often used to evidence phase II drug metabolism. 
2.5 Applications of hepatocyte hollow fiber bioreactors
Due to their conditions close to the physiological state, hepatocyte HFB are used for
several purposes. Three main axes of use can be drawn: 1) for the synthesis of cellular
products, 2) as artificial liver, and 3) as a tool for metabolic studies. Our aim here is not to
provide an exhaustive list of the HFB uses but to give an overview of their possible
applications.
2.5.1 Uses of hepatocyte HFB for the synthesis of cellular products
A significant part of the hepatocyte HFB used for the synthesis of cellular products is
associated with tumor-derived cell lines. The advantages of cell lines over primary cell
cultures are a continuous secretion, an easier purification and a better yield of cellular
products. Moreover, cell lines are immortal, which facilitates cloning, their culture is easier
and a higher cellular density is achievable. 
For instance, purified hepatitis B surface antigen can be produced from Alexander
hepatoma cells grown in HFB [66]. Today, human hepatitis B vaccines contain hepatitis B
surface antigen obtained from plasma of humans infected with the hepatitis B virus. However,
considering the risks linked to the use of human blood, the Alexander hepatoma cell line
which carries the hepatitis B virus genome and secretes surface antigen of hepatitis B
provides an interesting alternative antigen source for vaccine production.
Hep G2 cells, another human hepatoma cell line, are cultivated in HFB to produce Hep G2
crude conditioned medium (CCM) which contains high quantities of proteins, including the
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endothelial cell growth factor and platelet-derived growth factor [67]. Hep G2 CCM was
found to be comparable to or even better than fetal calf serum in supporting the growth of
cells in vitro. Serum is traditionally added to cell cultures to provide nutrients, notably growth
factors. But as the sources of serum are limited and its composition is subjected to variations,
the development of serum substitutes is important and Hep G2 CCM seems to be a good
candidate as a serum substitute. 
2.5.2 The hepatocyte HFB as a bioartificial liver
Currently, the major application of hepatocyte HFB is as a BAL to serve as a bridge to
transplantation for patients with acute liver failure (ALF). The use of BAL with patients
suffering from ALF permit to increase their survival rate, as ALF is associated with a very
high mortality rate. Symptoms of ALF include notably encephalopaty, reduced albumin
synthesis, prolonged prothrombin time and elevated bilirubine and ALT levels [68].
Orthotopic liver transplantation is for the moment the treatment of choice for patients with
ALF, but many of them are never transplanted because they do not survey until a donor organ
becomes available. 
Devices or techniques to support organisms suffering from ALF have been based primarily
on extracorporeal blood processing, using physical or biological techniques. Physical
techniques include dialysis, affinity chromatography, charcoal adsorption, and ion exchange.
Biological techniques include extracorporeal perfusion of animal livers, cross-circulation with
animals or cadavers, as well as simple exchange transfusion or plasmapheresis [59]. However,
none of these therapeutic modalities has succeeded in gaining wide clinical application. The
use of hepatic cells serves as an intermediate between physical and wholly biological
techniques. Several BAL designs have been proposed, including direct hemoperfusion of
microencapsulated hepatocytes in an extracorporeal chamber [40], plate dialyzer [69] and
hollow fiber BAL systems, on which we focus hereinafter.
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A BAL has to replace the multiple functions of the liver, including metabolic and secretory
functions. All the information given in the previous sections is applied in the development of
BAL to get an optimal functionality of the hepatocytes contained in the HFB. BAL functions
are first investigated in a series of in vitro (table 2.2) and in vivo animal experiments
(table 2.3) before being tested with humans (table 2.4). These tables list the characteristics of
the HFB used, e.g. the ECS volume, the fiber porosity, the type of cells used and the way they
are cultured. They also review the tests performed to check the viability and functionality of
hepatocytes during BAL use. In addition to these tests, several examinations are performed on
patients in clinical trials, including vital signs, neurological monitoring, whole blood cell
counts, and coagulation tests.
A HFB used as a BAL (figure 2.6) brings hepatocytes or liver-derived cells from both
human and animal origin into contact with patient whole-blood or plasma. Perfusing plasma
through the HFB instead of whole blood eliminates problems linked to hemolysis,
thrombocytopenia, clot formation, embolization and the need for heparinization [70], but the
use of whole blood has the advantage of containing erythrocytes, which improves oxygen
delivery to hepatocytes. A charcoal column is often included in the perfusion system before
the HFB to adsorb part of the toxic compounds in the plasma [33,71]. The best procedure is to
use primary human hepatocytes, but they are short in supply. Transformed human liver cells
grow to high cellular density but are inferior to primary cells in accomplishing hepatic
functions and bear the potential risk of tumor transmigration from the BAL into the patient’s
circulation [3,14]. Primary animal hepatocytes, on the other hand, have a limited life span in
vitro and have the disadvantage of an increased risk of immunological complications and
potential xenozoonosis. For clinical use, porcine hepatocytes are preferred to rodent
hepatocytes because higher cell yields are obtained.
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Figure 2.6: Schematic illustration of a hollow fiber bioartificial liver. The plasma separator is absent
when whole blood is perfused through the system. Toxic compounds in patients whole blood or
plasma are partially adsorbed on activated charcoal before being metabolized by the primary
hepatocytes or liver-derived cells contained in the hollow fiber bioreactor.
Cellular immunologic isolation is important to reduce complications. However, it is
difficult to determine the optimal molecular weight cut-off of HF membranes suitable for
BAL. Actually, the smaller it is, the better it prevents immune reactions on both sides of the
HF membrane, but the less it removes protein-bound toxins [72]. For example, HF
membranes with a cut-off of 100 kD could act as impermeable barriers to immunoglobulins
(~ 150 kD) and complement (> 200 kD) in the patient’s blood and provide a barrier to
transmission of pathogens, while allowing passage of soluble and albumin-bound toxins
(albumin ~ 60 kD). In this point of view, the rather large HF porosity of 0.2 m
(0.1 m ~ 1000 kD) of the porcine hepatocyte BAL HepatAssist can surprise. Its designers
argued that the use of plasma perfusion (no direct contact between immune cells in the blood
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and BAL cells), of purified isolated hepatocytes (no endothelial cells and other highly
antigenic cells) and of HF with a large porosity (permeable to immunoglobulins but allowing
excellent transport of molecules across the fibers) seemed to present a good compromise
between the need for efficient function and prevention of immune reactions [70]. 
Despite the considerable number of in vitro experimental studies and animal models of
ALF, only three systems have been recently assessed clinically, two of which in several
studies (table 2.4). The Hepatix device uses a human hepatoblastoma cell line (C3A cells
derived from the HepG2 cell line) in suspension within the ECS of the HFB, whole blood
being used for the perfusion. The HepaAssist BAL utilizes cryopreserved porcine hepatocytes
attached to collagen microcarriers contained within the ECS of the HFB. The treatment with
hepatocyte hollow fiber BAL was well tolerated by all patients with evidence of clinical
improvement. Patients were transplanted successfully after BAL treatments (6-7h), which
shows that BAL can be used as a bridge to transplantation for patients with ALF. A few cases
of spontaneous recovery without transplantation were even reported [73,74]. However, at the
present time, no BAL device has received FDA approval for use in ALF. 
Table 2.2: Bioartificial liver: in vitro tests.
Hepatocyte function  and viability testsBioreactor design
Cartridge model
Manufacturer
ECS vol
Porosity
Type of cells
Cell density or total
cell number
Type of culture
Treatment
Inside/outside the fibers
Medium
Flow rate Exogenous compounds
metabolism
Endogenous compounds
Ref
Single circuit (fig 2.3a)
Vitafiber 
Amicon, USA or
Dowex cell culture tube c/HFBI-05
Bio Rad Lab, USA
ns
50 kD
ns
30 kD
Rat hepatoma cell line
H4-II-E
ns
Adhesion (fig 2.4b)
No treatment
Outside the fibers
F12K
0.7-3.6 ml/min
ns Bilirubin, glucose, LDH, AST,
and GTP 
Wolf  1975 [59]
Single circuit (fig 2.3a)
Vitafiber XM50
Amicon, USA
ns 
50 kD
Neonatal murine
hepatocytes
Adhesion (fig 2.4b)
No treatment
Outside the fibers
Hams F12K
1 ml/min
Diazepam Glucose, albumin, fibrinogen,
transferrin, urea, cytidine 
Hager 1983 [22]
Multiple circuits (fig 2.3d)
H1P100
Amicon, USA
ns
100 kD
Primary rat hepatocytes
~ 5·106 cells/ml
Gel embedding (fig 2.4c)
Collagen I 0.15%
Inside the fibers
Williams' E
SP: 30 ml/min
FP: :9 ml/h
Lidocaine Albumin, oxygen Shatford
1992 [63,75]
Single circuit (fig 2.3b)
Minikap 225
Microgon, USA
33.5 ml
0.2 m
Primary rat hepatocytes
1·106 cells/ml
Microcarriers  (fig 2.4d)
Coated with collagen
Outside the fibers
PBS
10, 30, 50 ml/min
Cyclosporine
19-nortestosterone
ns Rozga  1993 [10]
Multiple circuits (fig 2.3d)
H1P100
Amicon, USA
ns
100 kD
Primary rat hepatocytes
or Hep G2 cells
5-10·106 cells/ml
Gel embedding (fig 2.4c)
Collagen I 0.15%
Inside the fibers
Williams' E
SP: 30 ml/min
FP: 9 ml/h
Lidocaine
4-MU
Albumin, urea, lactate, glucose,
insulin, aa and oxygen 
Nyberg 1992 [13]
1994 [14]
Single circuit (fig 2.3a)
ns
Grace & Co, USA
7.2 ml
ns
Primary rat hepatocytes
5.6·106 cells/ml
Adhesion (fig 2.4b)
Fiber coating with collagen (Vitrogen)
Outside the fibers
Chee’s EM
75 ml/min
Diazepam
PSP
ns Jauregui 1994 [24]
Multiple circuits (fig 2.3f)
Home-made
-
ns
ns
Primary pig hepatocytes
2.5·109 total cells
Adhesion and aggregates (fig 2.4b)
Fiber coating with collagen (Matrigel)
Outside the fibers
Williams' E
25 ml/min
Lidocaine
Midazolam
Galactose, LDH, AST, GPT,
GLDH, GGT, albumin 
Gerlach  1994
[17]
Single circuit (fig 2.3a)
Culture Flo G
Asahi Medical, Japan
2 ml
0.4 m
Primary rat hepatocytes
2·107 cells/ml
Gel embedding (fig 2.4c)
Collagen I 0.2%
Outside the fibers
Williams' E
1 ml/min
ns Urea, albumin, ammonia, AST Takeshita
1995 [27]
Single circuit (fig 2.3a)
Cellmax
Cellco, USA
ns
30 kD
Primary rat hepatocytes
1·106 cells/ml
Microcarriers (fig 2.4d)
Coated with fructose-modified chitosan 
Outside the fibers
Williams' E
25 ml/min
Lidocaine LDH, urea Yagi  1997 [29]
Multiple circuits (fig 2.3e)
Home-made
Home-made
11 ml
ns
Primary pig hepatocytes
2·107 cells/ml
Suspension / aggregates (fig 2.4a)
No treatment
Outside the fibers
Williams' E
30 ml/min
Lidocaine Galactose, urea, protein, amino
acids, lactate/ pyruvate, LDH,
AST, GPT, glucose 
 Flendrig 1997 [15]
Multiple circuits (fig 2.3d)
ns
Althin Medical, USA
ns
100 kD
Primary porcine
hepatocytes
3·107 cells/ml
Gel embedding (fig 2.4c)
Collagen I 0.15%
Inside the fibers
Williams' E
SP: ns
FP: 15 ml/h
ns Urea, albumin, oxygen Sielaff  1997 [61]
Single circuit (fig 2.3a)
HepatAssistTM BAL2000
Circe Biomedical, USA
ns
ns
Primary porcine
hepatocytes
ns
Microcarriers (fig 2.4d)
No treatment
Outside the fibers
Calf serum
100-600 ml/min
Diazepam Oxygen Custer 1998 [54]
Single circuit (fig 2.3c)
Duo-Flux M170D
JMS, Japan
145 ml
ICS 99 ml
68 kD
Primary porcine
hepatocytes
1·108 cells/ml
Suspension (fig 2.4a)
No treatment
Inside the fibers
80% Dubelcco +
20% human blood,
200 ml/min
Lidocaine Urea, galacose Iwata 1999 [11]
ns: non specified, LDH: lactate dehydrogenase, ALT: alanine aminotransferase, AST: aspartate aminotransferase, GPT: glutamic pyruvic transaminase, GLDH: glutamate
dehydrogenase, GGT: -glutamyl transpeptidase, PSP: phenolsulphonphtalein, SP: shell perfusate, FP: fiber perfusate, 4-MU: 4-methylumbelliferone, ECS vol: extracapillary space
volume, ICS: intracapillary space
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Table 2.3: Bioartificial liver: in vivo animal tests.
Animal
model
Hepatocyte function  and viability testsBioreactor design
Cartridge model
Manufacturer
ECS vol
Porosity
Type of cells
Cell density or total
cell number
Type of culture
Treatment
Inside/outside the fibers
Medium
Flow rate
Exogenous compounds
metabolism
Endogenous compounds
Ref
Single circuit (fig 2.3a)
Vitafiber, 
Amicon, USA or
Dowex cell culture tube c/HFBI-05
Bio Rad Lab, USA
ns
50 kD
ns
30 kD
Rat Rat hepatoma cell line
H4-II-E
ns
Adhesion (fig 2.4b)
No treatment
Outside the fibers
Blood
1 ml/min
ns Bilirubin Wolf
1975 [59]
Single circuit (fig 2.3a)
Minipure ES 1-12
Microgon, USA
7 ml
0.2 m
Rat Primary rat hepatocytes
5.7·106 cells/ml
Microcarriers (fig 2.4d)
Coated with collagen
Outside the fibers
Blood
10 ml/min
ns Bilirubin Arnaout
1990 [30]
Single circuit (fig 2.3a)
Cell-pharm 240-322
UniSyn Fibertec, USA
ns
70 kD
Dog C3A cells
ns
Suspension (fig 2.4a)
No treatment
Outside the fibers
Blood
ns
ns Albumin , ALT Sussman
1992 [68]
Single circuit (fig 2.3b)
Minikros M22M-030-01N
Microgon, USA
33.5 ml
0.2 m
Dog Primary porcine and
dog hepatocytes
1·106 cells/ml
Microcarriers (fig 2.4d)
Coated with collagen
Outside the fibers
Plasma
30 ml/min
ns Glucose, lactate, LDH, AST Rozga
1993 [10]
Single circuit (fig 2.3a)
Z22M-060-01X
Microgon, USA
177 ml
0.2 m
Dog Primary porcine
hepatocytes
3.4·106
Microcarriers (fig 2.4d)
Coated with collagen 
Outside the fibers
Plasma
200 ml/min
ns Glucose, lactate, haptoglobin,
fibrinogen , LDH, AST 
Rozga
1993 [31]
Multiple circuits (fig 2.3d)
H1P100
Amicon, USA
ns
100 kD
Rabbit Primary rat hepatocytes
5-10·106 cells/ml
Gel embedding (fig 2.4c)
Collagen I 0.15%
Inside the fibers
Blood
SP: 25 ml/min
Williams' E
FP: 9 ml/h
Lidocaine
4-MU
Albumin, ammonia, amino
acids, lactate, oxygen, glucose 
Nyberg
1993 [12]
Single circuit (fig 2.3a)
ns
ns
40 ml
0.15 m
Rabbit Primary rabbit
hepatocytes
1.4·107 cells/ml
Adhesion (fig 2.4b)
No treatment
Outside the fibers
Blood
25 ml/min
Lidocaine, 
Diazepam
ALT, LDH, bilirubin, glucose,
ammonia, creatinine 
Jauregui
1995 [64]
Single circuit (fig 2.3a)
Z22M-060-01ZX
Microgon, USA
ns
ns
Pig Primary porcine
hepatocytes
ns
Microcarriers (fig 2.4d)
Coated with collagen 
Outside the fibers
Plasma
30 ml/min
ns Glucose, lactate, ammonia, urea,
albumin, fibrinogen, creatinine,
amino acids 
Sheil
1996 [33]
Multiple circuits (fig 2.3f)
Home-made
-
ns
ns
Pig Primary pig hepatocytes
4·1010 total cells
Adhesion and aggregates (fig 2.4b)
ns
Outside the fibers
Blood
ns
ns ns Gerlach
1997 [76]
Multiple circuit (fig 2.3d)
ns
ns
ns
100 kD
Dog Primary porcine
hepatocytes
ns
Gel embedding (fig 2.4c)
Collagen I 
ns
Blood 
100-500
ml/min
ns ALT, AST, ammonia, lactate Patzer
1999 [28]
ns: non specified, LDH: lactate dehydrogenase, ALT: alanine aminotransferase, AST: aspartate aminotransferase, SP: shell perfusate, FP: fiber perfusate,
4-MU:4-methylumbelliferone, ECS vol: extracapillary space volume 
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Table 2.4: Bioartificial liver: clinical studies.
Bioreactor design
Cartridge model
Manufacturer
Single circuit (fig 2.3a)
Z22M-060-01X (HepatAssist)
Microgon, USA
Single circuit (fig 2.3b)
Hepatix ELAD
ns
Multiple circuits (fig 2.3f)
Home-made
-
ECS vol
Porosity
177 ml
0.2 m
125 ml
70 kD
ns
ns
Type of cell
Cell density or total cell
number
Primary porcine hepatocytes 
5-30·106 cells/ml
Human liver cell line (C3A)
2·108 cells/ml
Primary porcine hepatocytes
4·1010 total cells
Type of culture
Treatment
Inside/outside the fibers
Microcarriers (fig 2.4d)
Coated with collagen 
Outside the fibers
Suspension (fig 2.4a)
ns
Outside the fibers
Adhesion and aggregates
(fig 2.4b)
ns
Outside the fibers
Medium
Flow rate
Blood or plasma
40-400 ml/min
Blood
250-500 ml/min
Blood
ns
Exogenous compounds
metabolism
ns Lidocaine
Caffeine
ns
Endogenous compounds AST, ALT, LDH, ammonia,
urea, bilirubin, glucose, lactate,
amino acids, fibrinogen,
transaminases and creatinine
Galactose, bilirubine,
transaminases, lactate,
ammonia, albumin, oxygen,
coagulation factors, fibrinogen
and antithrombin III
ns
Clinical procedure 1 to 3 treatments of 6 hours Uninterrupted treatment for a
mean of 62 hours
Uninterrupted treatment for
40 hours
Number of patients treated ~ 120 ~ 30 1
Ref Rozga 1993 [31], 1994 [77]
Demetriou 1995 [70]
Chen 1996 [32]
Watanabe 1997 [71]
Mullon 1999 [78]
Didier 2002 [74]
Sussman 1994 [65,73]
Ellis 1996 [62]
Gerlach  1997 [76]
ns: non specified, LDH: lactate dehydrogenase, ALT: alanine aminotransferase, AST: aspartate aminotransferase
2.5.3 The hepatocyte HFB as a tool for the study of drug metabolism and transport
Drug metabolism studies using hepatocyte HFB are essentially performed for two distinct
reasons. One is to check the functionality and viability of the hepatocytes contained in the
HFB, as already discussed (see §2.4.2). On the other hand, HFB can be used as a cellular
model for the study of drug metabolism and transport. Table 2.5 summarizes the principle
advantages and disadvantages of the use of HFB for these purposes. HFB have several
benefits over plate or suspension cultures which are the most commonly used cellular model
for drug metabolism investigations. In particular, HFB mimic more closely the in vivo
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environment, and hepatocytes are continuously provided with nutrients and oxygen,
permitting a prolonged duration of experiments. Moreover, HFB facilitate sampling, as
perfusion solutions are already separated from cells by the semi-permeable membrane of the
fibers. Another advantage of HFB is that they are dynamic culture systems, allowing
continuous measurements and changes in perfusion conditions to study the influence of
several different factors during a single experiment. This aspect enables for instance to
perform a complete Michaelis Menten kinetic study and to investigate the effects of inhibition
in a single HFB experiment. 
Table 2.5: Advantages and disadvantages of HFB for the study of drug metabolism and transport.
Advantages Disadvantages
 Long lasting experiments  Complicated setup
 Study of slow metabolism  High cost
 High cell density achievable  Gradient of nutrients and cells
 Easy sampling
 Continuous measurement
 Study of different factors in the same
experiments
The equilibrium between the advantages and the disadvantages of HFB seem to be in favor
of HFB to study drug metabolism and transport. Nevertheless and despite the numerous
advantages cited, HFB are not currently used for that purpose probably because they are quite
difficult to set up and expensive compared to suspensions and plate cultures.
The use of liver cell lines has to be avoided, as they are dedifferentiated cells which often
lack important metabolic activities. For instance, the P450 and conjugation activities of
HepG2 cells are more than 200, respectively 30 times lower than that of primary rat
hepatocytes [14]. As high yields compensate low activities, these cells are nevertheless used
in BAL.
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In our laboratory, we use a HFB containing freshly isolated rat hepatocytes in suspension
to study the metabolic chiral inversion of ibuprofen (figure 2.7) and the transport mechanism
of magnetic resonance imaging (MRI) contrast agents (chapters 5 and 6). The use of a
hepatocyte HFB to study the chiral inversion of R-ibuprofen permitted to prolong the duration
of the experiment from 4 hours, as done for hepatocytes in conventional suspensions, to
10 hours. This increased duration of experiment, which allows to study the slow
biotransformation reactions, is especially due to a better supply of the hepatocytes with
nutrients and oxygen. It can even be prolonged over several days when hepatocytes are
cultured in adhesion [17,24]. 
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Figure 2.7: Incubation of (-)-R-ibuprofen 48,4 M in a hollow fiber bioreactor (Minikros Sampler
M22M 030 01N, Spectrum, Rancho Dominguez, USA) containing 4·107 hepatocytes/ml:
(-)-R-ibuprofen () and (+)-(S)-ibuprofen (). Modified Hanks's solution was perfused through the
hollow fiber bioreactor at a flow rate of 75 ml/min. Hepatocyte viability was checked during the
experiment by the dosage of the enzymes AST and LDH released [79].
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Hepatocyte HFB offer an interesting tool to study the transport mechanisms of contrast
agents by MRI, because of the high cellular density achievable and the dynamic aspect of the
system. Actually, HFB hepatocyte density can be sufficient to be detected by MRI. Moreover,
the continuous perfusion of the HFB inside the MR magnet permits to continually supply
hepatocytes with a 37°C oxygenated solution. 
During a single experiment, solutions perfused through the HFB can be changed several
times. Consequently, both uptake and excretion mechanisms of several contrast agents can be
investigated successively with the same HFB, reducing the number of experiments and
animals sacrificed.  The uptake is observed during perfusion with a solution containing a
contrast agent, while the excretion is studied during the following perfusion with a solution
free of contrast agent. 
2.6 Conclusion
HFB have several advantages compared to traditional cultures. The tri-dimensional matrix
provides cells with an environment close to the physiological state. The continuous perfusion
of a solution through the HFB continually supplies the cells with nutrients and oxygen. The
semi-permeable membrane of the fibers, which separates physically cells and solution,
protects them from a high shear stress and ensures a stable environment. The big surface of
the fibers allows a high transfer of oxygen, which is particularly important for the survival of
hepatocytes.
This chapter reviewed the design, setup, validation steps and uses of hepatocyte HFB. It
provides future users with the basic knowledge necessary for the development of their own
system. The different designs of HFB were first exposed. The concepts of these designs, in
particular the multiple circuits systems, were developed to avoid the non-uniform cell and
nutrient distribution observed with the simple design first described by Knazek et al. [4]. We
then summarized the different ways of culturing hepatocytes in HFB. Long term culture can
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be obtained when hepatocytes are attached to a support like the HF membrane, microcarriers
or gel embedding, while suspensions of hepatocytes present the advantage of being the
simplest method and yielding a higher cellular density. The importance of the experimental
setup, in particular efficient oxygenation, was underlined. Several tests like the determination
of nutrient consumption, the dosage of substances synthesized by the hepatocytes or the
assessment of the metabolism of test compounds, can be applied to demonstrate that the
developed HFB is able to sustain hepatocyte functionality and viability.
HFB containing immortalized cells derived from hepatocytes are used as culture device for
the synthesis of cellular products like the surface antigen of hepatitis B for vaccine production
or growth factors for the substitution of serum in cell culture solutions. However, the major
use of hepatocyte HFB at the present time is as a BAL, to serve as a bridge to transplantation
for patients suffering from ALF. Currently, several BAL devices including hollow fiber BAL
are undergoing clinical evaluation. These studies suggest that they are safe and may be useful
as a bridge to liver transplantation [32,65,70,71]. Finally, examples of the use of hepatocyte
HFB as a tool for the investigation of drug metabolism were mentioned. Long lasting
experiments can be performed, which permits the study of drugs with slow metabolism.
Moreover, due to the dynamic aspect of the process, continuous measurement and changes in
perfusion solutions become easy. Although having several interesting advantages, the high
costs and the difficulty to set them up probably explain why HFB are not commonly used for
drug metabolism studies. 
Beside HFB, other kinds of hepatocyte bioreactors have been described such as multiplated
hepatocyte monolayers, perfused beds containing suspensions of hepatocytes,
microcarrier-attached or microencapsulated hepatocytes [7,80]. These systems can be used as
the HFB but have the main disadvantage of exposing hepatocytes to high shear forces.
In summary, although being relatively difficult to set up, HFB represent a very attractive
method to cultivate hepatocytes. An environment similar to the physiological one ensures an
optimal viability and functionality of the hepatocytes. HFB can be used for several purposes,
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e.g. for the synthesis of cellular products, as BAL, or as a tool for the study of drug
metabolism and transport.
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Chapter 3
Medical imaging, principles of magnetic resonance imaging
(MRI), MRI of the liver, and MRI contrast agents
3.1 Introduction
During the last years, medical imaging has made incessant progresses. The details and the
resolution which can be obtained permit to visualize the inside of the body with a remarkable
precision. It enables both a better understanding of the anatomy and the detection of diseases.
Hence, imaging is of great importance in the medical diagnostic. 
The purpose of this chapter is to give an overview of magnetic resonance imaging (MRI),
in particular at the level of the liver imaging and with a focus on contrast agents. It intends to
give the basic knowledge necessary for a good comprehension of the experimental work
described in this thesis consisting of the study of the mechanisms of MRI contrast agents
towards hepatocytes.
The chapter begins with an outline of the techniques of medical imaging, including
conventional radiography, computed tomography (CT), ultrasound (US) and the methods
using nuclear medicine, such as scintigraphy and positron emission tomography (PET). The
following section is dedicated to MRI. The principles of nuclear magnetism, relaxation and
signal analysis, as well as the technical equipment and applications are described in more
details. Then, emphasis is put on the MRI of the liver and on the contrast agents used to image
this organ. 
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3.2 Medical imaging
Medical imaging is a diagnostic method which comprises different techniques of imaging.
This section gives an overview of the basis of physics, of the technical aspects and of the
diagnostic applications of the medical imaging techniques commonly used today [1,2]. The
electromagnetic waves used in clinical imaging are presented in figure 3.1.
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Figure 3.1: Electromagnetic spectrum showing the different waves used in clinical imaging. X-rays
are used for conventional radiography and computed tomography (CT), ultrasound (US) waves are
used for ultrasound imaging and radiofrequencies (RF) for magnetic resonance imaging (MRI). 
As can be seen, conventional radiography and CT use ionizing radiations while US and
MRI use non-ionizing radiations [3].
3.2.1 Conventional radiography
Conventional radiography, known to most people as X-ray, is the oldest and most
frequently used technique of medical imaging. For nearly a century, diagnostic images have
been created by passing small, highly controlled amounts of radiation through the body,
capturing the resulting shadows and reflections on a photographic plate. Due to their calcium
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content, bones are the most opaque and thus the most visible tissue on X-ray images. Soft
tissues are less opaque than bones, but more opaque than adipose tissues. Air and gas are
completely radio-transparent. Figure 3.2 shows an example of a conventional radiography.
Figure 3.2: X-ray of an ulna fracture with subsequent immobilization.
A similar imaging method, called fluoroscopy, uses X-rays to capture a moving image of
an organ while it is functioning. It is used in angiography (imaging of the blood vessels) for
diagnostic and interventional procedure (use of imaging to guide percutaneous procedures). 
Conventional radiography is the method of choice for the first line diagnostic of skeletal
pathologies. It is also currently used for imaging lungs and breasts (mammography). The use
of contrast agents, like barium and iodine salts, is often necessary when imaging soft tissues.
For instance, barium sulfate, a non-toxic and very radio-opaque contrast agent administrated
orally or in enema, is employed when imaging the gastrointestinal tract. 
Chapter 3 50
3.2.2 Computed tomography 
Computed tomography (CT, “scanner X” in French) exists since 1975. It consists of a tube
of X-rays which turns around the patient. The film of the regular radiography is replaced by
numerical sensors and the image of cross-sections of body tissues and organs is built by
computerized methods. CT scanning provides more detailed information than conventional
radiography. It can show bone, soft tissues, and blood vessels in the same images with great
differentiation and clarity (figure 3.3).
Figure 3.3: Computed tomography of a renal cell carcinoma.
Nowadays, CT encroaches on all fields of regular radiography, because of its better tissue
differentiation. CT is widely used for imaging all the body parts. As for conventional
radiography, the use of oral or rectal contrast agents, like barium and iodine salts, is necessary
for imaging the gastrointestinal tract. Contrast agents can also be injected intravenously to
increase the soft tissue differentiation. Despite its large medical applications, CT is now in
competition with MRI.
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3.2.3 Ultrasound 
Ultrasound (US, sonography or ultrasonography) imaging appeared in the 60's. It is a
method of imaging using high-frequency sound waves of frequencies ranging from 3 to
10 MHz. These waves are more or less reflected according to the different organic elements
encountered and the sound waves reflected are recorded and displayed as a real-time image.
No ionizing radiation is involved in ultrasound imaging.
US is a useful way of examining many of the body’s internal organs, including the heart,
liver, gallbladder, spleen, pancreas, kidneys, and bladder. And of course, pelvic ultrasound
examinations of the uterus and fetus are the method of choice to detect eventual fetus
malformations. Because US images are captured in real-time, they can show movement of
internal tissues and organs, and enable physicians to see blood flow and heart valve functions.
This can help to diagnose a variety of heart conditions and to assess damage after a heart
attack or other illness. It is also used for interventional imaging. Ultrasound is now being used
for abdominal imaging, to image the breasts and to guide biopsy of breast cancer. US
interpretation is difficult and requires a good training, as can be seen in figure 3.4.
Figure 3.4: Ultrasound of the gallbladder with sludge and calculi.
Chapter 3 52
Ultrasound waves are totally reflected by bones and gas. Thus US can not be used to image
the adult skeleton or lungs. For the same reason, a gel is applied on the imaged area prior to
apply the probe to avoid the presence of air bubbles.
Since the past decade, US contrast agents have been used to enhance ultrasonic signals.
They improve the detection of flow within abnormal vessels, including tumor vascularization
and stenotic vessels. They also hold promise for increasing the accuracy of US in the
assessment of focal parenchymal disease [4]. At the present time, research is performed to
allow detection of tissue enhancement similar to that obtained with CT or MRI.
3.2.4 Nuclear medicine
Nuclear medicine uses radioactive isotopes as a source of radiation. The medical
applications of isotopes are based on the fact that biological systems, like the human body, do
not distinguish between an isotope and a normal atom. Components marked with isotopes
behave in the body like their natural equivalent, which permits to follow them with radiation
detectors.
3.2.4.1 Scintigraphy 
Scintigraphy (or gamma scintigraphy) uses radioactive isotopes which emit gamma rays. A
gamma detector permits to follow the isotope transit in the body. Images obtained with
scintigraphy have a low resolution but give useful functional information, in particular when a
dynamic scintigraphy is performed.
The application of scintigraphy is large, its indications are notably the detection of tumors
in the brain, the liver and the lungs. An example of scintigraphy is shown in figure 3.5.
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Figure 3.5: Scintigraphy of the gastrointestinal tract showing the gastrointestinal transit.
3.2.4.2 Positron emission tomography
Positron emission tomography (PET) is a diagnostic examination that involves the
development of biologic images based on the detection of positrons. The positrons are emitted
from a radioactive substance given to the patient. The subsequent views of the human body
are used to quantitatively evaluate metabolic activities of different organs with a good
resolution.
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Figure 3.6: Positron emission tomography of a normal (left) and injured (right) brain.
Specifically, PET scans are used to detect cancer and to examine the effects of cancer
therapy by characterizing biochemical changes with the cancer. These scans are performed on
the whole body. PET scans of the heart can be used to determine the blood flow to the heart
muscle and help to evaluate signs of coronary artery disease. Combined with a myocardial
metabolism study, PET scans differentiate non-functioning heart muscle from heart muscle
that would benefit from a procedure, such as angioplasty or coronary artery bypass surgery,
which would re-establish adequate blood flow. PET scans of the brain (figure 3.6) are used to
evaluate patients who have memory disorders of an undetermined cause; who have suspected
or proved brain tumors; or who have seizure disorders that are not responsive to therapy, and
therefore, are candidates for surgery.
PET units are one of the most expensive installations of imaging. The reconstruction of the
image requires an electronic equipment of high performance and powerful computers, and a
cyclotron is necessary to produce the radio-labeled substances.
3.3 Magnetic resonance imaging
In 1946, Block and Purcell received the Nobel Prize for their observations on nuclear
magnetic resonance (NMR). NMR became a useful tool for the investigation of the structure
of organic molecules. It is only in the 70's that, thanks to the computer science progress, NMR
could be applied to the diagnostic imaging.
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3.3.1 Principle
3.3.1.1 Nuclear magnetism
Certain atomic nuclei that have unpaired protons or neutrons possess an intrinsic spin,
generating a small magnetic field, analogous to a microscopic bar magnet. The most abundant
of the naturally spinning nuclei in the body is the hydrogen nucleus or proton, which
represents 63% of the body atoms. Other nuclei that possess spin but are much less abundant
include 23Na, 31P, and 13C. If such randomly oriented spinning nuclei are placed within a static
magnetic field B0, they align parallel or antiparallel with the magnetic field. There is a small
excess of protons which tend to align in the lower energy parallel orientation. This creates a
resulting longitudinal magnetization in line with B0, which can be represented by a
magnetization vector M0 (figure 3.7). It is upon this small excess that NMR signals depend.
The spinning protons wobble about the axis of the main magnetic field at a rate given by the
Larmor frequency. These two motions of the proton have different rates: the precessional
motion is slow relative to the faster spinning motion.
Figure 3.7: At equilibrium, the net magnetization vector lies along the direction of the applied
magnetic field B0 and is called the equilibrium magnetization M0 [3].
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3.3.1.2 Relaxation
When a radiofrequency (RF) field is applied perpendicular to B0 at the same frequency as
the precessing nuclei, it excites protons in the lower energy level into a higher energy state.
The longitudinal magnetization is tipped out of its equilibrium position to a specific angle
called flip angle (FA). Various flip angles can be obtained by varying the duration or the
amplitude of the RF pulse. A 90° flip angle tips the longitudinal magnetization in the
transverse plane. The energy adsorbed during this transition is subsequently released as
electromagnetic waves to the environment as the protons relax back to their lower energy
state and equilibrium (resonance phenomenon). This release of energy can be recorded as an
electrical signal. The relaxation of the proton back to equilibrium is termed longitudinal
relaxation. It is an exponential increase process and has a time constant referred to as T1,
which is the time needed by the magnetization to recover 63% of the longitudinal
magnetization. Figure 3.8 describes the evolution of the magnetization after a 90° RF pulse.
Immediately after the RF pulse is applied, the excited protons precess together, in phase with
each other, at the resonant frequency. During relaxation, however, they quickly get out of
synchronism due to small variations in local magnetic fields that results in energy dissipation
between spins. This loss of phase is termed transverse relaxation. It is an exponential decay
process and possesses the time constant T2, which is the time needed for the dissipation of
63% of the transverse magnetization.
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Figure 3.8: After a 90° RF pulse, the longitudinal magnetization M0 is tipped in the transverse plane.
The T1 or longitudinal relaxation describes the evolution of the magnetization back towards M0. T1 is
the time needed by the magnetization to recover 63% of M0 [5].
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3.3.1.3 Signal analysis
As the transmitted RF pulse and the MR signal take place at different times, the RF coil
can act as both transmitter and receiver. The strength of radio waves or degree of whiteness or
blackness (signal intensity) depends principally on four tissue factors, namely proton density,
flow, T1 and T2 relaxation values as well as on pulse repetition time (TR), echo delay time
(TE), and inversion time (TI) which are imaging parameters controlled by the operator.
Proton density is the number of resonating hydrogen nuclei present in a particular volume of
tissue following application of an RF pulse. In tissue, the concentration of such protons is
related primarily to water content and secondarily to lipid content. Since signal intensity (SI)
is directly proportional to the proton density, gas and cortical bone demonstrate extremely low
SI (appearing black). Flow is a function of the speed at which hydrogen atoms move through
the region being imaged, and the percentage of protons in the region that are moving. Flowing
blood can appear black, white or any shade of gray depending on various factors. The
relationship of these four factors to SI is simply described in table 3.1.
Table 3.1: Relationship of proton density, T1, T2 and blood flow to signal intensity [6].
Signal intensity Proton density T1 T2 Blood flow
High (white) High Short Long Stationary, slow
Low (black) Low Long Short Turbulent, fast
The conventional RF pulse sequences used in imaging are total or partial saturation
recovery (SR), inversion recovery (IR), gradient echo (GRE) and spin echo (SE). These
sequences give different weighting in the received signal to proton density, T1 and T2. SR
gives a similar weight to these three parameters, while IR emphasizes T1 [6]. According to the
parameters TE and TR selected, GRE or SE images can be either proton density-weighted,
T1-weighted or T2-weighted.
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Magnetic resonance produces images of a slice through the human body. Each slice is
composed of several volume elements or voxels.  The volume of a voxel is approximately
3 mm3. The magnetic resonance image is composed of several picture elements called pixels.
The SI of a pixel is proportional to the SI of the contents of the corresponding voxel of the
object being imaged. 
A gradient system is used to generate small magnetic fields that are added to the main field
to select slices and to localize the signal. Data analysis is made by a computer, using the
Fourier transform.
3.3.1.4 Technical equipment
Magnetic resonance systems for clinical use include a magnet, RF coils, gradient coils, a
computer, a display unit, and digital storage facilities. 
The magnet produces the B0 field for the imaging procedure. There are currently three
main types of magnets used in MRI: permanent magnets, resistive magnets, and
superconducting magnets. While the first two types of magnets can generate a maximum
magnetic field of 0.3 to 1.0 Tesla (T), the super conducting magnet produces a higher field
strength of 0.5 to 4 T.  Such homogenous high field strength permits the production of high
quality images, but requires liquid helium and nitrogen to keep the electric resistance near
zero (4°K). 
The RF coil produces the RF necessary to excite the protons in the body and also detects
the signal from the spins within the body. There are two broad categories of RF coils used in
imaging. The volume coils (e.g. body, head or wrist coils) are most commonly used. They
completely surround the part of the body being imaged, and receive the same amount of
signal from deep and superficial tissues. The second type consists of surface coils which are
used to obtain high-resolution images of relatively superficial body structures.
The gradient system within the magnet consists of a set of gradient coils, covering each
dimension. They are resistive electromagnets that can be switched on and off and varied
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rapidly and precisely. This permits the selection of tissue slices in transverse, coronal, or
sagittal planes.
The scan room is surrounded by an RF shield. The shield prevents the high power RF
pulses from radiating out through the hospital. But it also prevents the various RF signals
from television and radio stations to be detected by the imager. The heart of the imager is the
computer, which controls all components on the imager.
3.3.2 Application and safety
Images obtained with MRI are remarkably good, as can be seen in figure 3.9. Tissue
discrimination is superior with MRI than with CT and all planes can be imaged, while CT
permits only to get transverse planes. MRI is widely applied, although the method is more
limited for the imaging of moving regions because the acquisition of the image takes a few
minutes. Nowadays, MRI is applied for a broad range of conditions in all parts of the body
including the intestines, kidneys, liver, heart, vascular system, head, spinal cord, bones and
joints. Contrast agents can be used to improve tissue discrimination. They are discussed in
detail in section 3.4. 
Chapter 3 61
Figure 3.9: Magnetic resonance imaging of head and neck.
MRI is safe, as US it does not use ionizing waves. Nevertheless, MRI is unsuitable for
some people who have metallic implants, or pacemakers, actually, the latter can act as a RF
receptor or be unintentionally activated by the magnetic field.
The constraints to MRI are in particular financial, a MRI system costs about 3 millions
CHF and an single exam about 800.- CHF, but also technical, as the system is heavy and
needs a lot of place.  
3.4 MRI of the liver
MRI is probably more advantageous to characterize hepatic lesions than CT scans, because
of its lack of ionizing radiation, safety of gadolinium chelates in comparison to iodinated
contrast agents and accuracy of the imaging. Nevertheless, CT remains the modality of choice
at many institutions due to the speed of acquisition, good resolution and the clinical
availability. 
MRI enables an accurate evaluation of a wide variety of focal and diffuse hepatic diseases,
although most imaging of the liver is performed to evaluate focal diseases.
3.4.1 Focal hepatic diseases
Liver cancers affect literally millions of people each year, hepatocellular carcinoma being
one of the most frequent cancers worldwide. Additionally, the liver is the most common organ
of the body to which cancer spreads from primary disease elsewhere. Accurate lesion
detection and characterization is therefore necessary to ensure appropriate management of
patients with liver cancer. One can distinguish two kinds of diagnoses: invasive and non-
invasive procedures.
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Invasive procedures include intraoperative ultrasonography, CT angio-portography, and
CT after intra-arterial injection of iodized oil. These diagnostic methods are considered as
having the highest sensitivity for the detection of focal liver lesions. Nevertheless, they are
clinically limited, mainly because of the risk and cost induced by the invasiveness. 
Most of the liver cancer patients undergo non-invasive diagnostic imaging, consisting of
ultrasonography and CT, despite the fact that the false-negative rate of these methods is
known to exceed 40% [7]. MRI is mostly applied as a diagnostic adjunct in cases where
ultrasonography and CT do not clarify the situation thought it is reported to have a similar or
even higher sensitivity for the detection of liver lesions. Unenhanced MRI also misses
35-40% of liver lesions, due to the fact that the liver and tumors within it often have similar
signal intensity. The use of contrast agents can be used to increase the contrast difference
between the liver and its lesions (figure 3.10).
Figure 3.10: Magnetic resonance imaging of a liver with metastases. Above are shown multiple MR
images after a contrast agent was injected (gadolinium based). Multiple small nodules are now seen
diffusely throughout the liver, some of which are indicated by the lines.
Chapter 3 63
3.4.2 Diffuse hepatic diseases
Nowadays, tests commonly used to assess liver function determine either the metabolic
capacity of the liver with indocyanine green, galactose and lidocaïne as test compounds or the
capacity of the liver to synthesize blood products, like cholinesterase, albumin, or coagulation
factors [8]. 
MRI is used for the detection and characterization as well as follow-up of diffuse liver
entities, such as fatty liver, hemochromatosis, and cirrhosis, obviating the need for biopsy in
many cases. It allows the diagnosis of fatty liver, and the quantification of the hepatic fat
content. This feature may be clinically useful in the evaluation of patients with metabolic and
hepatotoxic conditions [9]. MRI is a sensitive and specific technique for identifying hepatic
iron deposition, also allowing the characterization of its distribution. Patients with
hemochromatosis or cirrhosis have an increased risk for hepatocellular carcinomas. 
3.5 MRI contrast agents
MRI contrast agents are substances with magnetic properties which are used to improve
tissue discrimination. They are intravenously administered to patients during the MRI exam.
Their indication includes lesion characterization and detection as well as angiographic MR
sequences. This section begins with the description of the effects of contrast agents on the MR
signal. Then, the different categories of contrast agents used for MRI of the liver such as
nonspecific extracellular gadolinium chelates, hepatobiliary and reticuloendothelial system
(RES) contrast agents are discussed. Finally, the hepatic transporters suspected to play a key
role in the transport of hepatobiliary contrast agents are introduced. 
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3.5.1 Effect of contrast agents on the MR signal
As already discussed in section 3.3.1.3, the contrast of MR images depends on the tissue
characteristics (proton density, T1 and T2) and on the parameters of the sequences. The
mechanism of action of MR contrast agents is indirect: they exert their effects by shortening
the relaxation times T1 and T2 for protons that surround the molecule of the contrast agent. In
other words, they increase the relaxation rates 1/T1 and 1/T2, which either enhances or
diminishes the signal intensity.
The relaxation rates observed (1/T1 and 1/T2) are the addition of the intrinsic rate of the
tissues and of the rate due to the contrast agent, as expressed by equation 3.1 [10]:
1/T observed = 1/T intrinsic + 1/T contrast agent [Equation 3.1]
3.5.1.1 Concentration of contrast agent and relaxation rate
The effect of the contrast agent on the relaxation rate is linearly correlated to its
concentration, according to equations 3.2 and 3.3.
1/T1 = 1/T1(0) + (r1·c) [Equation 3.2]
1/T2 = 1/T2(0) + (r2·c) [Equation 3.3]
These relations permit to determine, under fixed conditions (magnetic field, temperature,
dilution solution), the r1 and r2 relaxivities, defined as the slope of the straight lines obtained
by plotting the relaxation rates 1/T1 and 1/T2 as a function of the concentration of contrast
agent (figure 3.11).
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Figure 3.11: Plot of the relaxation rate 1/T1 and 1/T2 as a function of the contrast agent concentration.
3.5.1.2 Relaxation rates and contrast agent classes
Two classes of contrast agents are used: the paramagnetic and the superparamagnetic
contrast agents. The effect of these two classes on the MR signal at usual doses is globally
opposed. 
A macroscopic magnetization appears when paramagnetic agents are placed in a magnetic
field. They are composed of chelates of the paramagnetic metals gadolinium (Gd3+) or
manganese (Mn2+). Chelation of Gd3+ and Mn2+ is necessary to decrease the high acute
toxicity of the free metal ions. The r1 and r2 relaxivities of paramagnetic contrast agents are in
the same range of values. Hence, they decrease both T1 and T2. As T1 of the tissues is much
higher than T2 (about 10 times), the T1 effect predominates the T2 effect. The decrease of T1
produces an enhancement of the MR signal intensity on T1-weighted sequences. For this
reason, these contrast agents are called positive or T1-enhancing agents.
Superparamagnetic agents are substances which have a permanent macroscopic
magnetization. They are composed of iron oxide nanoparticules [11]. As their r2 relaxivity is
very high and preponderant over the r1 relaxivity, the T2 effect predominates the T1 effect. The
decrease of T2 diminishes the MR signal intensity on T2-weighted but also to some extent on
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T1-weighted sequences. This class of contrast agents that decrease T2 are called negative or
T2-enhancing agents.
3.5.1.3 Effect of the concentration of contrast agent on the MR signal
Although the relation between the relaxation rate and the concentration is linear, the MR
signal is not linearly correlated to the concentration of contrast agent. Actually, the signal
intensity is related to T1, T2 and the parameters of the data acquisition sequence by a
nonlinear function. For instance the spin-echo sequence, which is commonly used in MRI, is
described by equation 3.4, where s is a constant depending on the sensitivity of the signal
detection of the scanner,  expresses the spin density, TR and TE are the repetition and echo
times.
SI = s ·  · (1-exp(-TR/T1)) · exp(-TE/T2) [Equation 3.4]
In this sequence, the signal is weighted by T1 and T2 in an opposite manner. Thus, a decrease
of T1 induces an increase of SI as long as the decrease of T2 is not too important to diminish
considerably the signal intensity. 
Hence, the conversion of the MR signal into contrast agent concentration, which is useful
for the quantification of tissue perfusion or for a pharmacokinetic analysis, is not trivial. In
the first step, the MR signal has to be converted into 1/T1 or 1/T2, which requires a signal
calibration for each sequence used. In the second step, 1/T1 or 1/T2 has to be converted into
the contrast agent concentration according to the linear relation existing between these
parameters. 
3.5.2 Contrast agents used for the MRI of the liver
Regarding their target tissue, contrast agents used for the MRI of the liver can be divided
in two main categories: nonspecific extracellular and hepatospecific intracellular contrast
agents. The later can be further subdivided in hepatobiliary and reticuloendotelial system
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(RES) contrast agents. The different types of contrast agents and their distribution are
presented schematically in figure 3.12.
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Figure 3.12: Hepatic distribution of the MRI contrast agents [11].
3.5.2.1 Nonspecific extracellular contrast agents
There are several nonspecific extracellular gadolinium chelates available on the market:
Gd-DTPA, Gd-HP-DO3A, Gd-DOTA and Gd-DTPA-BMA, Gd-DTPA-BMEA, and
Gd-DO3A-butriol. Their generic and trade names are listed in table 3.2. They are of relatively
small molecular weight (<1000 Dalton) and follow the same kind of kinetics. They diffuse
freely into and out of the interstitial space of the liver and are excreted exclusively by the
kidneys. They improve tissue differentiation between normal parenchyma and tumors because
of the differences in perfusion, capillary permeability and interstitial leakage of normal and
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tumoral tissue [11]. They have no protein binding and are not metabolized [12]. Besides liver
enhancement, gadolinium chelates are able to detect blood-brain barrier (BBB) defects,
myocardial infarction and vascular disorders.
Table 3.2: Classification of some resonance magnetic contrast agents approved, or to be approved, for
clinical use.
Short name Generic name Trade name Firm
Extracellular contrast agents
Gd-DTPA Gadopentetate
dimeglumine
Magnevist Schering AG, Berlin,
Germany
Gd-HP-DO3A Gadoteridol ProHance Bracco SpA, Milan,
Italy
Gd-DOTA Gadoterate Dotarem Guerbet, Aulnay-sous-
Bois, France
Gd-DTPA-BMA Gadodiamide Omniscan Nycomed, Oslo,
Norway
Gd-DTPA-BMEA Gadoversetamide Optimark Mallinckrodt, St.Louis,
USA
Gd-DO3A-butriol Gadobutrol Gadovist Schering AG, Berlin,
Germany
Reticuloendothelial  system contrast agents
AMI-25 Ferumoxides Endorem / Feridex Advanced Magnetics,
Cambridge, USA
SH U 555 Ferucarbotran Resovist Schering AG, Berlin,
Germany
AMI-227 Ferumoxtran Sinerem / Combidex Advanced Magnetics,
Cambridge, USA
Hepatobiliary contrast agents
Mn-DPDP Mangafodipir trisodium Teslascan Nycomed, Oslo,
Norway
Gd-BOPTA Gadobenate
dimeglumine
MultiHance Bracco SpA, Milan,
Italy
Gd-EOB-DTPA Gadoxetic acid Eovist Schering AG, Berlin,
Germany
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3.5.2.2 Hepatospecific intracellular contrast agents
A variety of hepatospecific contrast agents have been developed for contrast-enhanced MR
imaging of the liver. They have been targeted either to hepatocytes (hepatobiliary contrast
agents) or to phagocytic reticuloendothelial system cells such as Kupffer cells (RES contrast
agents) [13]. 
3.5.2.2.1 Reticuloendothelial system contrast agents
Reticuloendothelial system (RES) contrast agents consist of coated crystalline
superparamagnetic iron oxide particles of 30 to 150 nm diameter, also called SPIO or MION
particles. The coating of anchored surface molecules, usually a polysaccharide like dextran,
stabilizes the particles in aqueous colloïdal solution. 
Three iron oxide contrast agents have reached the commercial status: 
AMI-25 is a SPIO colloid with low molecular weight dextran coating, resulting in a particle
size of 50  19 nm as determined by electron microscopy and 120 to 180 nm by
photocorrelation spectroscopy.
SH U 555 is a SPIO colloid with carboxydextran coating, the resilatant microparticles having
a mean hydrodynamic diameter of 61 nm and
AMI-227 is a USPIO (ultrasmall SPIO) consisting of a 5 nm-diameter iron oxide core covered
with T10 dextran, yielding a particle with a mean diameter of 17 to 20 nm.
Their generic and trade names are listed in table 3.2.
RES contrast agents are cleared from the blood by phagocytosis by the reticuloendothelial
system, so that uptake is observed in particular by Kupffer cells in the liver [11], but also in
the spleen, lymph nodes, and bone marrow [9]. Iron oxide particles increase the sensitivity of
MR imaging for the detection of lesions located in those tissues. Most focal liver lesions,
particularly metastases, are composed of tissue without Kupffer’s cells or without the capacity
to take up particles. As a result, the contrast between lesion and liver is increased.
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After the uptake of the RES contrast agents into phagocytic cells by receptor mediated
endocytosis, they are transported to the lysosomal compartment where final breakdown
appears to occur. From there, elemental iron is slowly released and subsequently used for
hemoglobin synthesis [14].
3.5.2.2.2 Hepatobiliary contrast agents 
Hepatobiliary contrast agents are soluble paramagnetic molecules taken up in hepatocytes
and partially excreted into the bile. The property of being specifically taken up by functional
hepatocytes gives these contrast agents a dual imaging capability: as extracellular agents, and
as liver-specific agents whose properties permit an improved lesion to liver contrast.
Hepatocyte-directed MRI contrast agent enter the hepatocytes and generate a high and long
lasting contrast-to-noise ratio that significantly increases the sensitivity of MRI for the
detection of focal and diffuse liver impairment. As they are eliminated in part through the
biliary system, they permit evaluation of hepatocyte function, of the liver excretory function
and of the appearance and integrity of the biliary tree. Intracellular uptake is a specialized
function of hepatocytes lacking in other tissues, such as metastases. 
There are essentially two types of hepatobiliary agent: the manganese-based and the
gadolinium-based agents. Generic and trade names are listed in table 3.2.
Manganese-based contrast agents
Mn-DPDP is the only commercially available example of a manganese-based contrast
agent. The dissociation of Mn-DPDP to free manganese ions (Mn2+) and free DPDP ligands
occurs primarily in the liver, whereas a minor portion of the dissociated Mn2+ found in the
liver comes from dissociation of the complex in the blood. Most of the dissociated Mn2+ in the
liver becomes bound to macromecules and is responsible for the enhancement of the
relaxivity observed with this agent [15].
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The uptake mechanism of Mn-DPDP still remains unknown. Mn-DPDP is related
synthetically to the vitamin B6 analogue pyridoxal phosphate, a biochemical similarity that
suggests that Mn-DPDP exploits the vitamin B6 pathway of uptake into hepatocytes [16,17].
But other authors affirm that the vitamin B6 carrier is not involved in the uptake of the
paramagnetic complex [18,19]. The uptake of the free Mn2+ resulting from the minor
decomplexation in the blood could be ascribed to the presence of a selective transporter for
this cation. The uptake of the complex is hypothetical: passive diffusion through the
membrane or nonspecific uptake by an anion transporter.
The amount of Mn2+ excreted into the bile represents 22-47% of the total dose in rats [20],
and 50-60% [21] in humans, the remaining of the dose being excreted through the kidneys.
None of the references cited mentioned the mechanisms involved in the excretion of Mn2+
into the bile.
Gadolinium-based contrast agents
There are two commercial examples of hepatobliary gadolinium-based contrast agents:
Gd-BOPTA and Gd-EOB-DTPA. Both have the same basic Gd-DTPA structure into which a
lipophilic moiety has been introduced (figure 3.13). 
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Figure 3.13: Chemical structure of the extracellular MRI contrast agent Gd-DTPA, and the
hepatospecific contrast agents Gd-BOPTA and Gd-EOB-DTPA. 
An increased liver distribution space compared to that available for purely extracellular
fluid contrast agents appears to be the main mechanism behind the enhancement of normal
parenchymal signal intensity by hepatospecific gadolinium chelates. Microviscosity effects
inside hepatocytes and, to a lesser extent, affinity for intracellular macromolecules may also
add to their relaxation effectiveness. Gd-BOPTA and Gd-EOB-DTPA have a weak affinity
for proteins [12,22,23] and undergo no biotransformation [23,24] .
The transport of the hepatospecific contrast agents Gd-BOPTA and Gd-EOB-DTPA into
rat hepatocytes has not been fully elucidated (table 3.3). Some authors suggest a transport
through passive diffusion [25], while others evoke that Gd-BOPTA is transported by the
specific organic anion transporting polypeptide OATP1/oatp1 [26]. The possible inhibition by
bromosulfophtalein (BSP) is debated, too.
Table 3.3: Study of the uptake mechanisms of Gd-BOPTA and Gd-EOB-DTPA.
Experimental models Gd-BOPTA Gd-EOB-DTPA References
Rats Partial inhibition by
BSP
Not studied De Haën, 1995 [27]
Phospholipid
monolayers
No transport 
No passive diffusion
No transport 
No passive diffusion
Moncelli, 1998 [28]
Rat sinusoidal
membrane vesicles
Passive diffusion
Not inhibited by BSP
Passive diffusion
Not inhibited by BSP
Pascolo, 1999 [25]
Oocytes transfected
with human OATP
cRNA
No transport No transport Pascolo, 1999 [25]
Van Montfoort,
1999 [26]
Oocytes transfected
with rat oatp1 cRNA
Not studied Oatp1 mediated
transport inhibited by
BSP, taurocholate
rifamycin and
rifampicin 
Van Montfoort,
1999 [26]
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Table 3.4: Summary of the properties and pharmacokinetic parameters of the different categories of contrast agents used for MRI of the liver [17].
Extracellular Gd3+ RES contrast Hepatobiliary contrast agents
chelates agents Gd-BOPTA Gd-EOB-DTPA Mn-DPDP
Target tissue Blood / interstitial space RES Hepatocytes Hepatocytes Hepatocytes 
Typical dose [mol/kg] 100 10-15 50-500 30-100 3-10
Uptake transport No Phagocytosis OATP1/oatp1? OATP1/oatp1? Vitamin B6 transporter ?
Excretion transport No No MRP2/mrp2 MRP2/mrp2 ?
Plasma half-life [min] 10 10 15 10 120
Elimination route 100% renal 100% iron
metabolism
Hepatobiliary:
Rat: 44 - 52%
Human: 2-7% 
Hepatobiliary:
Rat: 63-80%
Human: 50% 
Hepatobiliary:
Rat: 22-47%
Human: 50-60%
Protein binding No Nf Weak affinity for
albumin 
10-17% to plasma
proteins
Mn2+ complexes: no
Mn2+: yes
Biotransformation No Iron metabolism No No In vivo dissociation to
Mn2+ and DPDP  
Imaging properties T1 enhancement T2, T1 enhancement T1 enhancement T1 enhancement T1 enhancement
References are found in the text related to each contrast agent (? = not fully understood, Nf = not found in the literature)
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The excretion of Gd-BOPTA and Gd-EOB-DTPA into the bile occurs via the multidrug
resistance-associated protein MRP2/mrp2 at the canalicular side of the hepatocyte [22,29-31]
and is highly dependant on the species. In the rat, 44-52% of the dose of Gd-BOPTA is
excreted into the bile, whereas this percentage is only 2-7% in humans [24,25] . In the case of
Gd-EOB-DTPA, 63-80% of the dose is excreted in the bile in rats [20] and about 50% in
humans [16].
To summarize, table 3.4 provides a comparative compilation of properties and
pharmacokinetics of the different categories of contrast agents used for MRI of the liver. 
3.5.3 Hepatic transporters 
The liver plays the principal role in the clearance and metabolism of endogenous and
xenobiotic substances. Following uptake into the hepatocytes, compounds undergo
biotransformation and are subsequently eliminated from the liver cell via excretion into the
bile or via transport back to the sinusoid (figure 3.12). Thus, there are several kinds of
transporters present in the hepatocyte membrane. In this section, we will focus on the
transporters involved in the transport of bile acids, in particular the OATP and MRP families,
as they are known or suspected to play a key role in the transport of hepatobiliary contrast
agents.
Table 3.5 summarizes the OATP/oatp and MRP/mrp transporters expressed in the liver,
with respect to their tissue distribution, function, substrates and modulation of their
expression. As a convention, capital and small letters are used when referring to human and
rat, respectively. Differences between species exist in terms of the amino acid sequence of
transporters. Some transporters have their orthologue in rats and in humans, others not.
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Table 3.5: Characteristics of OATP/oatp and MRP/mrp transporters of the hepatocyte
membrane [32,33].
Transporter Tissue distribution Function and substrates Expression
Rat
oatp1 liver (sinusoidal),
kidney, brain
entry of bile acids and organic
anions, BSP, steroids, ouabain,
temocaprilat, Gd-BOPTA?,
Gd-EOB-DTPA? 
 cholestase
oatp2 liver (sinusoidal),
kidney, brain
entry of bile acids, digoxin, T4,
temocaprilate
oatp3 liver, brain, kidney entry of bile acids
oatp4 liver (sinusoidal) entry of bile acids, bilirubin
monoglucuronide, conjugated
steroids, T4, peptides
mrp1 liver (sinusoidal) export of organic anions and di-
anionic bile salts, glucuronide and
glutathione conjugates
 endotoxaemia
mrp2 liver (canalicular),
kidneys
export of glucuronide and
glutathione conjugates, Gd-
BOPTA, Gd-EOB-DTPA
mrp3 liver (sinusoidal),
cholangiocytes
export of organic anions and di-
anionic bile salts, monovalent bile
acids, glucuronide and glutathione
conjugates
 in EHBR (mrp2 defect)
and cholestasis
Human
OATP-A liver (sinusoidal?), lung,
kidney
entry of bile acids and organic
anions
OATP-C liver (sinusoidal) entry of bile acids and organic
anions, bilirubin
monoglucuronide, conjugated
steroids, T4, peptides 
OATP-8 liver (sinusoidal) entry of bile acids and organic
anions, BSP, digoxin
MRP1 liver (sinusoidal) export of organic anions and di-
anionic bile salts, glucuronide and
glutathione conjugates
 in proliferation cells
MRP2 liver (canalicular),
kidneys
export of conjugated bile acids,
conjugated bilirubin, and organic
anions, glucuronide and
glutathione conjugates, Gd-
BOPTA, Gd-EOB-DTPA
MRP3 liver (sinusoidal),
cholangiocytes,
enterocytes
export of conjugated bile acids,
glucuronide and glutathione
conjugates
 in Dubin-Johnson
syndrome (MRP2 defect)
and cholestasis
BSP: bromosulfophtalein, T4: thyroxine, EHBR: Eisai hyperbilirubinaemic rats, ?: not fully understood
Chapter 3 77
3.5.3.1 Organic anion-transporting polypeptide
The organic anion-transporting polypeptides are members of a growing family that
mediates the Na+-independent uptake of many amphiphatic compounds, including conjugated
and unconjugated bile acids [34]. Other substrates include cardiac glycosides, steroids,
peptides, and selected organic cations [33].
At the present time, four rat oatps (oatp1, oatp2, oatp3 and oatp4) and 3 human OATPs
(OATP-A, OATP-C, and OATP-8) have been localized in the liver for which bile salts are
substrates. Beside their expression in the liver, some of them are found in other tissues.
OATPs/oatps can function as bidirectional transporters [32]. Under these conditions, they
could take part in the efflux of bile salts at the sinusoidal membrane when accumulation
occurs in hepatobiliary diseases [33]. The hepatobiliary MRI contrast agents, Gd-BOPTA and
Gd-EOB-DTPA, appear to be specific oatp1 substrates [26].
3.5.3.2 Multidrug resistance proteins
Multidrug resistance proteins are "Traffic ATPases" belonging to a superfamily of proteins
found in all cellular organisms and characterized by an ABC (ATP-binding cassette) in their
primary structure.
The first member of the MRP family, MRP1, was cloned from a multidrug resistant human
lung cancer cell line. Since then, at least five further members have been identified. MRP2 is
localized at the canalicular domain of hepatocytes and exports a range of organic anions. That
is why it is also called canalicular multispecific organic anion transporter (cMOAT). A
mutation in the MRP2 gene is the basis of the Dubin-Johnson syndrome, a liver disorder
characterized by chronic conjugated hyperbilirubinemia. Eisai hyperbilirubinaemic rats
(EHBR) have an equivalent mrp2 defect. A third MRP member, MRP3/mrp3, is found in the
liver. Both MRP1/mrp1 and MRP3/mrp3 are expressed at the basolateral surface of normal
hepatocytes, but at very low levels. They are able to export bile acids at the basolateral
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surface of hepatocytes. Gd-BOPTA and Gd-EOB-DTPA are known to be excreted into the
bile via mrp2 [29,30] .
3.5.3.3 Expression in injured livers
Some diseases can modify the expression of certain hepatic transporters (table 3.5). For
instance, oatp1 is down regulated in experimental cholestasis, induced either by a bile duct
ligation or by endotoxin [32]. MRP1 is upregulated in the endotoxaemic rat liver. MRP3 is
induced in patients with the Dubin-Johnson syndrome and in primary biliary cirrhosis. Rat
mrp3 is similarly induced in livers of EHBR rats and in experimental cholestasis. The
inducible nature of MRP1 and MRP3 and their location at the basolateral surface of
hepatocytes may explain the shift towards renal excretion as the major mechanism for bile
acid elimination in patients with some forms of cholestasis. 
According to these changes in the expression of receptors induced by definite diseases,
hepatospecific contrast agents are expected to modify their distribution in the presence of
hepatic diseases. The resulting change in the liver MRI signal enhancement has a potential to
evaluate the hepatic function. 
3.6 Conclusion
This chapter underlines the fact that powerful techniques of medical imaging are now
available. These techniques permit to get very useful information about the inside of the body
and to distinguished pathologies, which could otherwise not be detected. In particular, MRI
enables to obtain a very high degree of anatomic precision without the use of ionizing
radiation and, despite a high cost, its use is now spreading over the world.
The section dealing with the contrast agents used for MRI of the liver emphasizes that the
mechanisms of action of some contrast agents, in particular hepatobiliary contrast agents, are
still not fully understood. A better understanding of the mechanisms of action of these
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contrasts agents as well as how these mechanisms are altered in focal and diffuse hepatic
diseases could constitute a supplementary useful tool in MRI diagnostics. These reflections
were taken as a basis for the initiation of the project of this thesis and thus, the experiments
described in the following chapters.
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Chapter 4
Isolation and preservation of hepatocytes
4.1. Introduction
The aim of this work was to define a procedure to enable us to keep freshly isolated
hepatocytes alive, without loss of viability and function, for a long period of time. Actually, it
is difficult to maintain durably the viability and functionality of freshly isolated hepatocytes.
Hepatocytes maintained in suspensions are known to have a survival span of only about
4 hours [1]. To perform experiments with hepatocyte hollow fiber bioreactors (HFB), a large
supply of hepatocytes was needed, which implied more than one liver isolation procedure and
preservation of hepatocytes since experiment could not be performed immediately after
isolation. Hence, it was imperative to have a means to preserve hepatocytes, without loss of
integrity. To this end, we tested different methods with a view to preserve hepatocytes for
periods up to 48 hours. 
Techniques currently used to preserve cells include cryopreservation and preservation at
4°C. The danger of hepatocyte cryopreservation is a considerable loss of viability and
metabolic activity after thawing [2,3], although some authors succeeded in freezing
hepatocytes with very good efficiency [4-7]. It has also been reported that isolated
hepatocytes could be stored at 4°C for several days in organ preservation solutions, such as
the University of Wisconsin (UW) solution, without loss of viability and transport
functions [8-10]. 
The steps to isolate rat hepatocytes are described below. Freshly isolated hepatocytes were
cryopreserved for 10 days and their viability assessed after thawing and incubation at 37°C. In
addition, isolated hepatocytes were used to evaluate the potential of different solutions for the
preservation of hepatocytes at 4°C and for the subsequent incubation at 37°C.
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4.2 Materials and methods 
4.2.1 Chemicals
Bovine serum albumin (BSA, fraction V, 97%) and ethyleneglycol-O,O'-bis(2-
aminoethyl)-N,N,N',N'-tetraacetic acid (EGTA) were purchased from Fluka. Collagenase
from Clostridium histolicum type IV (collagen digestion activity: 295 U/mg solid), fetal calf
serum (FCS), Williams E medium, and bovine pancreas insulin were obtained from Sigma
Chemical (St-Louis, MO, USA). Trimetazidine (TMZ) was generously donated by Servier,
Institut de Recherche International, France. All other chemicals were of analytical grade.
4.2.2 Animals
Adult male Sprague-Dawley rats (250 to 350 g) came from Charles River Lab (Iffa Credo,
L'Arbresle, France). They were maintained in cages in an air-conditioned room (21-25°C,
50% humidity) with circadian day/night rhythm of 12 hours. Standard lab chow (n° 950.9,
Protector S. A., Lucens, Switzerland) and water were given ad-libitum. The protocol of these
studies was approved by the Cantonal Veterinary Service (authorization n° 1313).
4.2.3 Isolation of hepatocytes
Hepatocytes were isolated by a two-step collagenase perfusion of the liver first described
by Seglen et al. [11]. The rats were anesthetized by an intraperitoneal injection of sodium
pentobarbital (80 mg/kg). The rat abdomen was opened, a cannula (1.7 mm, 5.1 cm) was
inserted into the portal vein and fixed with two silk threads (3 m, 2/0 USP, B. Braun
Melsungen AG, Switzerland), as seen in figure 4.1. Simultaneously with opening the vena
cava in its abdominal part, perfusion of the liver was started with preperfusion solution
(isolation buffer containing 0.50 mM EGTA, adjusted to pH 7.4, 37°C). Perfusion started with
a flow rate of 5 ml/min and was then progressively increased over 1 minute to 30 ml/min;
perfusion was maintained at this flow rate during 10 minutes. The perfusion was then
switched over to perfusion solution (isolation buffer containing 0.05% collagenase and
2.00 mM CaCl2, adjusted to pH 7.55, 37°C). The composition of the isolation buffer was the
following: 151 mM NaCl, 5.37 mM KCl, 0.63 mM Na2HPO4, 0.44 mM KH2PO4, 4.2 mM
NaHCO3, 5.55 mM glucose.
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Figure 4.1: Scheme of the liver perfusion for hepatocyte isolation. The rat abdomen was opened, a
cannula was inserted in the portal vein and fixed with threads.
After 10 minutes perfusion at a flow rate of 30 ml/min, the tissue was very swollen and
tended to fall apart; sometimes, perfusion had to be stopped before 10 minutes. The liver was
removed and transferred to an ice cold wash solution (isolation buffer containing 0.5% BSA
and 0.41 mM MgSO4, adjusted to pH 7.4). The hepatocytes were released by gentle shaking
after disruption of the Glisson capsule (figure 4.2). The resulting cell suspension was filtered
through 100 m nylon mesh. The viable cells were allowed to sediment and the supernatant
containing debris and dead cells was discarded. Cell viability was assessed by trypan blue
exclusion, according to equation 4.1.
  100  
cellsofnumber  total
cells living ofnumber 
  %viability  [Equation 4.1]
The cells were washed one more time with the wash solution followed by slow
centrifugation (50 g, 2 min, 4°C) to remove collagenase, damaged cells, and non-parenchymal
cells. The remaining cell pellet was used to perform the experiments of cryopreservation and
cold preservation at 4°C.
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Figure 4.2: Diagram of the hepatocyte isolation procedure after perfusion with collagenase. The liver
was removed from the rat abdomen, and hepatocytes were released in ice cold solution after disruption
of the Glisson capsule. Cells were filtered and viability was assessed with trypan blue.
4.2.4 Cryopreservation 
Two freshly isolated hepatocyte suspensions were prepared in modified Hanks's solution,
with a hepatocyte density of 2·106 and 1·107 cells/ml. The composition of the modified
Hanks's solution is given in table 4.1. The samples to be frozen were prepared by mixing
0.5 ml of each suspension with 0.5 ml of freezing solution in freezing tubes of 1.8 ml. Two
freezing solutions were tested. Both consisted of Hanks's solution supplemented with 10%
dimethylsulfoxide (DMSO), one additionally containing 10% FCS. The tubes were wrapped
in padding and introduced in an expended polystyrene box, which was then placed in a –80°C
freezer for 4 hours. The tubes were then rapidly transferred to liquid nitrogen, where they
were kept for 10 days.
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After cryopreservation, cells were thawed by rapid immersion of the freezing tubes in a
water bath at 37°C. When thawing had started, the tubes were placed in ice. Hanks's solution
at 4°C was added to the hepatocytes drop by drop to a volume of 1.8 ml. The suspensions
were transferred in 15 ml centrifuge tubes and the addition of Hanks's solution was continued
to reach 10 ml. Hepatocyte viability and recovery were immediately assessed by trypan blue
exclusion, according to equations 4.1 and 4.2 respectively.
  100  
freezingafter  cells ofnumber  total
freezing before cells ofnumber  total
  %recovery  [Equation 4.2]
Cell suspensions were centrifuged (50 g, 2 min, 4°C) and the supernatant was removed to
eliminate the freezing solution and damaged cells. To wash the cells, 10 ml of Hanks's
solution were added to the cell pellets and the hepatocyte suspensions were centrifuged again.
The cell pellets were suspended in Hanks's solution to obtain a final density of 2·105 cells/ml.
To check the evolution of the viability of hepatocytes after cryopreservation and thawing, the
hepatocyte suspensions were incubated (37°C, shaking, 5% CO2 in air atmosphere) in an
incubator (EG 110IR, Société Juan, Saint Herblain, France) for 3 hours. A control experiment
was carried out by incubating suspensions of freshly isolated hepatocytes. Cell viability was
checked every hour by trypan blue exclusion test. 
4.2.5 Preservation at 4°C
Samples for the preservation of hepatocytes at 4°C were prepared by mixing 5·107 freshly
isolated hepatocytes with 5 ml preservation solution in a 15 ml centrifuge tube. The tested
preservation solutions were: modified Hanks's solution with or without 5% of
polyethyleneglycol (PEG), modified UW solution, and Williams E medium with or without
5% of PEG, the solutions were supplemented with 0.5% of BSA and 280 U/l insulin; pH was
adjusted to 7.4. The detailed composition of these solutions is given in table 4.1. The tubes
were kept at 4°C in the fridge for 4, 20 or 24 hours. During the preservation at 4°C, the
hepatocyte viability was assessed every hour by trypan blue.
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Table 4.1: Composition of the solutions used for the preservation and incubation of hepatocytes.
  modified Hanks's  modified UW  Williams E
Component Mol wt. g/l mM  g/l mM  g/l mM
Inorganic salts
CaCl2 111 0.222 2.00 0.265 2.39
KCl 74.55 0.40 5.4 0.4 5.4
K2HPO4 136.1 0.06 0.44 3.402 25.00
MgCl2 · 6 H2O 203.3
MgSO4 · 7 H2O 246.5 0.10 0.41 1.232 5.000 0.0977 0.396
NaCl 58.44 7.365 126.0 6.8 116.4
NaHCO3 84.01 1.5 17.9
Na2HPO4 · 2 H2O 177.99 0.112 0.629 0.122 0.685
Na2HPO4 · 7 H2O 268.1
NaOH 40 1.00 25.0
KOH 56.1 3.09 ~55
Energy metabolism
Glucose 180.2 1.5 8.3 2.0 11.1
Sodium pyruvate 110 0.025 0.227
Other components
Lactobionic acid 358.3 28.664 80.0
Raffinose 594.5 7.835 30.0
Allopurinol 136.1 0.136 1.0
PEG 8000 8000 50 6.25
Phenol red 376 0.0107 0.0285
Nucleosides, etc.
Adenosine 267.2 1.336 5.0
Trace elements 
CuSO4 · 5 H2O 160 1E-07 6.E-07
Fe(NO3)3 · 9 H2O 404 1E-07 2.E-07
MnCl2 · 4 H2O 125.8 1E-07 8.E-07
ZnSO4 · 7 H2O 288 2E-07 7.E-07
Antioxidants
Glutathione red. 307 0.00005 0.0002
Lipids and precursors
Linoleic acid methyl esther 280 0.00003 0.0001
Amino acids
L-alanine 89 0.09 1.01
L-arginine 211 0.05 0.24
L-asparagine 132 0.02 0.15
L-aspartic acid 133 0.03 0.23
L-cysteine 176 0.04 0.23
L-cystine 240 0.02 0.08
L-glutamic acid 147 0.0445 0.3027
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L-glutamine 146 0.292 2.000
Glycine 75 0.05 0.67
L-histidine 210 0.015 0.071
L-isoleucine 131 0.05 0.38
L-leucine 131 0.075 0.573
L-lysine HCl 183 0.08746 0.47792
L-methionine 149 0.015 0.101
L-phenylalanine 165 0.025 0.152
L-proline 115 0.03 0.26
L-serine 105 0.01 0.10
L-threonine 119 0.04 0.34
L-tryptophane 204 0.01 0.05
L-tyrosine 181 0.05045 0.27873
L-valine 117 0.05 0.43
Vitamins
Ascorbic acid Na 176 0.00227 0.01290
D-biotin 244 0.0005 0.0020
Calciferol 300 0.0001 0.0003
Choline chloride 140 0.0015 0.0107
Folic acid 441 0.001 0.002
Myo-inositol 180 0.002 0.011
Menadione 172 0.00001 0.00006
Niacinamide 122 0.001 0.008
DL-pantothenic acid 238 0.001 0.004
Pyridoxal HCl 204 0.001 0.005
Retinol acetate 329 0.0001 0.0003
Riboflyavin 376 0.0001 0.0003
Thiamine HCl 337 0.001 0.003
DL--tocopherol 430 0.00001 0.00002
Vitamin B12 1355       0.0002 0.0001
After cold preservation, the viability of hepatocytes was immediately evaluated by trypan
blue exclusion. The tubes were then centrifuged (50 g, 2 min, 4°C), and the supernatant was
removed to eliminate the preservation solution. The cell pellets were washed once more with
10 ml incubation solution. The cell pellets were mixed with 10 ml incubation solution at 4°C.
The resulting suspensions were poured in Erlenmeyers of 500 ml and 90 ml of incubation
solution at 37°C were added to each suspension. To assess the evolution of the viability of
hepatocytes after preservation at 4°C, the hepatocyte suspensions were incubated at 37°C for
2 hours. The tested incubation solutions were modified Hanks's solution with or without
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TMZ 10-6 M and Williams E medium, the solutions were supplemented with 0.5% of BSA
and 280 U/l insulin, pH 7.2. A control experiment was carried out by incubating suspensions
of freshly isolated hepatocytes. The viability of hepatocytes was checked at 30 minutes
intervals by trypan blue exclusion. 
4.3 Results 
4.3.1 Isolation of hepatocytes
The isolation procedure by a two-step collagenase perfusion resulted in a yield of
4-6·108 hepatocytes per liver. Cell viability was routinely greater than 90% as assessed by
trypan blue exclusion. The criterion for positive trypan blue staining was a visible blue
nucleus, while living cells were smaller, round and yellow. The hepatocytes were purified
from cell debris, dead cells and other smaller cells of the liver by slow centrifugation.
The isolation procedure was initiated by a perfusion of a calcium-free EDTA buffer.
EDTA is a Ca2+ and K+ chelator, which weakens the intercellular bonds and thus facilitates
the action of collagenase, perfused in a second time. Calcium is necessary for collagenase
action and was added to the collagenase solution.
4.3.2 Cryopreservation
To assess the viability and recovery of isolated hepatocytes after cryopreservation,
suspensions of hepatocytes at densities of 1·106 and 5·106 cells/ml in freezing solutions
containing 10% DMSO with or without FCS were kept in liquid nitrogen for 10 days. Their
viability and recovery immediately after thawing as determined by trypan blue exclusion are
depicted in figure 4.3.
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Figure 4.3: Viability and recovery of hepatocytes after thawing of suspensions containing 1·106 and
5·106 cells/ml in freezing solution with or without FCS, kept in liquid nitrogen for 10 days
(n = 3).
Cell recovery indicates the amount of hepatocytes still detectable with trypan blue after
freezing. It is expressed as a percentage of the number of cells detectable before freezing.
Thus, it includes viable and dead cells, as classified according to the blue or yellow coloration
of the hepatocytes by trypan blue. The measure of viability takes into account the viable cells
only and is expressed as a percentage of the total number of cells detectable after freezing.
Recovery after freezing was about 50-60%, as seen in figure 4.4. These results indicate that
about 30-40% of the hepatocytes were totally disintegrated during cryopreservation. Among
the 50-60% of hepatocytes recovered after thawing, viability assessment indicated that only
about 20-30% were viable. Thus, only about 15% of the total number of cryopreserved
hepatocytes were viable after 10 days of cryopreservation and thawing. Cell density and FCS
had no considerable effect on cell recovery.
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The evolution of viability of cryopreserved hepatocytes in suspension incubated at 37°C
for 3 hours is shown in figure 4.4.
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Figure 4.4: Evolution of viability of hepatocytes incubated in suspension for 3 hours after 10 days of
cryopreservation. The legend indicates the freezing conditions. Hepatocytes were frozen at a density
of 1·106 or 5·106 cells/ml in freezing solution containing 10% DMSO, with or without FCS (n = 3).
As can be seen, the already low viability of hepatocytes immediately after thawing
dramatically fell to less than 10% after 2 hours when these cryopreserved hepatocytes were
further incubated at 37°C. This indicates that, although the hepatocytes were classified as
viable by trypan blue exclusion, they were not in a good state for further incubation at 37°C.
A control experiment showed that the viability of freshly isolated hepatocytes in suspension
remained near 90% during 3 hours of incubation.
As already seen immediately after thawing, none of the different freezing conditions did
significantly improve the viability of cryopreserved hepatocytes incubated in suspension after
thawing. In summary, the results presented here show that cryopreservation of hepatocytes is
not a good method of preservation.
Chapter 4 91
4.3.3 Cold preservation 
The effect of the composition of the preservation solution on the viability of hepatocytes
maintained at 4°C for 20 hours is shown in figure 4.5.
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Figure 4.5: Evolution with time of the viability of hepatocytes conserved at 4°C for 20 hours in
different solutions (n = 1).
After 5 hours, all investigated solutions maintained a hepatocyte viability of nearly 85%,
although Williams E medium seemed to be slightly less efficient. Viability decreased slightly
between 5 and 20 hours of preservation at 4°C, the decline being more pronounced with
Williams E medium. The results further show that PEG had no effect on cell viability. Indeed,
Williams E medium with additional PEG gave a better viability than Williams E medium
alone, but Hanks's solution alone gave better results than Hanks's supplemented with PEG. 
The morphological examination of the cells showed an alteration of the cell shape when
hepatocytes were preserved in Hanks's solution, Hanks's solution + PEG, Williams E medium,
Chapter 4 92
and Williams E medium + PEG. Processes of vacuolisation and cell swelling were observed,
the phenomenon becoming more pronounced with time. Only hepatocytes preserved in UW
solution retained a stable round shape. To summarize, the best results were obtained with a
UW solution which maintained a cell viability of 85% after 20 hours of preservation at 4°C,
without loss of membrane integrity. With all other preservation solutions a cell viability of
about 80% could be ensured after 20 hours of storage at 4°C and alterations of the membrane
were observed. 
The evolution of the viability during incubation at 37°C after cold preservation was also
assessed. Figure 4.6 presents the effect of the preservation solution, in which hepatocytes
were kept at 4°C for several hours, and the effect of the incubation solution, in which
hepatocytes were incubated for 2 hours at 37°C after the cold storage.
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Figure 4.6: Evolution with time of the viability of hepatocytes incubated at 37°C for 2 hours in
Williams E or Hanks's solution after preservation at 4°C for 4 or 24 hours in UW or Hanks's solution.
In the legend, the first name indicates the preservation solution and the second, the incubation
solution. A control experiment was performed by incubating suspensions of freshly isolated rat
hepatocytes without cold preservation (n = 3).
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The viability at time zero indicates the viability after the period of preservation at 4°C.
After 4 and 24 hours of preservation at 4°C in UW and Hank's solutions, the viability of
hepatocytes was better than 85%, as already seen in figure 4.5. 
For all investigated incubation conditions, hepatocytes viability decreased slightly during
the 2 hours of incubation at 37°C. Better viabilities during incubation were obtained when the
hepatocytes had been preserved at 4°C in UW solution. Hence, the preservation solution
influenced not only the viability during cold storage, but also the viability during incubation
at 37°C. When looking more closely at the effect of the incubation solution, it can be
observed that hepatocytes incubated in Hanks's solution had a better viability than those
incubated in Williams E medium. Hence, the best results were obtained when hepatocytes
were preserved at 4°C in UW solution and incubated at 37°C in Hanks’s solution. Under these
conditions, hepatocytes could be kept 24 hours at 4°C and incubated for 2 hours without a
significant loss of viability. 
To investigate the possible effect of TMZ on the cold preservation of hepatocytes, TMZ
was added to the UW solution at a concentration of 10-6 M. Figure 4.7 shows the evolution of
the viability of hepatocytes incubated in suspension in Hanks's solution at 37°C for 2 hours,
after preservation at 4°C for 24 or 48 hours in UW solution with or without TMZ.
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Figure 4.7: Evolution with time of the viability of hepatocytes incubated at 37°C for 2 hours in
Hanks's solution after preservation at 4°C for 24 or 48 hours in UW solution with or without 10-6 M
TMZ. A control experiment was performed by incubating suspensions of freshly isolated rat
hepatocytes without cold preservation (n = 3).
As can be seen, TMZ had no positive effect on the viability of hepatocytes during cold
preservation. The evolution of the viability of hepatocytes with time during incubation at
37°C was the same after cold preservation in the presence or absence of TMZ in the UW
solution. It could also be seen that the duration of cold preservation influenced both the
viability of hepatocytes immediately after the time of preservation at 4°C and the decline of
viability during 2 hours of incubation at 37°C. Actually, the initial viability of hepatocytes
after 24 hours of preservation in UW solution was 90%, while it dropped to 80% when
hepatocytes were stored during 48 hours in the same solution. Moreover, the viability of
hepatocytes kept 48 hours at 4°C decreased more rapidly during incubation than that of cells
preserved only 24 hours at 4°C. These observations are in good agreement with the results
shown above (figure 4.6): the poorer the initial viability after cold preservation, the more
rapid the decline of viability during incubation.
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4.3 Discussion
On average, 4 to 6·108 cells were obtained from the two-step collagenase isolation
procedure of the liver, which represented about 50% of the total hepatocyte population of the
liver [12]. Cell viability was routinely greater than 90% as assessed by trypan blue exclusion.
The yield values found in the literature with the same isolation procedure range from to 2 to
6·108 cells, with a cell viability average of 85-90% [12-14]. The first techniques to obtain
hepatocytes used mechanical methods, such as forcing the tissue through stainless steel
screens or cheesecloth, then chelators such as citrate or EDTA to neutralize Ca2+ and K+ ions
which play a key role in intercellular bonds, and finally enzymes, such as trypsin, papain,
lysozym, neuraminidase, or pepsin. With all these techniques, the cell yield did not exceed
5% of the total population of hepatocyte and the functional properties of most cells were
lost [13]. An important step in the preparation of intact hepatocytes was made by the
introduction of collagenase. Berry and Friend set up the basic protocol of the in situ two-step
collagenase perfusion of the liver, which was further modified by Seglen [11].
Centrifugation permitted to separate the hepatocytes (sediment) from cell debris, dead cells
and other smaller cells of the liver (supernatant). Other techniques exist to obtain pure
hepatocyte suspensions, but they are more sophisticated. For instance, hepatocytes can be
purified by Percoll density gradient separation [4,15,16]. This procedure results in the
separation of single and viable parenchymal cells from cell aggregates, debris, and
nonparenchymal cells, based on the density of the different elements. 
The fine structure of isolated hepatocytes is comparable to the one of cells in vivo [13], the
functionality of the cytochromes P450 is similar in the entire liver and in the freshly isolated
hepatocytes [17], but membrane polarity is altered  during isolation [18]. In vivo, the
hepatocyte is a polar cell with two different surfaces, which are in contact with two different
compartments: the sinusoidal cell membrane is in contact with the blood while the canalicular
membrane is in contact with the bile. Microscopic observation of freshly isolated hepatocytes
shows a spherical shape of the cells with a uniform membrane, and recognition of the
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different poles of the membrane is no longer possible. Hence freshly isolated cells have
altered cell surface receptors for attachment and/or binding of xenobiotics and endogenous
toxic products [19,20], although isolated hepatocytes exhibit transport characteristics similar
to those of livers in vivo [21,22]. Nevertheless, on must be aware of this problem when using
freshly isolated hepatocytes to study drug transport or/and metabolism. 
The preservation of primary cells, especially hepatocytes, is difficult and there are different
points to respect. First, the cellular density has to be adequate. Freshly isolated hepatocytes
are usually suspended at 1·106 to 2·107 cells/ml. Powis et al. [4] found that freezing with
densities of 108 cells /ml was unsuccessful. When the number of hepatocytes was decreased to
106 cells/ml, cell recovery was increased. Second, the freezing solution must contain a
preservative such as DMSO, glycerol or propyleneglycol at a final concentration of 5 – 10%,
10% serum is sometimes added, too. DMSO has been shown to give a better cell recovery
than propyleneglycol [4]. Third, the freezing process must be slow and controlled. The use of
the expended polystyrene box allowed a slow freezing of about 1°C per minute. And finally,
after cryopreservation, cells have to be thawed rapidly, for instance by immersion in a water
bath at 37°C. 
Our experiments showed that only about 20% of freshly isolated hepatocytes were viable
after cryopreservation, and that they did not survive when incubated at 37°C. We used only
trypan blue exclusion to measure cell viability. Dye exclusion tests are approximate measure
of viability, and functional viability tests such as metabolic studies could give better results.
Some authors found that cryopreservation produces altered cells [2], while others reported
that hepatocytes were normal after cryopreservation [4]. As hepatocytes are anchorage-
dependent cells, better results can be obtained when hepatocytes are bound to a surface. For
instance, microcarrier-attached hepatocytes [5,6] and hepatocytes immobilized in calcium-
alginate beads [7] have shown to have a good recovery after thawing.
To avoid the inevitable hazard of freezing and thawing, short-term cold storage of
hepatocytes was also investigated. All solutions used for preservation maintained a good
hepatocyte viability of about 85% after 4 hours of storage at 4°C, Williams E medium gave
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the worst results and UW solution the best. The protective capacity of UW solution for cold
storage was particularly evident when hepatocytes were incubated at 37°C after a longer
period of cold preservation, i.e. 24 hours. Actually, hepatocytes preserved for 24 hours at 4°C
in UW solution had a viability after preservation identical to that before cold preservation
(90%), and when incubated at 37°C they kept a viability greater than 85% after 2 hours of
incubation. 
The loss of viability during cold preservation is mainly due to cell swelling [23]. Cooling
lowers the rate of chemical reactions and thus has a general depressive effect on metabolism.
A disturbance in the maintenance of the intracellular ionic composition may occur. Passive
fluxes tend to be less affected by temperature than energy-dependent pumps and the rate of
ion pumping at hypothermia is unable to match passive ion flux. The net result is an
intracellular gain of Na+ and Cl- which draws in water by osmosis and leads to cell
swelling [24].
The UW solution was originally developed for pancreas preservation [25] and has now
become the standard cold storage preservative for most organs, including the kidney, liver,
pancreas, and heart [25,26]. Different UW solutions have been described, all deriving from
the original one. UW solutions contain agents to suppress hypothermic cell swelling
(lactobionic acid, raffinose, hydroxyethyl starch, PEG), a hydrogen ion buffer (phosphate),
and other agents that may be beneficial (gluthathione, adenosine, allopurinol, magnesium). In
our studies, we did not observe any effect of PEG when added to the cold preservation
solution (figure 4.6). UW solutions have a high concentration of potassium, which is thought
to suppress the efflux of potassium from cold-stored cells. Calcium appears to play a role in
the suppression of cell swelling as well as maintenance of mitochondrial function. Amino
acids are important in preventing loss of viability and maintaining respiratory activity [27].
Glutahthione (GSH) is often omitted because it is unstable. The autooxidation of GSH
produces H2O2, shortens the shelf life and reduces the antioxidant capacity of organ storage
solutions since it can act simultaneously as an antioxidant and prooxidant [28]. 
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UW is now used by numerous workers to preserve hepatocytes for long periods of time
without loss of viability and transport function [8-10]. Hepatocytes can be preserved for
22 hours in UW at 0°C without significant loss of viability and transport function, but in
Krebs-Henseleit buffer, viability and transport function of hepatocytes deteriorate after
22h [29,30]. Krebs-Henseleit buffer is a balanced salt solution (BSS) like Hanks's solution,
whose protective properties were found to be inferior to UW solution (figure 4.6). Thus, our
results obtained with different preservation solutions are in good agreement with the
literature. However, this is not quite the case with the tested incubation solutions. Marsh et
al. [31] showed that the viability of rewarmed hepatocytes was more reduced upon incubation
with BSS than with tissue-culture media. In contrast, we observed that hepatocytes incubated
after cold preservation with Hanks's solution remained more viable than hepatocytes
incubated in Williams E, a complete tissue-culture medium (figure 4.7), although the
difference was slight. Although Williams E medium is a complete medium, including notably
amino acids and vitamins (table 4.1), we did not observe any viability improvement during
incubation after cold preservation. Williams E medium was used because it is a medium
currently employed for hepatocyte culture [32,33-36]. 
Hepatocytes tolerate a wide range of pH values in the storage solution (7.0 to 8.0) [37].
Mamprin et al. [38] analyzed the effect of different pH of resuspension solutions on the
viability of hepatocytes preserved for 96 hours in UW solution. The viability was significantly
higher for cells incubated at pH 7.2. The importance of the pH was not studied here.
However, this information was taken into account when preparing preservation and
incubation solutions. The pH of the incubation solutions was adjusted to 7.2 instead of a
usual 7.4.
We did not detect any positive effect of TMZ on the cold preservation of hepatocytes. The
addition of TMZ to the UW solution did not improve viability of hepatocytes during the
period of cold preservation, or during incubation. The concentration of TMZ added was
10-6 M, which is the concentration usually described in the literature [39-43]. During
preliminary studies, TMZ was tested at a concentration of 10-5 M without producing any
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beneficial effect. In further studies, TMZ could be added at lower concentrations or directly to
the solutions used to isolate hepatocytes. 
TMZ has shown a beneficial effect on the viability of transplanted organs such as
kidney [40-44], intestines [45], heart [39], and liver [46], when added to the organ
preservation solution at a concentration of  10-6 M. The mechanism of action of TMZ is not
fully understood but could be a protection against ischemia/reperfusion injury.
4.4 Conclusion
The viability of cryopreserved hepatocytes dramatically dropped after thawing and
incubation at 37°C. According to these results, cryopreservation does not appear appropriate
to preserve hepatocytes when large numbers of viable cells are needed for the preparation of a
hepatocyte HFB. Even if the procedure was improved, it would require a very large number
of freezing tubes, due to the low density of cells during freezing, and this would complicate
the preparation of the HFB. 
Conversely, the cold preservation of hepatocytes in UW solution appears suitable for our
purpose. It preserves hepatocytes during 24 hours at 4°C without significant loss of viability
during cold preservation and subsequent incubation in Hanks's solution at 37°C for 2 hours.
These results provide a framework for the future preparation and perfusion of the hepatocyte
HFB. If several rat livers have to be used to isolate a sufficient number of hepatocytes, cells
resulting from the first liver isolation procedures can be kept at 4°C in UW solution, until
enough cells are isolated to load the HFB. Further, if the experiment can not be performed
immediately after hepatocyte isolation, the HFB containing hepatocytes in suspension in UW
solution can be kept at 4°C. The cells can be preserved 24 hours without loss of viability,
meaning that the HFB experiment could be performed 24 hours after hepatocyte isolation.
Hanks's solution can be used to perfuse the HFB, as it was shown to be a suitable solution to
sustain hepatocytes during incubation at 37°C after cold preservation. TMZ did not
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demonstrate any additional beneficial effect on hepatocytes viability during cold preservation,
when added to UW solution at a concentration of 10-6 M.
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Chapter 5
Development and validation of a hepatocyte hollow fiber
bioreactor as a cellular model for the study of contrast agents by
magnetic resonance imaging
5.1 Introduction
Magnetic resonance imaging (MRI) is a non-invasive and safe method for the detection
and characterization of a wide variety of diffuse (e.g. fatty liver, hemochromatosis, and
cirrhosis) and focal (e.g. cancers) hepatic diseases. It has become an important tool in the
clinical routine of liver imaging to evaluate focal diseases. The most commonly used contrast
agents are the nonspecific extracellular gadolinium (Gd3+) chelates, like Gd-DTPA. Indeed,
they are inexpensive, safe, well-tolerated, and allow to detect and characterize a wide range of
hepatic diseases. However, as a method for assessing liver function, MRI is still at a research
stage, but it has a great potential thanks to hepatobiliary contrast agents, such as the
gadolinium-based Gd-BOPTA or the manganese-based Mn-DPDP. They distribute initially
into the interstitial space, as the nonspecific extracellular contrast agents do, but are also taken
up specifically by hepatocytes and are partially excreted into the bile. Because the uptake of
these contrast agents relies on the functional state of the hepatocytes, they could be used to
obtain quantitative information on the functional state of the liver. However, before MRI can
be used clinically as a routine tool for this purpose, more research is needed to elucidate the
mechanisms by which these hepatobiliary contrast agents interact with hepatocytes, and how
these mechanisms are disturbed or altered in different liver diseases. In vitro cellular models
are of great value for the study of such mechanisms.
Methods currently used for contrast agent detection with in vitro cellular models include
radioactivity measurements of radio-labeled contrast agents, 31P NMR spectroscopy in the
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case of Mn-DPDP, and fluorescence for iron oxide particle-based contrast agents. MRI is not
currently used as an analytical tool for the study and quantification of contrast agents in vitro,
due to the low MRI resolution achievable with the current MR systems, the difficulty to
obtain reproducible results, and the impossibility to use metallic devices inside the magnet
room. The latter point is incompatible with most tissue or cell cultures, which require
controlled temperature and oxygenation. Nevertheless, MRI has an interesting advantage over
the quantification techniques cited above: it can detect not only one specific but all kinds of
MRI contrast agents without the need of radio-labeled molecules.
The aim of this work was to develop a MRI compatible cellular in vitro model containing
freshly isolated rat hepatocytes, where the effects of contrast agents could be directly
measured by MRI. A dynamic perfusion system including a hollow fiber bioreactor (HFB),
and a system of circulation, heating, and oxygenation, was set up according to the difficulty
due to the magnetic field. The system was validated by measuring the signal intensity of the
hepatocyte bioreactor during perfusion of an extracellular (Gd-DTPA) and a hepatobiliary
contrast agent (Gd-BOPTA). The system permitted to evidence a reproducible difference
between both contrast agents, due to the uptake of Gd-BOPTA into hepatocytes. 
5.2 Materials and methods
5.2.1 Chemicals
Solution of Gd-BOPTA 0.5 M was generously provided by Bracco Research S.A. (Geneva,
Switzerland). A commercially available solution of Gd-DTPA 0.5 M (Magnevist, Schering,
Germany) was used. Bovine serum albumin (BSA, fraction V, 97%) and ethyleneglycol-O,O'-
bis(2-aminoethyl)-N,N,N',N'-tetraacetic acid (EGTA) were purchased from Fluka.
Collagenase from Clostridium histolicum type IV (collagen digestion activity: 295 U/mg
solid) and bovine pancreas insulin were obtained from Sigma Chemical (St-Louis, MO,
USA). All other chemicals were of analytical grade.
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5.2.2 Set up of the MRI compatible perfusion system
The MRI compatible perfusion system comprised a solution circulation system, a heating
system, an oxygenation system, a bubble trap and a HFB. A schematic drawing of the
perfusion system is presented in figure 5.1.
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Adjacent room MRI coil
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1 2
Figure 5.1: Schematic drawing of the hollow fiber bioreactor perfusion system. The system was
composed of  solution reservoirs  and  (A), a gas bottle (B), a peristaltic pump (C), a heating
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circulator (D), a sampling port (E), a temperature probe (F), a magnetic stirrer (G), a refrigerant (H),
an oxygenator (I), a bubble trap (J) and a hollow fiber bioreactor (K). Elements A to G were placed in
a room adjacent to the magnet room.
To avoid interference with the magnetic field, all material used in the magnet room was
exempt of any metallic piece and made of plastic and glass; the heating system, the gas bottle
and the pump were installed in an adjacent room. All elements inside the magnet were fixed
to a PVC support. The dimensions of the magnet were measured and the PVC support was
built so that the HFB could be fitted at the exact isocenter of the magnet.
5.2.2.1 Solution circulation system
The solution was contained in glass bottles closed with a three-way cap, one for solution
outlet, one for solution inlet and one for venting (figure 5.1). A 0.22 m filter (Millex FG,
Millipore Co., Bedford, MA, USA) was set on the venting outlet in order to prevent
microbiological contamination of the system. The installation included two solution
reservoirs, which permitted to switch perfusion solution during experiment. Magnetic
agitation ensured good homogeneity of the solutions. Solution bottles were connected to the
HFB by 15 meters of tubing (Tygon 2257, ID 1/8", OD 3/16", and Pharmed 65, ID 1/4",
OD 3/8", Saint-Gobain Performance Plastics Co., Akron, Ohio, USA). The tubing was chosen
in order to minimize adsorption phenomena. A peristaltic pump (ISM 915, Ismatec SA,
Glattbrugg-Zürich, Switzerland) continually circulated the solution into the system. To avoid
gas bubbles getting through the HFB a plastic bubble trap was installed just before its inlet. A
sampling port allowed sampling for analysis during the experiment. The different elements of
tubing were connected to each other with nylon luer and Kent fittings (Value Plastics, Fort
Collins, CO, USA).
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5.2.2.2 Heating system
The solution was heated by circulation through a glass spiral of a refrigerant while warm
water from the heating circulator (Haake N6, Karlsruhe, Germany) flowed outside the spiral.
The refrigerant was installed in the magnet, just before the oxygenator system.
Temperature measurements were made using a thermocouple thermometer (Extech
Instruments Corp., n° 422315, Waltham, MA, USA) with two Kapton insulated probes
type T (Physitemp Instruments Inc., Clifton, NJ, USA). The probes were hermetically fixed to
luer fittings in order to be included in the perfusion system. 
The relation between the water temperature in the heating circulator, the temperature in the
inlet, the temperature inside the HFB, and in the outlet tubing near the solution reservoir was
determined in preliminary studies. To avoid interference with the magnetic signal, only the
temperature probe in the outlet near the solution reservoirs was fitted during MRI
experiments.
5.2.2.3 Oxygenation system
An efficient oxygenation was assured by a silicone membrane oxygenator [1] which
consisted of 7 meters of thin-walled silicone tubing (Silastic, ID 0.132", OD 0.183",
Dow Corning Co., Midland, MI, USA) permeable to oxygen and carbon dioxide and coiled in
a plastic box. It was fed with a mix of oxygen (95%) and carbon dioxide (5%), at the minimal
rate which saturated it with oxygen. The oxygenator box comprised four apertures: one for
unoxygenated solution entrance, one for oxygenated solution exit, one for gas inlet, and one
for gas outlet, the later two being connected to a 0.22 m filter (Millex FG, Millipore Co.,
Bedford, MA, USA) in order to prevent microbiological contamination of the system.
To investigate possible adsorption in the silicone tubing of the contrast agents, one liter of
0.2 mM Gd-BOPTA or Gd-DTPA solution was recirculated through the perfusion system and
its UV absorbance at 210 or 190 nm respectively was regularly measured with a
spectrophotometer UV (1601, Shimadzu Co., Kyoto, Japan). 
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5.2.2.4 Hollow fiber bioreactor
The HFB consisted of a network of semi-permeable artificial capillaries bundled together
within a transparent plastic shell (figure 5.2). The HFB was composed of two compartments
separated by a porous membrane, the intracapillary space (ICS) and the extracapillary space
(ECS). The perfusion solution, continually pumped from a reservoir, oxygenated and heated,
flowed within the capillaries from where it diffused through the semi-permeable membrane
into the ECS. 
The used HF devices (Minikros Sampler, Spectrum, Rancho Dominguez, CA, USA) were
made of hydrophilic polyethersulfone fibers, with a diameter of 0.5 mm and had a length of
15 cm and an ECS volume of 25 ml. Module 1 (product n° M15E 220 01N) had a fiber
surface area (FSA) of 140 cm2 and a porosity of 0.5 m, module 2 (product
n° M15E 260 01N) had a FSA of 420 cm2 and a porosity of 0.5 m and module 3 (product
n° M12E 220 01N) had a FSA of 140 cm2 and a porosity of 0.2 m. During perfusion, the
HFB was surrounded by an Armaflex jacket for thermal insulation.
Figure 5.2: Picture of the hollow fiber module 1 made of hydrophilic polyethersulfone fibers with a
diameter of 0.5 mm, ECS volume of 25 ml, fiber surface area of 420 cm2 and porosity of 0.5 m. The
hollow fibers are bundled together within a transparent plastic shell. 
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5.2.3 Preparation of the hepatocyte HFB
5.2.3.1 Isolation of hepatocytes
Hepatocytes were isolated from adult male Sprague-Dawley rats (250 to 350 g) by a
two-step collagenase perfusion of the liver first described by Seglen [2] and described in
detail in chapter 4. 
An average of 5·108 hepatocytes were obtained from the isolation procedure of one rat
liver, with a cell viability greater than 90% as assessed by trypan blue exclusion. The
suspension of freshly isolated hepatocytes obtained after the isolation process was centrifuged
(50 g, 2 min, 4°C) and the cell pellet was mixed with 30 ml of ice cold modified University of
Wisconsin (UW) solution containing 80 mM lactobionic acid, 30 mM raffinose, 25 mM
KH2PO4, 25 mM NaOH, 10 mM glycine, 5 mM MgSO4, 5 mM adenosine, 1 mM allopurinol,
165,700 U/l Penicillin G, 5% PEG 800, and 0.5% BSA; pH was adjusted to 7.3 with KOH
2.5 N (~55 mM). The UW solution was filtered aseptically before use (Millex GS, 0.22 m,
Millipore Co., Bedford, Massashuset, USA). This suspension was kept at 4°C till the loading
of the bioreactor.
5.2.3.2 Loading of the bioreactor
The HF module 2 was first rinsed by flowing 1l of high purity water in a single pass
through the fibers with a flow rate of 50 ml/min. The HF module was then autoclaved by a
30-minute cycle at 121°C (Varioclav 300 E, H+P Labortechnik AG, Oberschleissheim /
München, Germany).
Just before the inoculation of hepatocytes, the ECS and ICS of the HFB were filled with
UW solution, taking care not to introduce air bubbles. The hepatocytes suspended in UW
solution were (50 g, 5 min, 4°C) centrifuged to decrease the volume of the cell suspension.
Supernatant was removed and the remaining hepatocyte suspension was inoculated into the
ECS of the sterile HF module through the ECS port as depicted in figure 5.3. The hepatocyte
suspension was gently poured in a sterile 50 ml luer-lock syringe without piston which was
fixed to a ECS port. Cells were aspirated in the ECS by another syringe fixed to the second
ECS port. The bioreactor was preserved at 4°C for up to 4 hours till experiment.
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Figure 5.3: Preparation of the hepatocyte hollow fiber bioreactor (HFB). Hepatocytes suspended in
the University of Wisconsin solution were inoculated in the extracapillary space of the HFB using a
system of two syringes.
5.2.4 Viability assessment of hepatocytes 
During HFB perfusion experiments cell viability was checked by dosing the cytosolic
enzyme lactate dehydrogenase (LDH) and the mitochondrial enzyme aspartate
aminotransferase (AST) released in the perfusate (UV kits n° 1442616 and 1442490
respectively, Roche Diagnostics, Rotkreuz, Switzerland) and by determining oxygen
consumption (ABL 500, Radiometer Copenhagen, Brunson, DK) of hepatocytes.
Amounts of LDH and AST released in the perfusion solution were expressed as percentage
of the total amount of LDH and AST contained in the hepatocytes. Total quantities of LDH
and AST were obtained by determining the quantity of enzymes released after cellular lysis
with Triton X-100 [3]. Briefly, 0.5 ml of freshly isolated hepatocyte suspension containing
5·106 cells were mixed with 9.5 ml of Triton X-100 solution 0.1% and agitated for 1 hour.
The mixture was centrifuged (400 g, 4 min), the supernatant was removed and LDH and AST
were dosed by UV. This permitted to calculate the total quantity of LDH and AST contained
in a million hepatocytes. For the bioreactor experiments, the percentage of enzymes released
was calculated as the activity in the perfusion solution compared to the total activity contained
in a million hepatocytes multiplied by the total million number of cells in the HFB. 
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PO2 determination of samples taken simultaneously at the bioreactor inlet and outlet, as
well as the perfusate flow rate were used to calculate the oxygen consumption of the
bioreactor. Oxygen consumption (O2) by the hepatocytes in the HFB was determined with
the following equation [4]:
O2 = S(O2) · [Pin - Pout] · QE [Equation 5.1]
where Pin and Pout are the oxygen tensions (kPa) in the HFB inlet (solution from bubble trap)
and outlet (solution from sampling port) respectively, QE is the flow rate (ml/h), and S(O2) is
the oxygen solubility in water at 37°C (9.68·10-6 mol O2/ml/kPa).
5.2.5 HFB perfusion conditions
The perfusion system was first sterilized by circulating ethanol 70% V/V for 15 minutes.
The system was then emptied, rinsed with 1l sterile water and emptied again. After this
sterilization step the perfusion system was filled with perfusion solution contained in
reservoir 1, which had the following composition: 76.0 mM NaCl, 5.37 mM KCl, 0.63 mM
Na2HPO4, 0.44 mM KH2PO4, 17.9 mM NaHCO3, 2.00 mM CaCl2, 0.41 mM MgSO4,
40.0 mM HEPES Na, 5.55 mM glucose, 99420 U/l Penicillin G, 77700 U/l
streptomycin sulfate, 280 U/l insulin and 0.5% BSA, pH was adjusted to 7.2. Perfusion
solutions were aseptically filtered before use (Millex GP50, 0.22 m, Millipore Co., Bedford,
Massashuset, USA) and kept at 4°C in sterile glass bottles till experiment. The first 50 ml
were discarded to eliminate residual water from the previous washing step. Solution was
recirculated in the perfusion system till the required temperature was obtained. At that time,
the HFB was introduced in the perfusion system. When desired, the solution was switched to
solution with contrast agent contained in reservoir 2.
Solution sterility following experiment was evaluated by incubation on agar-agar (Biotest
Hycon GK-A/HS, Biotest AG, Dreieich, Germany) at room temperature for 3 days.
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5.2.5.1 Determination of the optimal concentration of hepatocytes
To determine the optimal concentration of hepatocytes in HF module 2 hepatocyte
densities of 2·107 and 4·107 cells/ml were compared in terms of cellular viability. HFB were
perfused during 4 hours with a solution free of contrast agent at a solution and gas flow rate of
100 ml/min and 4 l/min respectively. Samples were taken every hour and checked for their
content of LDH and AST.
5.2.5.2 Choice of the hollow fiber module
To choose the hollow fiber module, diffusion in the extracapillary space of Gd-DTPA
2 mM was assessed by MRI in HF modules 1, 2 and 3 free of hepatocytes, with a flow rate of
100 ml/min. Each module and the perfusion system were first separately filled with perfusion
solution without contrast agent. The first module was then introduced in the perfusion system,
in the wrist coil, and imaged. Perfusion with solution free of contrast agent for 15 seconds
was followed by perfusion with Gd-DTPA 2 mM for 10 minutes. The same procedure was
repeated with the two other modules. 
5.2.5.3 Optimization of the flow rate
The effect of flow rate on the time to reach contrast agent equilibrium between ICS and
ECS was also measured in the absence of hepatocytes by MRI. HFB filling with Gd-DTPA
0.2 mM at flow rates of 50, 75 and 100 ml/min was studied with module 2 following the same
protocol as already described for the choice of the HF module.
5.2.5.4 Validation of the hepatocyte hollow fiber bioreactor
The developed HFB system was validated by perfusion of HF module 2 containing
4·107 hepatocytes/ml with solutions of Gd-DTPA and Gd-BOPTA at different concentrations.
Each perfusion with contrast agent was followed by a washing period with solution free of
contrast agent. The perfusion and the following washing period lasted 20 minutes each when
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Gd-DTPA and 30 minutes when Gd-BOPTA was perfused. Solution and gas flow rate were
100 ml/min and 4 l/min respectively.
5.2.6 Magnetic resonance imaging
The wrist coil - HFB system was laid on a plastic support built so that the middle of the
HFB was exactly in the isocenter of the magnet. During perfusion, eight cross sections of the
HFB inlet tubing, reference vials containing 0.5, 2 and 4 mM of Gd-DTPA, and the HFB were
imaged on an Eclipse 1.5 T MR system (Philips Medical Systems Inc., Cleveland, OH, USA). 
Dynamic T1-weighted imaging was performed using fast gradient echo sequence FAST [5]
with the following imaging parameters: 90°-180° magnetization preparation, TI/TR/TE
28/10.52/4 ms, FA 90°, FOV 10 cm, matrix size 256 x 256, slice thickness 5 mm. The inter-
image delay was 2.5 seconds for the choice of the HFB and 20 seconds for all other
experiments. Results were expressed as the mean SI of a cross-section as a function of time.
Bioreactor SI - time curves obtained with different experiments were compared after
normalization with the SI values of the 4 mM reference vial obtained during the experiment
and corrected for the baseline.
A high resolution image was taken after each perfusion using a T1-weighted spin echo
sequence with the following imaging parameters: TR/TE 400/20 ms, bandwidth 20.83 kHz,
slice thickness 5 mm, matrix size 512 x 512, number of averages 2, slices 8.
5.2.7 Kinetic modeling
For the choice of the HF module and flow rate, MR signal intensities (SI) of a HFB cross-
section by respect to time were submitted to compartmental analysis using the software
MicroPharm (version 4.0, 1995, Inserm, France). Equation 5.2 described the one-
compartment model while the two-compartment model was described by equation 5.3, where
k1 and k2 are the rate constants of phase 1 and 2 respectively.
-k tSI = A 1- e  
 
[Equation 5.2]
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1 2-k t -k tSI = A 1- e + B 1- e     
   
[Equation 5.3]
The relationship between the rate constant (k) and the half-life (t½) is given by equation 5.4:
k
ln2 t 1/2  [Equation 5.4]
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5.3 Results and discussion
5.3.1 Set up of the MRI compatible perfusion system
The major challenge was to build a MRI compatible perfusion system which did not
contain any metallic piece inside the magnet room. This was possible by using only plastic
and glass materials and by installing the heating system, the gas bottle and the pump in an
adjacent room. A picture of the MRI part of the perfusion system is shown in figure 5.4.
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Figure 5.4: Picture of the MRI part of the perfusion system. The hollow fiber bioreactor was located
in the isocenter of the magnet and wrist coil to have the best MRI resolution. The bioreactor was
surrounded by the reference vials. The picture also shows the bubble trap and the oxygen-delivering
tubing.
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The HFB was imaged with the wrist coil because its size best suited for imaging the HFB.
Strongest MR signal is obtained when imaging an object with a coil adapted to the size of the
object and the wrist coil was the smallest coil available for the HFB.
5.3.1.1 Solution circulation system
The solution pH was adjusted to 7.2 during preparation. It rose and stabilized at pH 7.4 in
the perfusion system, because of the increased oxygen concentration. HEPES enabled to
stabilize the pH around 7.4, which was not possible with a bicarbonate buffer alone.
Antibiotics were added to ensure sterility.
Long tubing was necessary to connect the different elements of the perfusion system, as
they were located in two different rooms; the total dead volume was 275 ml. Hence, an
efficient control was required to ensure a temperature of 37°C in the hepatocyte HFB.
5.3.1.2 Heating system 
The temperature recommended for most human and warm-blooded animal cells is 37°C,
close to body heat. It was set a little lower for safety reasons, as overheating is a more serious
problem than underheating [6].
In order to have a culture temperature of 36.5°C inside the HFB the heating circulator
temperature had to be set at 38.6°C. The corresponding temperature indicated by the probe at
the outlet of the HFB near the reservoir was 32.0°C. During HFB perfusion experiments, only
this latter temperature was continually checked, because of the risk of causing interferences
with the magnetic signal if a probe was set at the HFB inlet, in the magnet. A reproducible
temperature control of 32.0  0.1 °C was obtained and considered as acceptable. Long tubing
and big dead volumes explain the temperature decrease observed between the heating
circulator, the HFB and the reservoir.  
The refrigerant was installed in the magnet, just before the oxygenator system and the
HFB. This avoided bubble formation due to temperature elevation, as oxygen solubility
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decreases when temperature increases. Actually, if the solution had been oxygenated prior to
heating, it would have produced bubbles.
5.3.1.3 Oxygenation system
As hepatocytes do consume a lot of oxygen, an improved oxygenation had to be ensured.
This required the use of an artificial lung. We used a silicone membrane oxygenator similar to
the one first described by Knazek et al. [7]. It consisted of silicone tubing through which O2
and CO2 can diffuse readily. 
A gas flow rate of 3 l/min was found to be the minimal one which saturated the solutions
with oxygen. For more security, the flow rate was fixed to 4 l/min during experiments.
Actually, oxygen plays a key role in hepatocyte function and anoxia may lead to cell
death [8]. An insufficient oxygenation of the system would cause a poor hepatocyte function
and viability.
When using silicone tubing, one must be aware of possible adsorption phenomena of
solutes contained in the perfusion solution. In our lab, we saw 7-ethoxycoumarin (7-EC)
adsorption in the oxygenator. The evolution of Gd-BOPTA and Gd-DTPA concentrations in
the perfusion solution with time during perfusion of the whole system is shown in figure 5.5.
The adsorption of 7-EC in the system, was added to the graph for comparison.
In contrast to 7-EC, no adsorption of Gd-BOPTA or Gd-DTPA in the perfusion system
was detected. The absence of adsorption of Gd-DTPA and Gd-BOPTA was also confirmed
during MRI experiments by measuring the inlet tubing signal intensity during HFB perfusion
which stayed stable during the whole period of perfusion with Gd-DTPA and Gd-BOPTA.
Like 7-EC, other drugs are also adsorbed by silicone, e.g. antibiotics [9] or fentanyl [10].
Nevertheless, silicone tubing is used to improve oxygenation in various cell culture systems,
and in particular for HFB [11].
Other kinds of oxygenators have been described, mainly polypropylene-based oxygenators,
which are less susceptible to drug adsorption [10]. For instance, Gerlach et al. [12] developed
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an HFB with a direct oxygenation of the hepatocytes. The system was composed of a separate
network of HF which did not contained the perfusion solution but oxygen. Polypropylene
hollow fibers are also used clinically for blood oxygenation during cardiopulmonary
bypass [13,14]. 
As the simple and good value silicone membrane oxygenator allowed an improved
oxygenation of the hepatocytes without adsorbing the investigated contrast agents
Gd-BOPTA and Gd-DTPA, it was further used in the MRI perfusion experiments.
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Figure 5.5: Adsorption in the perfusion system of Gd-BOPTA, Gd-DTPA and 7-ethoxycoumarin
(7-EC).
5.3.2 Determination of the optimal hepatocyte concentration in the HFB
The hepatocyte concentration in the HFB is a crucial point as it must be as large as
possible to mimic liver cellular density and permit MRI detection. However, it should avoid
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causing cellular toxicity due to density and a minimum of animals should be sacrificed. Two
different cellular densities were compared: 2·107 and 4·107 cells/ml. 
According to the literature [15-17], the mean hepatocyte diameter is estimated at 25 m,
which gives a mean hepatocyte volume of 8181 m3. It is assumed that the total hepatocyte
volume represents 80-85% of the liver volume and hepatocyte density is 108 cells/cm3. In
comparison, with a cell density in our HFB of 2·107 cells/ml, the volume occupied by
hepatocytes is only about 20% of the ECS of the HFB (25 ml). This volume is about 40%
when the cell density in the HFB is 4·107 cells/ml. A density of 2·107 cells/ml corresponds to
500 millions of hepatocytes inoculated in the 25 ml ECS of the bioreactor. This quantity was
isolable from a single rat liver. On the other hand, 4·107 cells/ml was achievable with
hepatocyte extraction of two rat livers, which could be made in less than 8 hours. While
extracting cells from the second liver, hepatocytes already isolated from the first liver were
kept in ice-cold UW solution. Hepatocytes preserved at 4°C in this solution remain functional
and viable for several hours [18-21] without deterioration of transport functions, as shown in
chapter 4. 
The percentage of LDH and AST released in the perfusion solution as a function of time
was used as a toxicity index to validate the optimal HFB cellular density. The percentage of
LDH and AST released in the perfusion solution was calculated as the percentage of LDH and
AST activity in the perfusion solution compared to the total LDH and AST activity contained
in hepatocytes. The total activity of enzymes contained in hepatocytes determined after
disruption of the membrane with Triton X-100 was 6.46  0.73 U/106 cells for LDH and
2.55  0.26 U/106 cells for AST (n = 18).
Figure 5.6 shows the evolution of LDH and AST release in the solution as a function of
time of perfusion. These results suggest that increasing the HFB hepatocyte density from
2·107 cells/ml to 4·107 cells/ml did not result in increased cellular toxicity. Actually, AST and
LDH activity in the perfusion solution showed similar progressions, the curves obtained with
4·107 cells/ml rose a little more than the curves obtained with 2·107 cells/ml, but the
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difference was not significant. After 4 hours of perfusion, about 16% of total intracellular
LDH and about 5% of total intracellular AST were released in the perfusion solution. 
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Figure 5.6: Evolution of LDH and AST release in the solution as a function of time of perfusion,
expressed as percentage of the total LDH and AST activity contained in hepatocytes.
Most cell viability tests rely on direct coloration with dye (e.g. trypan blue, fluorescein).
These tests could not be applied to monitor cell viability during our experiments as HFB are
closed systems, rendering cell sampling impossible. The methods currently used to quantify
cell vitality in HFB perfusion systems include oxygen consumption, enzyme release, and
evaluation of complex synthetic and metabolic activities [22]. The concentration of
intracellular enzymes released due to membrane leakage (e.g. LDH, AST, ALT, GPT, GLDH,
GGT and transaminases) is used as a criterion of cellular integrity and quality [23]. The
percentage of LDH liberation observed is more important than that of AST because LDH is
located in the cytosol, while AST is found in the mitochondria. When cell death begins, the
cell membrane is damaged first, leading to LDH release, and the mitochondrial membrane is
affected only later, with its consequent AST liberation. Among all enzymes, LDH is the most
sensitive marker of cell damage [23]. Baur et al. [22] observed a correlation between the
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percentage of total cells stainable by trypan blue and the percentage of total LDH release;
LDH release was even a little more sensitive than the trypan blue exclusion test. Using LDH
release as a cellular viability marker, our results suggest that hepatocyte viability was about
85% after 4 hours of perfusion. 
It is difficult to compare our results of total enzyme activities in hepatocytes with values
from the literature, as they vary markedly among authors. For instance, Chao et al. [24] found
that fresh hepatocytes treated with 0.1% Triton X-100, yielded 3500-4500 U LDH/106 cells.
Baur et al. [22] demonstrated that a liver with a fresh weight of 12 g corresponded to a total
LDH activity of 4200 U. Considering that liver density is 1 g/ml and hepatocyte density
108 cells/cm3 [15], this gives a total LDH activity of 3.5 U/106 hepatocytes. Thus, our result of
the total activity of LDH, 6.5 U/106 hepatocytes, is situated close to the value of Baur et al.
To summarize, increasing the HFB hepatocyte density from 2·107 cells/ml to 4·107 cells/ml
did not increase cellular toxicity, and the higher the cellular density, the better it will mimic
the physiological state. Hence, a cellular density of 4·107 cells/ml was used for further MRI
experiments. This represents a cellular density in the ECS of 40%, which allows a good
compromise between cellular toxicity, animal sacrifice, and physiological state, where the
hepatocyte density is about 80%. A picture illustrating HFB before and after inoculation of
4·107 cells/ml in the ECS is presented in figure 5.7.
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Figure 5.7: Hollow fiber bioreactor before (at the bottom) and after inoculation of 4·107 cells/ml (in
the top) in the extracapillary space.
5.3.3 MRI of the bioreactor
SI was maximal in the zone situated in the middle of the HFB which corresponded to the
isocenter of the magnet. As seen in figure 7.8, this zone corresponded to the 4th and 5th of the
eight cross-sections measured. The value of the maximal SI decreased as the slices moved
away from the isocenter. Indeed, the SI of the second and 7th slice were lower than the one of
the 4th and 5th. The very low SI of the first cross-section may suggest that it was situated
outside the HFB.
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Figure 7.8: Evolution of MR signal intensity with time of a hollow fiber bioreactor perfused with
solution + Gd-DTPA 0.2 mM for 10 minutes and with solution free of contrast agent for 8 minutes.
The SI obtained with different slices were corrected for the baseline. Only 5 of the 8 cross-sections
measured were represented for a better legibility of the graph.  
Consequently, the 4th slice was taken for the different calculations and interpretations made
with the HFB. Results of dynamic imaging were expressed as signal intensity - time curves.
Chapter 5 128
An example of a high resolution image of a typical experiment at the level of the 4th slice of
the HFB is depicted in figure 5.8. This image represents a cross section of the elements
located in the wrist coil. The hollow fibers and packs of hepatocytes could be observed inside
the bioreactor, which was not possible by dynamic imaging. Reference vials and HFB inlet
and outlet tubing were surrounding the HFB. 
Figure 5.8: High resolution image (spin echo sequence, TR/TE 400/20 ms, bandwidth 20.83 kHz,
slice thickness 5 mm, matrix size 512 x 512) of the hepatocyte hollow fiber bioreactor (HFB). The
HFB (in the middle) was surrounded by three reference vials containing 0.5 (at the bottom left), 2 (at
the bottom right) and 4 mM (at the top right) of Gd-DTPA, and by HFB inlet and outlet tubing (at the
bottom). Hollow fibers were distinguishable inside the bioreactor.
5.3.3.1 Choice of the hollow fiber module 
There are many kinds of HFB modules available on the market, but we decided to test only
a small number of HF modules which corresponded to our criteria, namely: 
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Large fiber porosity to have a maximal exchange rate between the ICS and the ECS, i.e. to
rapidly obtain contrast agent concentration equilibrium, and to provide hepatocytes with
maximal nutrients and oxygen;
HF module diameter large enough to allow MRI analysis, and 
Length short enough to get an important cell density. 
The three modules tested differed from each other by fiber surface area (FSA) and
porosity: module 1 had a FSA of 140 cm2 and a porosity of 0.5 m, module 2 had a FSA of
420 cm2 and a porosity of 0.5 m and module 3 had a FSA of 140 cm2 and a porosity of
0.2 m. 
The diffusion of Gd-DTPA 2 mM into the ECS of the three different HF modules tested at
a flow rate of 100 ml/min is depicted in figure 5.9. HFB were first perfused with a solution
without contrast agent, and after 15 seconds with a solution containing 2 mM Gd-DTPA.
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Figure 5.9: Normalized MRI signal intensity – time curves of hollow fiber bioreactor (HFB) filling
with Gd-DTPA 2 mM, flow rate = 100 ml/min, module 1 = 0.5 m, 140 cm2, module 2 = 0.5 m, 420
cm2, module 3 = 0.2 m, 140 cm2. HFB were first perfused with a solution without contrast agent, and
after 15 seconds with a solution containing 2 mM Gd-DTPA for 10 minutes.
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As shown in figure 5.9, steady-state was rapidly reached with modules 1 and 2. On the
contrary, with module 3 steady-state was not reached after 10 minutes. 
SI – time curves were analyzed according to equations 5.1 and 5.2. Results of the kinetic
compartmental analysis are given in table 5.1.
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Table 5.1: Results of the kinetic compartmental analysis of the SI - time curves.
Kinetic model t ½ phase 1 t ½ phase 2
Module 1 1 compartment 1.19  0.01 min -
Module 2 1 compartment 0.29  0.00 min -
Module 3 2 compartments 0.06  0.01 min 4.56  0.13 min
Compartmental kinetic analysis enabled to quantify the filling process of the HFB with
contrast medium. While the filling process of modules 1 and 2 followed a one-compartment
model, the one of module 3 corresponded to a two-compartment model (table 5.1). 
These results suggest that in the case of modules 1 and 2, both fiber filling with Gd-DTPA
and its diffusion through the fibers in the ECS were so rapid as not to be distinguishable. The
filling of Gd-DTPA was more rapid with module 2 than with module 1, as shown by the
half-lives of 0.3 and 1.3 minutes respectively. Generally, it is considered that 4 half-lives are
necessary to reach 90 % of the steady-state. Consequently, one can estimate that module 1
was completely filled with Gd-DTPA after 4.8 minutes while it took only 1.2 minutes for
module 2. These results are in good agreement with the curves depicted in figure 5.9. 
In contrast, for module 3 the filling of the fibers with contrast solution and the diffusion
process in the ECS showed different rate constants. The first phase, characterized by a short
half-life of 0.1 minute corresponded to the filling of the hollow fibers with Gd-DTPA,
whereas the second phase corresponded to the diffusion of contrast medium through the fibers
in the ECS as it was observed on the images obtained during the dynamic imaging of the
HFB. The latter was slow and was the limiting step of HFB filling. It had a half-life of
4.6 minutes, which means that 18.4 minutes were necessary to reach 90 % of the steady-state.
Indeed, one can observe in figure 5.9 that steady-state was not obtained after 10 minutes
perfusion with Gd-DTPA. 
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The slow diffusion of Gd-DTPA observed with module 3 was probably due to the smaller
pore size of 0.2 m compared to 0.5 m. Module 2 filling was faster than the one of module 1
because of its larger fiber surface area of 420 cm2, whereas it was only 140 cm2 for module 1.
Module 2 was used for further hepatocyte HFB experiments as it permitted to reach the
steady-state after the shortest time period (1.2 minutes). 
5.3.3.2 Optimization of the flow rate
Figure 5.10 shows the influence of the perfusion solution flow rate on the diffusion of
Gd-DTPA 0.2 mM in module 2, as a function of time. The three different flow rates tested
were 50, 75 and 100 ml/min. The HFB was first perfused with solution without contrast agent
and after 3 minutes with a solution containing 0.2 mM Gd-DTPA.
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Figure 5.10: Normalized MRI signal intensity – time curves of hollow fiber bioreactor (HFB) filling
(module 2, 0.5 m, 420 cm2) with Gd-DTPA 0.2 mM, at three different flow rates (50, 75 and 100
ml/min). HFB was first perfused with solution without contrast agent and after 3 minutes with a
solution containing 0.2 mM Gd-DTPA.
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The results presented in figure 5.10 clearly indicate that the steady-state was obtained with
the three flow rates tested, but with different velocities. Whereas the steady-state was obtained
rapidly and almost at the same time with flow rates of 75 and 100 ml/min, diffusion of
Gd-DTPA in the ECS of the HF module was slower with a flow rate of 50 ml/min.
Kinetic analysis enabled to measure the diffusion difference between flow rates of 75 and
100 ml/min. The two curves were well described by a one-compartment model, with
half-lives of 1.00  0.05 and 0.82  0.04 minutes respectively. Hence, diffusion of contrast
medium through the HF membrane in the ECS was more rapid with a flow rate of
100 ml/min, although the difference with diffusion at a flow rate of 75 ml/min was slight. The
relation between the rate of solute appearance in the ECS and the flow rate has also been
observed by other authors [25,26]. 
One could have tested greater flow rates. Based on the previously shown results, the
greater the flow rate, the more rapid the diffusion. However, diffusion did not accelerate
significantly when increasing the flow rate from 75 to 100 ml/min. This suggests that
increasing the flow rate over 100 ml/min would not have considerably changed diffusion, but
it could have improved oxygenation and oxygen is the most important nutrient for
hepatocytes [11]. On the other hand, increasing the flow rate also increases cell shear stress
when hepatocytes are present in the HFB extracapillary space, which is prejudicial. Thus, a
compromise between optimal diffusion, oxygenation and minimal cell shear stress was chosen
and the flow rate was fixed to 100 ml/min for the hepatocyte HFB experiments.
A closer look at figure 5.10 shows that signal intensity did not remain stable after having
reached the steady-state. Signal intensity oscillations were greater with flow rates of 50 and
100 ml/min than with a flow rate of 75 ml/min. The source of these SI oscillations is still
unknown, but they seem to be related to the flow rate. Indeed, oscillation period and
amplitude looked like being two times greater with a flow rate of 50 ml/min than with a flow
rate of 100 ml/min. These oscillations were maybe due to a kind of resonance phenomenon in
the perfusion system. This aspect will be investigated in a near future.
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5.3.3.3 Validation of the hepatocyte hollow fiber bioreactor
To validate our in vitro model, we studied the behavior of an extracellular contrast agent
(Gd-DTPA) and an intracellular contrast agent (Gd-BOPTA) by MRI during perfusion of the
HFB with the two contrast agents. Typical rough SI - time curves are presented in figure 5.11.
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Figure 5.11: Evolution of MR signal intensity with time in a hollow fiber bioreactor (HFB) containing
4·107 hepatocytes/ml. The HFB was perfused with a solution + 0.05 mM Gd-BOPTA for 30 minutes,
with a solution free of contrast agent for 30 minutes, with a solution + 0.05 mM Gd-DTPA for 20
minutes, with a solution free of contrast agent for 20 minutes, with a solution + 0.2 mM Gd-BOPTA
for 30 minutes, and finally with a solution free of contrast agent for another 30 minutes. Dashed lines
indicate the baselines.
These results indicate that the hepatocyte HFB system was able to show differences
between Gd-DTPA and Gd-BOPTA. As can be seen in figure 5.11, at the beginning of the
perfusion with Gd-BOPTA 0.05 mM the SI rapidly increased, followed by a slower increase.
During the washing step, SI decreased rapidly to a value different from the one before the
perfusion. Beyond that point, SI remained stable or very slightly decreased but without
returning to the baseline. The subsequent perfusion of the hepatocyte HFB with Gd-DTPA
0.05 mM showed that the SI rapidly reached a steady-state and returned to the value of the
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residual SI observed before the initiation of the perfusion with Gd-DTPA when the perfusion
was switched to solution without contrast agent. This indicates that the residual amount of
Gd3+ resulting from the first perfusion with Gd-BOPTA remained in the bioreactor or at least
was released so slowly that the decrease was not detectable during the time period of the
experiment. Consequently, it was possible to continue with an additional perfusion using the
same hepatocytes in the same HFB by simply taking into account this new baseline. In the
case presented in figure 5.11, the HFB was further perfused with a solution containing
Gd-BOPTA 0.2 mM. The shape of the SI-time curve was similar to the one obtained with
Gd-BOPTA 0.05 mM but with a higher SI. This procedure allowed to use the same
hepatocyte HFB for up to three consecutive experiments, which represented a gain in time
and animals. Indeed, the preparation of the hepatocyte HFB is time-consuming and a reduced
number of sacrificed animals is an advantage from an ethical and economic point of view.
The rapid and reversible evolution of SI obtained with the extracellular contrast agent
Gd-DTPA can be explained as follows: Gd-DTPA rapidly diffused from the ICS through the
hollow fibers and filled the ECS of the bioreactor, i.e. the space between hepatocytes. When
perfusion was changed to solution without contrast agent, Gd-DTPA completely disappeared
from the HFB. During perfusion of the intracellular contrast agent Gd-BOPTA, the same
observable processes of diffusion and filling occurred, but with a supplementary
phenomenon: Gd-BOPTA had an additional distribution space, as it can penetrate
hepatocytes, and this was the rate-limiting step. After 30 minutes perfusion with solution free
of contrast medium, Gd-BOPTA was not completely washed out from the bioreactor. A
residual SI was observed (figure 5.11), indicating that a part of the Gd-BOPTA remained in
the hepatocytes. Actually, this residual SI could not be due to adsorption of Gd-BOPTA
anywhere in the bioreactor as no adsorption of Gd-BOPTA was detected by fluorescence and
MRI in the whole perfusion system (5.3.1.3).
The reproducibility of the method was assessed with two additional experiments in which
solutions of  Gd-BOPTA 0.2 mM were perfused in the hepatocyte HFB (figure 5.12). 
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Figure 5.12: Evolution of normalized MRI signal intensity with time in three hollow fiber bioreactors
containing 4·107 hepatocytes/ml. Bioreactors were perfused with solution + 0.2 mM Gd-BOPTA for
30 minutes, and then with solution exempt of contrast agent for 15 minutes. SI were first corrected to
zero and then normalized according to the SI of reference vials.
These results indicate that reproducible SI - time curves were obtained with Gd-BOPTA
perfusion during different experiments, after normalization according to SI values of the
4 mM reference vial and correction to zero. Actually, the SI obtained after 30 minutes of
perfusion with Gd-BOPTA 0.2 mM with three experiments are the same (15.1  0.9;
16.1  0.8; 17.1  1.2). The same reproducibility was obtained with perfusion of Gd-DTPA
(data not shown). Correction to zero was necessary as SI obtained with a solution free of
contrast agent had a positive initial SI value. MRI does not give identical SI from one
experiment to the other. Therefore, normalization with reference vials was crucial. Indeed,
uncorrected SI - time curves obtained during diverse experiments performed under identical
experimental conditions (e.g. concentration of contrast agent, etc.) could differ from each
other by more than 50%. 
The cellular viability during experiments was checked by determination of the oxygen
consumption and release of intracellular enzymes, AST and LDH. As seen in table 5.2, the
oxygen consumption was about 1000 M/h after 3 hours of experiment; it did not decline
with time but seemed to have an upward trend. The viability of hepatocytes, based on the
Chapter 5 137
amount of AST and LDH released was routinely greater than 90% after 3 hours of
experiment. These results confirm that the perfusion system was able to ensure a good cellular
viability.
Table 5.2: Cell viability monitoring with oxygen consumption and LDH and AST release (n = 3).
time [min] 0 30 60 90 120 150 180
O2 consumption
[M/h]
0.0
 0.0
700.0
 35.6
626.5
 8.2
908.3
 105.1
1068.1
 61.7
1025.1
 203.2
1017.6
 144.2
LDH release 
[%]
0.0 
 0.0
1.1 
  0.4
2.0
 0.2
3.6
 0.4
5.6
 0.2
6.5
 0.1
8.3
 0.8
AST release 
[%]
0.0 
 0.0
0.2
 0.1
0.6
 0.1
0.8
 0.2
1.3
 0.2
1.9
 0.2
2.2
 0.4
No bacterial growth was observed in agar-agar cultures, indicating that the perfusion
system remained sterile during the whole experiment. 
5.4 Conclusion
The purpose of this work was to develop and to validate a MRI compatible in vitro cellular
model permitting the study of contrast agents. The cell culture device consisted of a HFB
containing freshly isolated rat hepatocytes. The HFB perfusion system was set up according
to the MRI requirements, in particular the absence of metallic components in the MRI room.
The elements located in the magnet room were made of plastic or glass material, and the
equipment containing metal pieces was set in an area adjacent to the magnet room. 
The perfusion system developed was able to supply hepatocytes contained in the ECS of
the HFB with a thermoregulated and oxygenated solution. The use of a silicone membrane
oxygenator alimented with a mix of oxygen (95%) and carbon dioxide (5%) at a flow rate of 4
l/min resulted in a good oxygenation without adsorption of the investigated contrast agents.
Perfusion experiments were performed using a HF module with a porosity of 0.5 m, which
was the biggest porosity available on the market, and a surface area of 420 cm2. These
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characteristics, together with the use of a high flow rate of 100 ml/min permitted to rapidly
reach a concentration equilibrium between the intra- and the extracapillary space of the
bioreactor. Rapid and total diffusion of contrast agents was very important as we wanted to
see their behavior towards hepatocytes; rapid diffusion of oxygen and other nutrients is also
crucial for the maintenance of hepatocytes viability. As a result, we obtained a good cellular
viability during perfusion experiments; based on LDH release, one can estimate that
hepatocyte viability was greater than 85% after 4 hours perfusion. HFB hepatocyte density
was 4·107 cells/ml. This density did not cause cellular toxicity and did not require an
excessive sacrifice of animals, but permitted to obtain a hepatocyte density close to the half of
the in vivo hepatocyte density.
Normalization of the SI – time curves by means of reference vials allowed the comparison
of results generated by different experiments and it was shown that the results were
reproducible. These results also demonstrated that the in vitro model developed permitted to
differentiate the behavior of the intracellular contrast agent Gd-BOPTA and the extracellular
contrast agent Gd-DTPA, the contrast agents being directly measured by MRI. Moreover, the
consecutive perfusion of a single hepatocyte HFB with up to three different solutions of
contrast agent was a procedure which represented an important gain in time and animals. 
In summary, we succeeded in developing an in vitro cellular model for the study of MRI
contrast agents, where the effects of the contrast agents investigated were directly measured
by MRI. We offer a tool to better understand the mechanisms of hepatobiliary contrast agents
both in healthy and diseased hepatocytes.
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Chapter 6
Complementary studies: effect of contrast agent concentration on
the MR signal, image analysis and metabolism study
In the previous chapter, we described the development of a magnetic resonance imaging
(MRI) compatible hepatocyte hollow fiber bioreactor (HFB) for the study of MRI contrast
agents. It was shown that the system allowed to distinguish in a reproducible manner between
the behavior towards hepatocytes of the hepatobiliary contrast agent Gd-BOPTA and the one
of the extracellular contrast agent Gd-DTPA. In the present chapter, we investigated whether
there was a domain of linearity between the MR signal intensity and the concentration of
contrast agents. This linear correlation is important for further investigation of contrast agent
mechanisms using the MRI compatible HFB. Hence, in the first part of this chapter, we
studied the relation between the concentration of contrast agent and the signal intensity (SI) of
tubes containing solutions of Gd-DTPA and Gd-BOPTA.
Another objective was to study a possible improvement of the MR image analysis. Two
different approaches of image treatment were applied to improve the quality of the results by
focusing on the effects due to hepatocytes. Unfortunately neither the delimitation of regions
of interest (ROI) nor the creation of a mask of the fibers improved the results and will thus not
be used for further experiments.
Finally, we tried to set up an additional test for the evaluation of the viability of
hepatocytes contained in the HFB consisting of a continuous in-line assessment of the
metabolic functions of the cells. Due to important adsorption phenomena of the substrate in
the HFB perfusion system, it was not possible to perform this test to detect a metabolic
reaction.
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6.1 Effect of contrast agent concentration on the MR signal 
As already mentioned in chapter 3, the MR signal depends on the characteristics of the
object imaged, such as the proton density, on the relaxation times T1 and T2, and on the
parameters of the data acquisition sequence. The signal intensity depends on these factors in a
nonlinear way. On the other hand, the decrease of the relaxation times T1 and T2 by contrast
agents is linearly correlated to their concentration but depends on various factors such as the
temperature and the composition of the solution containing the contrast agents.
The present study aimed at an improved quantification of the MR signal. The influence of
the concentration of Gd-DTPA and Gd-BOPTA on the signal intensity with tubes containing
concentrations of contrast agent ranging from 0 to 50 mM was studied. Actually, to
investigate the mechanisms of contrast agents in our future experiments, we would like to
study the effect of the concentration of contrast agent perfused through the hepatocyte HFB,
and this implies that the signal intensity is linearly correlated with the contrast agent
concentration so that the results can be compared to each other.
6.1.1 Materials and methods
6.1.1.1 Chemicals
Solution of Gd-BOPTA 0.5 M was generously donated by Bracco Research S.A. (Geneva,
Switzerland). A commercially available solution of Gd-DTPA 0.5 M (Magnevist, Schering,
Germany) was used. Bovine serum albumin (BSA, fraction V, 97%) was purchased from
Fluka. All other chemicals were of analytical grade.
6.1.1.2 Preparation of the tubes and measurement of the signal intensities
Solutions of Gd-DTPA and Gd-BOPTA with concentrations ranging from 0 to 50 mM
were prepared by diluting the concentrated solutions of Gd-DTPA and Gd-BOPTA in purified
water and in modified Hanks's solution with or without 0.5% BSA. The solutions were
filtered aseptically (Millex GS, 0.22 m, Millipore Co., Bedford, Massashuset, USA) in
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plastic tubes of 50 ml and kept at 4°C till magnetic resonance imaging. The tubes were
imaged using the same dynamic T1-weighted sequence as for the HFB experiments described
in chapter 5 but with the head coil instead of the wrist coil.
6.1.2 Results and discussion
Tubes containing solutions of Gd-DTPA and Gd-BOPTA in water with concentrations
ranging from 0 to 50 mM were imaged in order to see the relation between signal intensity
and the concentration of contrast agent (figure 6.1).
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Figure 6.1: Plots of the signal intensity of tubes containing 0 to 50 mM of Gd-BOPTA and Gd-DTPA
in water as a function of the contrast agent concentration.
When increasing the concentration of contrast medium from 0 to 7 mM, SI increased, too,
but with a saturation of the signal intensity. Beyond 7 mM, SI declined with the increase of
concentration, due to the growing importance of the T2 effect. Hence, the SI of tubes
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containing solutions of contrast agents ranging from 0 to 50 mM was not linearly correlated
with concentration.
However, there seemed to be a linear correlation between SI and low concentrations of
Gd-BOPTA and Gd-DTPA. Thus, we tested low concentrations of the two contrast agents to
see whether there was a domain of linearity. We also studied the influence of the presence of
0.5% BSA as this is the amount of protein present in the modified Hanks’s solution used for
the HFB experiments.
The imaging of tubes containing solutions of Gd-DTPA and Gd-BOPTA with or without
0.5% of BSA showed that SI was linearly correlated to the concentration of contrast agent up
to 0.4 mM (figure 6.2). Parameters of the linear regressions are compiled in table 6.1.
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Figure 6.2: Plot of the signal intensity of tubes containing 0 to 0.4 mM of Gd-BOPTA and Gd-DTPA
in Hanks’s solution with or without 0.5% albumin as a function of the contrast agent concentration.
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Table 6.1: Linearity between the signal intensity and the concentration of contrast agent (0 - 0.4 mM).
Regression parameters
slope Y-intersept n r2 s F
Gd-DTPA
Gd-DTPA + 0.5% BSA
Gd-BOPTA
Gd-BOPTA + 0.5% BSA
455.2 ± 6.905
647.1 ± 40.69
600.2 ± 26.56
733.6 ± 37.07
63.71 ± 1.424
100.4 ± 8.388
77.03 ± 5.475
101.5 ± 7.641
5
5
5
5
0.999
0.988
0.994
0.992
2.184
12.87
8.398
11.72
4346
252.9
510.8
391.7
BSA: bovine serum albumin, r2: squared correlation coefficient, s: standard deviation of the residuals, F: Fisher
test for significance of the equation
As the SI changed linearly with the concentration of Gd-DTPA and Gd-BOPTA up to
0.4 mM, with and without BSA in the Hanks’s solution, this range of concentrations will be
used for the further experiments performed with the HFB. Actually, within this range signal
intensities obtained with different concentrations of contrast agent can be directly compared
to each other. However, the linear regressions obtained cannot be used to convert signal
intensities to concentrations in HFB perfusion experiments and the SI-time curves obtained
from MR images of the HFB cannot be compared to dynamic concentration-time curves. In
fact, the linear relationships obtained were observed in static tubes, while a flux is present in
the HFB and flux is known to influence the SI. Moreover, when hepatocyte HFB were
perfused with a solution containing Gd-BOPTA, the contrast agent was partially taken up by
the hepatocytes. As the composition of the intracellular fluid is not identical to the one of the
solution perfused, in particular richer in macromolecules which are known to change the
relaxivity of several contrast agents, including Gd-BOPTA and Gd-DTPA, relaxivities are
different in the intracellular fluid and the perfusion solution [1]. Hence, the non-homogeneity
of the different compartments contained in the hepatocyte HFB impede the conversion of SI
to concentration of contrast agent, at least at the present time where more research is needed
to permit a better calibration of the MR signal.
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As also shown in figure 6.2, the presence of albumin increased the SI by about 10% for
Gd-BOPTA and Gd-DTPA. It is known that contrast agents have in general higher relaxivities
in protein solutions than in water or saline. This has been attributed to so-called
microviscosity effects [2]. Published values of the r1 relaxivities of Gd-BOPTA are
4.4 mM-1s-1 in protein-free aqueous solution and ~8.0 mM-1s-1 in 4% BSA solution, while
these values are 3.8 mM-1s-1 and ~4.3 mM-1s-1 respectively for Gd-DTPA [1,2]. Hence, the
improvement of Gd-BOPTA relaxivity in the presence of 4% albumin is reported to be about
two times higher than in saline solution, whereas the one of Gd-DTPA is more moderate. This
is explained by the weak binding of Gd-BOPTA to albumin [3], while Gd-DTPA does not
bind to albumin at all [1]. In our case, the increase of the SI of Gd-BOPTA in the presence of
albumin was not so important (figure 5.9), probably because there was only 0.5% of albumin
in the solutions. We investigated a concentration of 0.5% of albumin because it was the
concentration used for the hepatocyte HFB experiments. Nevertheless and contrary to the
literature, we observed that the SI of Gd-DTPA was even slightly more sensitive to the
presence of 0.5% BSA than Gd-BOPTA. 
At the same concentration, Gd-BOPTA gave a SI about 10% higher than the one of
Gd-DTPA, with and without 0.5% BSA in the Hanks’s solution. This will have to be taken
into account when interpreting the signal intensities obtained with the hepatocyte HFB.
Indeed, differences in SI were also observed when perfusing a bioreactor free of hepatocytes
with Gd-BOPTA and Gd-DTPA 0.1 mM, as presented in figure 6.3. Thus, a higher SI
observed when perfusing a hepatocyte HFB with Gd-BOPTA, compared to Gd-DTPA, can
not simply be interpreted as being the consequence of the uptake of Gd-BOPTA in the
hepatocytes. In fact, at least a part of this increase of SI is due to the higher relaxivity of
Gd-BOPTA.
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Figure 6.3: Evolution of the signal intensity with time in a hollow fiber bioreactor free of hepatocytes.
The bioreactor was perfused with Hanks’s solution + 0.1 mM of Gd-DTPA or Gd-BOPTA for 15 min,
and washed with solution free of contrast agent for 15 min. SI was first corrected to zero to facilitate
comparison. 
6.1.3 Conclusion
The MRI of tubes containing increasing concentrations of contrast agents indicated that SI
was linearly correlated to the concentration of Gd-DTPA and Gd-BOPTA as long as the
concentration did not exceed 0.4 mM, in presence and in absence of albumin. According to
these results, this range of concentrations will be used for further hepatocyte HFB
experiments. Within this range, SI obtained with different concentrations of Gd-BOPTA and
Gd-DTPA can be directly compared to each other. 
At the same concentrations, with and without albumin, the signal intensities obtained with
Gd-BOPTA were a little higher than with Gd-DTPA. Furthermore, the presence of 0.5%
albumin slightly increased the SI for both of them. The higher SI of Gd-BOPTA compared to
Gd-DTPA will have to be considered when interpreting results obtained with the hepatocyte
HFB.
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6.2 Approaches to improve the hollow fiber bioreactor image analysis
6.2.1 Introduction
In chapter 5, the MRI results obtained with the HFB were expressed as the mean SI of a
cross section with time. Thus, the SI included the contribution of at least three elements: the
fibers, the hepatocytes and the extracellular space surrounding the hepatocytes outside the
fibers. 
In this section, we tried different approaches of image treatment to see if it was possible to
improve the quality of the results by focusing on the effects due to hepatocytes. The first
approach was to see whether more information could be obtained from the SI generated by
regions of interest (ROI) defined in the extracapillary space (ECS) of the bioreactors, and
centered on hepatocytes. Secondly, we investigated the contribution of the intracapillary
space (ICS) of the fibers to the signal intensity of the total cross section of the HFB and tried
to eliminate it by building a mask of the fibers.
6.2.2 Materials and method
6.2.2.1 Chemicals
Solution of Gd-BOPTA 0.5 M was generously donated by Bracco Research S.A. (Geneva,
Switzerland). A commercially available solution of Gd-DTPA 0.5 M (Magnevist, Schering,
Germany) was used. Bovine serum albumin (BSA, fraction V, 97%) was purchased from
Fluka. All other chemicals were of analytical grade.
6.2.2.2 Isolation of hepatocytes, preparation of the bioreactor, and perfusion of the system
Hepatocytes were isolated from two rat livers by a two-step collagenase perfusion as
described in chapter 4 and loaded in a HFB (Minikros Sampler M15E 260 01N, Spectrum,
Rancho Dominguez, CA, USA) at a final density of 4·107 cells/ml. The hepatocyte HFB was
set in the wrist coil, and perfused with a 37°C oxygenated Hanks’s solution containing
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0.5% BSA with or without contrast agent at a flow rate of 100 ml/min. The viability of the
hepatocytes was greater than 85% after 4 hours of experiment as assessed by the release of
lactate dehydrogenase (LDH) and aspartate aminotransferase (AST) in the perfusate and by
determining the oxygen consumption of hepatocytes. The setup of the whole procedure was
described in detail in chapter 5.  
6.2.2.3 Magnetic resonance imaging
Cross sections of the HFB were imaged with high resolution and dynamic sequences, as
already described in chapter 5. The image treatments were based on the 4th slice of the HFB.
High resolution images were used to define ROI in the extracapillary space of the HFB and to
build a mask to remove the signal intensity coming from the hollow fibers. ROI were
delimited by drawing a region in the ECS by hand. The construction of the mask began with
the subtraction of two high resolution images, one with a flux of solution in the fibers and the
other without flux, by stopping the peristaltic pump at the end of the experiment. This
permitted to separate the fibers from the remaining of the section thanks to a threshold of SI.
The images coming from the dynamic sequences were then reanalyzed considering only the
signal intensity of the ROI or the signal intensity of the whole cross section without the fibers.
6.2.3 Results and discussion
6.2.3.1 Regions of interest
Figure 6.4 shows a high resolution image of a cross section of the HFB which served to
delimitate a ROI in the extracapillary space of the hepatocyte HFB, where hepatocytes were
located and where cell packs could be seen.
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Figure 6.4: High resolution image of the hepatocyte hollow fiber bioreactor (HFB) with a delimitation
of a region of interest (ROI). The ROI was drawn inside the bioreactor (in the middle) which was
surrounded by three reference vials containing 0.5, 2 and 4 mM of Gd-DTPA, and by HFB inlet and
outlet tubing (at the bottom). Hollow fibers were distinguishable inside the bioreactor.
After their creation in the high resolution images, ROI were applied to the whole dynamic
imaging sequences during the hepatocyte HFB perfusion with Gd-DTPA and Gd-BOPTA.
The evolution of the signal intensity in two different ROI and in the whole section of the HFB
during the perfusion of Gd-DTPA and Gd-BOPTA 0.1 mM is shown in figure 6.5.
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Figure 6.5: Evolution of MRI signal intensity with time in two different regions of interest delimited
in the extracapillary space of a bioreactor containing 4·107 hepatocytes/ml. The bioreactor was
perfused with Hanks’s solution + 0.1 mM Gd-DTPA for 15 minutes, solution without contrast agent
for 15 minutes, solution + 0.1 mM Gd-BOPTA for 20 minutes, and finally solution without contrast
agent for 20 minutes. SI was corrected to zero for a better legibility of the figure.
The curves obtained with the ROI reached maxima which were lower than the one of the
whole cross section of the HFB, while the residual SI observed after the perfusion with
Gd-BOPTA were slightly higher. The difference between the SI of the whole section of the
HFB and the ROI is due to the fact that ROI were drawn in the ECS in places where packs of
hepatocytes could be seen. Thus, ROI permitted the withdrawal of regions in the ECS free of
hepatocytes but also filled with contrast agent and to concentrate on the cells. As seen in
chapter 5, the effect due to the cells is reflected by the residual SI. ROI permit to decrease the
effect of the extracellular area, which was expressed as an inferior maximum of SI, while
increasing the effect of hepatocytes, which was expressed as an amplified residual SI.
The fluctuations of SI obtained with ROI were larger than the ones obtained with the
whole cross section of the HFB. These high fluctuations impeded the quantitative analysis of
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the ROI SI-time curves. Results of only two ROI were presented here, although we assayed a
larger number of them. Some ROI could not be used because of a huge fluctuation of SI and
an absence of the characteristic shape of the curves. This illustrates the poor reproducibility of
the results obtained with ROI, which can be explained by their location in spaces with more
or less hepatocytes, or even with a piece of fiber. The high resolution images were of good
quality, nevertheless, the determination by hand of ROI free of fiber pieces was not easy. 
Though being an interesting approach, the use of ROI did not seem to be a useful way to
analyze our results, considering the impossibility to perform quantitative analysis of the ROI
SI-time curves and the complexity of the delimitation of ROI. Thus, it will not be applied in
future experiments.
6.2.3.2 Mask of the fibers
High resolution images were used to build a mask which permitted to eliminate the signal
intensity coming from the hollow fibers. The progression of the signal intensity of the whole
cross section of the HFB with or without the contribution of the SI due to the fibers is shown
in figure 6.6. 
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Figure 6.6: Progression of the MRI signal intensity of a cross section of a bioreactor containing
4·107 hepatocytes/ml with or without the contribution of the hollow fibers. The bioreactor was
perfused with Hanks’s solution + 0.2 mM Gd-DTPA for 20 minutes, solution without contrast agent
for 15 minutes, solution + 0.2 mM Gd-BOPTA for 20 minutes, and finally solution without contrast
agent for 15 minutes. SI was corrected to zero for a better legibility.
The curves obtained with the cross section of the HFB without the contribution of the
fibers reached maxima which were lower than the ones of the whole cross section of the HFB.
This difference can be totally assigned to the effect of the fibers. The fluctuations of the SI
with or without fibers were similar. The residual SI visible after the perfusion with
Gd-BOPTA were comparable, though being very slightly greater when the contribution of the
fibers was eliminated. 
The quantitative analysis of the SI-time curves with and without fibers indicated that both
had the same rate constant. Since it did not confirm our expectations of getting improved
results and as it is a rather complicated and long lasting technique, we will neither use masks
of the fibers nor ROI in the future.
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6.2.4 Conclusion
Two approaches to improve image analysis of the HFB, delimitation of ROI and building
of a mask of the fibers, were compared in terms of SI to the standard image analysis, which
considered the whole cross section of the HFB. Both approaches were interesting but none
brought new information, as compared to the total section of the HFB. Moreover, the
reproducibility of results obtained with ROI was not satisfactory. As they were time-
consuming and did not bring new elements, we decided not to pursue these methods for the
analysis of future HFB experiments. Only the treatment of the SI coming from the whole
cross section of the HFB will be taken into account for future experiments.
6.3 Metabolism study
6.3.1 Introduction
The evaluation of the metabolic activity is a possibility to quantify the viability and
functionality of isolated hepatocytes. Other tests, like coloration of cells with dye,
quantification of enzymes released, and evaluation of the synthesis of endogenous
compounds, and the consumption of nutrients, are often used for the same purpose.
Throughout the development of the MRI compatible bioreactor (chapter 5), the viability of
hepatocytes during the HFB experiments was assessed by the determination of oxygen
consumption and the enzymes LDH and AST released in the perfusion medium. The aim of
the present study was to set up a metabolic test with continuous in-line detection, which
would complete the evaluation of the viability of hepatocytes contained in HFB. 
We used the substrate 7-ethoxycoumarin (7-EC) which is transformed to
7-hydroxycoumarin (7-HC) by cytochrome P450 1A1 as presented in figure 6.6. 7-EC was
chosen because it can be analyzed by fluorimetry directly in the solution used for the
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bioreactor perfusion [4,5]. Furthermore, the method could have been adapted in a second time
so that the solution perfused went through a small fluorimetric cell allowing a continuous
measurement of the fluorescence during the HFB experiments.
7-hydroxycoumarin7-ethoxycoumarin
0-deethylation
P450 1A1
Figure 6.6: Biotransformation of 7-ethoxycoumarin to 7-hydroxycoumarin by cytochrome P450 1A1.
First the analytical conditions permitting the dosage of 7-EC and 7-HC were determined.
Then, the feasibility of the method was assessed by performing a blank experiment, i.e. with
the whole system including a HFB but free of hepatocytes.
6.3.2 Materials and methods 
6.3.2.1 Chemicals
7-ethoxycoumarin and 7-hydroxycoumarin were obtained from Sigma Chemical (St-Louis,
MO, USA). All other chemicals were of analytical grade.
6.3.2.2 Set up of the analytical method 
7-EC and 7-HC were dissolved in acetonitrile at a concentration of 25 mM. The
concentrated stock solutions were diluted with a modified Hanks's solution of the following
composition: 76.0 mM NaCl, 5.37 mM KCl, 0.63 mM Na2HPO4, 0.44 mM KH2PO4,
17.9 mM NaHCO3, 2.00 mM CaCl2, 0.41 mM MgSO4, 40.0 mM HEPES Na, 5.55 mM
glucose, 99420 U/l Penicillin G, 77700 U/l streptomycin sulfate, 280 U/l insulin and 0.5%
BSA, pH 7.4. Fluorimetric assays of diluted solutions of 7-EC and 7-HC were performed with
a spectrofluorimeter (LS 50 B, Perkin Elmer Instruments, USA), with a bandwidth of 2.5 nm
and an integration time of 1 second. Determination of the maximal wavelengths of excitation
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and emission of 7-EC and 7-HC was made using the "scan" mode of the fluorimeter with
10 M solutions. Fluorescence intensities at fixed wavelengths were obtained with the
"read" mode. The linearity field was determined with solutions of 7-EC and 7-HC at 20°C and
at concentrations ranging from 1.25 to 50 M at the maximal wave lengths of excitation and
emission determined before. The stability of the concentrated and diluted solutions was
checked by measuring the fluorescence at 20°C before and after 12 days of preservation at
4°C. The effect of a slight change in pH was assessed by measuring the fluorescence 10 M
solutions of 7-EC and 7-HC diluted from the concentrated stock solutions with Hanks's
solution at pH 7.3 and 7.5. The effect of temperature was tested by measuring the
fluorescence of a 10 M solutions of 7-EC and 7-HC at 4°C and 20°C.
6.3.2.3 Adsorption of 7-ethoxycoumarin in the HFB perfusion system
The HFB perfusion system comprised a solution reservoir, a peristaltic pump, a heating
circulator, a refrigerant, an oxygenator, a bubble trap and a HFB (Minikros Sampler M12E
220 01N, Spectrum, Rancho Dominguez, CA, USA). These elements were connected to each
other by 15 meters of Tygon tubing. The peristaltic pump continually circulated the solution
in the system at a flow rate of 100 ml/min. The solution was heated by circulation through the
glass spiral of the refrigerant while warm water from the heating circulator flowed outside the
spiral tubing. The oxygenator consisted of 7 meters of thin-walled silicone tubing permeable
to oxygen and carbon dioxide and coiled in a plastic box [6]. The system is described in detail
in chapter 5.
The adsorption of 7-EC was assessed by circulating 1l of Hanks's solution containing
15 M of 7-EC at 20°C or 37°C for 75 minutes in the whole system or in the system without
oxygenator or bioreactor. Samples were taken every 15 minutes, diluted if necessary, and
analyzed by fluorimetry to determine the concentration of 7-EC at the maximal wave lengths
of excitation and emission determined before.
To investigate whether the adsorption followed a saturable and irreversible process, 1l of
Hanks's solution containing 230 M of 7-EC was circulated in the whole system at 37°C for
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4 hours. After 4 hours, the solution containing 7-EC was replaced by 1l of Hanks's solution
free of 7-EC. This solution was circulated through the system during 90 minutes and then
substituted with 1l of ethanol 96% which was circulated for another 90 minutes. Samples
were taken every 15 minutes, diluted if necessary, and analyzed by fluorimetry to determine
their concentration of 7-EC.
6.3.3 Results 
6.3.3.1 Set up of the analytical method
7-EC and 7-HC were dissolved in acetonitrile because this solvent was shown not to
interfere with cytochromes P450, in contrast to other solvents like methanol or DMSO [7].
Excitation and emission spectra of 7-EC and 7-HC are presented in figure 6.7.
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Figure 6.7: Excitation and emission fluorescence spectra of solutions containing 10 M of
7-ethoxycoumarin (7-EC) and 7-hydroxycoumarin (7-HC).
As can be seen, both 7-EC and 7-HC had the same maximal wavelength of excitation of
333 nm, and the maximal wave lengths of emission were 394 and 454 nm respectively.
Compared to the maximum fluorescence of about 520, the fluorescence of 7-HC at 394 nm,
equal to 15, represented 3% of the total fluorescence, which is sufficiently low as to be
neglected. In contrast, the fluorescence of 7-EC at 454 nm, equal to 80, represented 15% of
the total fluorescence, which is significant. Hence, the 7-EC concentration was calculated
from the emission at 394 nm while the concentration of 7-HC was determined by subtraction
of the contribution of 7-EC calculated from the emission at 394 nm from the total
fluorescence obtained at 454 nm.
A good linearity was found for 7-EC at 394 nm and 454 nm and for 7-HC at 454 nm as
long as concentrations did not exceed 10 M, as shown in table 6.2.
Table 6.2: Linearity between the fluorescence and the concentration of 7-ethoxycoumarin and
7-hydroxycoumarin (0 - 10 M). 
Regression parameters
slope Y-intercept n r2 s F
7-EC, 394 nm
7-EC, 454 nm
7-HC, 454 nm
29.5 ± 1.3
4.48 ± 0.22
46.5 ± 1.3
18.8 ± 8.5
4.1 ± 1.4
11.5 ± 6.9
5
5
5
0.994
0.993
0.998
9.854
1.595
10.39
459.9
405.0
1205
7-EC = 7-ethoxycoumarin, 7-HC = 7-hydroxycoumarin, r2: squared correlation coefficient, s: standard deviation
of the residuals, F: Fisher test for significance of the equation
The fluorescence of solutions of 7-EC and 7-HC at a concentration of 10 M at 20°C were
identical before and after 12 days of conservation at 4°C, as well as the one of solutions of
10 M prepared with the concentrated stock solutions after their preservation for 12 days at
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4°C. This indicates that both concentrated and diluted solutions of 7-EC and 7-HC could be
stored at 4°C during 12 days without loss of stability. 
We also showed that a small variation of pH did not influence the fluorescence reading.
Indeed, the fluorescence of 10 M solutions of 7-EC and 7-HC at 20°C were identical at
pH 7.3 and 7.5. This slight variation of pH is the one observed with the samples of the
perfusion solution taken during the HFB experiments. In practice, this means that within a pH
range of 7.3 to 7.5 the fluorescence of samples can be compared to each other. As the samples
were kept in the fridge till analysis, we wondered if the temperature had an influence on the
fluorescence, and we found that the fluorescence of 10 M solutions of 7-EC and 7-HC was
about 10% higher at 4°C than at 20°C. Thus, all samples had to be at the same temperature
when measuring their fluorescence. 
6.3.3.2 Adsorption of 7-ethoxycoumarin in the HFB perfusion system
The adsorption of 7-EC in the HFB perfusion system at 20°C or 37°C, with or without
oxygenator, is shown in figure 6.8. The complete system consisted of Tygon tubing,
oxygenator, HFBfree of hepatocytes, and bubble trap.
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Figure 6.8: Adsorption of 7-ethoxycoumarin (7-EC) in the Tygon tubing, in the HFB perfusion
system without oxygenator, or in the complete system at 20°C or 37°C.
The concentration of 7-EC remaining in solution after 75 minutes of perfusion of the
different elements present in the system are shown in table 6.3.
Table 6.3: Remaining concentration of 7-ethoxycoumarin (7-EC) in solution after 75 minutes of
perfusion. The initial concentration of 7-EC was 15 M.
Conditions Concentration
of 7-EC [M]
Remarks
Complete system, 37°C 3 Huge adsorption 
Complete system, 20°C 6 Temperature   adsorption 
Complete system without HFB, 20°C 6 No adsorption in the HFB
System without oxygenator, 20°C 11 Oxygenator responsible for the
adsorption of 5 M 
Tygon, 20°C 13 Tygon responsible for the
adsorption of 2 M 
These results indicate that only a small amount of 7-EC was adsorbed to Tygon tubing.
Actually, the concentration of 7-EC in the solution only decreased from 15 to 13 M after
75 minutes of circulation at 20°C, which is in good agreement with the manufacturer's
indications. The kind of Tygon tubing used was chosen because it was known to minimize
adsorption phenomena. Withdrawal of the bioreactor did not change the adsorption profile,
indicating that no adsorption of 7-EC occurred in the bioreactor. The content of 7-EC in the
solution decreased from 15 to 6 M after 75 minutes of circulation in the whole system. The
comparison between the adsorption of 7-EC in the whole system and in the system without
oxygenator indicates that the oxygenator was responsible for the adsorption of 5 M of 7-EC.
As already seen, 2 M were adsorbed to Tygon tubing and another 2 M were adsorbed
elsewhere in the system, for instance in the bubble trap. Hence, more than 50% of the total
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amount of 7-EC adsorbed was lost in the oxygenator. As the oxygenator is an indispensable
element of the perfusion system, due to the requirement of a good oxygenation of
hepatocytes, it cannot be omitted and an important 7-EC adsorption cannot be avoided.
Perfusion experiments of the whole system at 37°C showed that the adsorption of 7-EC was
even more pronounced at this physiological temperature. 
The saturability and the reversibility of the adsorption of 7-EC were assessed by
circulating a solution containing 230 M of 7-EC in the whole system at 37°C for 4 hours,
followed by washing with Hanks's solution free of 7-EC for 90 minutes and ethanol for
75 minutes. The concentration-time profiles obtained are sown in figure 6.9.
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Figure 6.9: Assessment of the saturability and reversibility of 7-ethoxycoumarin (7-EC) adsorption at
37°C. A Hanks's solution containing 230 M of 7-EC was circulated in the whole system for 4 hours.
The system was then washed with Hanks's solution free of 7-EC for 90 minutes and finally with
ethanol for 90 minutes.
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These results suggest that the adsorption of 7-EC was a non-saturable process. The
concentration of 7-EC in the solution was increased from 15 to 230 M, as compared to the
previous experiment. But even with this about 20 times higher concentration, no saturation of
the adsorption was observed. The results further show that the adsorption was a reversible
process. 7-EC was slowly released into Hanks's solution free of 7-EC, and readily released
into ethanol. Indeed, 14 M of 7-EC were liberated in Hanks's solution after 90 minutes and
this quantity was increased to 145 M after the circulation of ethanol for 90 minutes
(figure 6.9). This is easily explained by the low, respectively high solubility of 7-EC in water
and in ethanol.
Hence, 7-EC would not be a good substrate to assess the functionality of hepatocytes in our
HFB. Actually, 7-EC was adsorbed in the perfusion system in a huge quantity, moreover, the
adsorption was not saturable and reversible. This means that, in the presence of hepatocytes, it
would be difficult to differentiate between the decrease of 7-EC due to metabolism and the
decrease due to adsorption. Furthermore, one could imagine that the amount of 7-EC
metabolized would be compensated by a release of 7-EC adsorbed, and this could totally
mask the biotransformation of 7-EC. The dosage of the 7-HC produced would neither be
suitable, as Sakai et al. [5] showed that the concentration of 7-HC detectable in the solution
after 8 hours was only about 1% of the initial concentration of 7-EC. 7-HC is probably
immediately further metabolized. 
The high adsorption of 7-EC in the oxygenator can be explained by its silicone
composition. Like 7-EC, other drugs are also adsorbed by silicone, e.g. antibiotics [8] or
fentanyl [9]. Nevertheless, silicone tubing is often used to improve oxygenation in various
cell culture systems, and in particular for HFB [10].
6.3.4 Conclusion
A good analytical method was set up for the dosage of 7-EC and 7-HC by fluorimetry. But
a blank experiment performed with the whole system without hepatocytes in the HFB
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demonstrated that 7-EC was readily adsorbed in the system, and that the adsorption process
was neither saturable, nor irreversible. Hence, 7-EC is not a suitable substrate to assess the
functionality of hepatocytes in our HFB perfusion system. These results illustrate that
adsorption which could take place in silicone membrane oxygenators is a problem that cannot
be neglected.
The same study could be done with other fluorescent substrates to find one which would
not be adsorbed to silicone tubing. Another solution would be to use a system of oxygenation
that does not include silicone, for instance polypropylene-based oxygenators, which are less
susceptible to drug adsorption [9]. Nevertheless, we decided not to pursue this project because
of lack of time. We will satisfy ourselves with the dosage of LDH and AST and the
determination of the oxygen consumption, which have shown to be totally reliable for the
assessment of the hepatocyte viability (chapter 5).
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Chapter 7
Study of Gd-BOPTA transport in freshly isolated rat hepatocytes
and pharmacokinetic analysis of MRI data obtained with a
hepatocyte hollow fiber bioreactor 
7.1 Introduction
Gd-BOPTA is a hepatobiliary MRI contrast agent which is taken up specifically by
hepatocytes and partially excreted into the bile. Due to these properties, Gd-BOPTA has a
dual imaging capability: on the one hand it can be used as an extracellular agent for the MRI
of diverse parts of the body, and on the other hand it can be used for the MRI of the liver to
facilitate the MRI detection of hepatic diseases. In this organ it distributes not only in the
extracellular space but also enters hepatocytes.
As already discussed in chapter 3, the transport of Gd-BOPTA into hepatocytes is not fully
understood and different hypotheses have been proposed. Moncelli et al.  [1] found that
Gd-BOPTA did not diffuse through phospholipid monolayers and therefore concluded that
the uptake of Gd-BOPTA was not due to free diffusion of the contrast agent through the
lipidic membrane. They suggested the presence of a specific transport system which allows
Gd-BOPTA to enter hepatocytes. Conversely, Pascolo et al.  [2] observed that the uptake of
Gd-BOPTA in rat sinusoidal membrane vesicles occurred by passive diffusion. They also
found that Gd-BOPTA was not taken up into oocytes transfected with human OATP cRNA.
This latter result is in good agreement with the one of Van Montfoort et al.  [3] who showed
that Gd-EOB-DTPA, a hepatobiliary contrast agent related to Gd-BOPTA, was not
transported into oocytes transfected with human OATP cRNA, while they observed that it
was taken up into oocytes transfected with rat oatp1 cRNA according to a saturable
mechanism, which may indicate that there is a difference between species. The possible
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inhibition of the transport of Gd-BOPTA into hepatocytes by bromosulfophthalein (BSP) is
also debated. De Haën et al.  [4] observed a partial inhibition of the uptake of Gd-BOPTA by
BSP in rat liver, while Pascolo et al.  [2] found that the passive diffusion of Gd-BOPTA
through rat sinusoidal membrane vesicles was not inhibited by BSP. On the other hand, the
excretion mechanism of Gd-BOPTA into the bile is known, it occurs via the multidrug
resistance-associated protein MRP2/mrp2 (capital letters refer to the human protein) at the
canalicular side of the hepatocyte [5-7].
As seen in the previous paragraph, there are different techniques available to study the
hepatobiliary transport of drugs, ranging from the intact liver in vivo to the isolated perfused
liver, isolated hepatocytes, liver slices, membrane vesicles and transport proteins [8]. In vivo
studies provide useful general data related to the transport mechanisms of drugs, but there are
numerous factors that cannot be controlled, which complicates the interpretation of the
results. The isolated perfused liver has the advantage of eliminating the extrahepatic
influences while keeping the liver architecture intact. Liver slices offer the possibility to
perform many experiments with a single liver. Freshly isolated hepatocytes showed to have
similar transport characteristics to those of the liver in vivo and the isolated perfused liver [9],
despite of the loss of their membrane polarity. Moreover, they are superior as a model for
drug transport than cultured hepatocytes or hepatocyte derived cell lines, which have deficient
transport functions [10]. Plasma membrane vesicles can be separately prepared from the
sinusoidal and canalicular membranes, but the integrity of the transport proteins is hard to
assess. Liver slices, isolated hepatocytes, and plasma membrane vesicles can be obtained also
from human source. So far numerous transport proteins have been isolated and characterized,
notably thanks to molecular biology.
The aim of this work was to study the transport of Gd-BOPTA in freshly isolated rat
hepatocytes. As the isolation process is rather aggressive and results in hepatocytes that have
lost their membrane polarity, we first assessed the expression of the transporters known or
suspected to play a role in the transport of Gd-BOPTA and compared it to the one of an entire
liver. In a second step, we checked the functionality of the uptake mechanisms by incubating
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hepatocyte suspensions with Gd-BOPTA. Finally, we studied the uptake of different
concentrations of Gd-BOPTA into hepatocytes by means of the MRI compatible hepatocyte
hollow fiber bioreactor (HFB) developed in chapter 5. In this last step, particular attention
was paid to the development of a compartmental pharmacokinetic model to describe the MRI
data. 
7.2 Materials and methods
7.2.1 Chemicals
Solution of Gd-BOPTA 0.5 M was generously donated by Bracco Research S.A. (Geneva,
Switzerland). A commercially available solution of Gd-DTPA 0.5 M (Magnevist, Schering,
Germany) was used. Bovine serum albumin (BSA, fraction V, 97%) and ethylene glycol-
O,O'-bis(2-aminoethyl)-N,N,N',N'-tetraacetic acid (EGTA) were purchased from Fluka.
Collagenase from Clostridium histolicum type IV (collagen digestion activity: 295 U/mg
solid), bovine pancreas insulin, 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride
(AEBSF), aprotinin, leupeptin, bestatin, pepstatin A and N-(trans-epoxysuccinyl)-L-leucine
4-guanidinobutylamide (E-64) were obtained from Sigma Chemical (St-Louis, MO, USA).
The rabbit polyclonal antibodies against rat-oatp1, rat-oatp2, rat-oatp4 and rat-mrp2 were
kindly provided by Dr B. Stieger (University Hospital, Zurich, Switzerland)  [11-15]. All
other chemicals were of analytical grade. 
7.2.2 Isolation of hepatocytes
Hepatocytes were isolated from adult male Sprague-Dawley rats (250 to 350 g) by a
two-step collagenase perfusion of the liver first described by Seglen et al.  [16] and described
in detail in chapter  4. An average of 5·108 hepatocytes were obtained from the isolation
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procedure of one rat liver, with a cellular viability greater than 90% as assessed by trypan
blue exclusion. 
7.2.3 Determination of the expression of hepatic transporters by Western blotting
Cell samples containing 5·107 freshly isolated hepatocytes were introduced in 1.5 ml
"Eppendorf" tubes, frozen in liquid nitrogen and kept at -80°C until use. The expression of the
transporters was evaluated with hepatocytes resulting from the separate isolation procedure of
three rat livers and compared to the one of an entire rat liver.
Liver tissue or, alternatively, cell samples were homogenized in a potter with ice-cold Tris
buffer (100 mM Tris-HCl, pH 7.6) containing protease inhibitors, AEBSF, Aprotinin,
Leupeptin, Bestatin, Pepstatin A and E-64. The homogenates were centrifuged at 10 000 g for
10 minutes at 4°C. This first supernatant was used for the detection of oatp1 and oatp4. The
extraction of the two transporters was quantitative because they could not be detected in the
pellet. On the other hand, no mrp2 was present in the first supernatant. Therefore the pellet
was homogenized with the same buffer containing 1% Triton X-100. After centrifugation at
10 000 g for 10 minutes at 4°C, this second supernatant was used for the detection of mrp2.
To better extract oatp2 a different Tris buffer was used [17]; it contained 50 mM Tris-HCl,
0.1 mM EGTA, 0.1 mM ethylenedinitrilo tetraacetic acid (EDTA), 0.1% sodium dodecyl
sulfate (SDS), 0.1% deoxycholic acid, 1% Triton X-100, pH 7.5. Protein concentrations were
determined according to Bradford [18] (Bio-Rad, Glattbrugg, Switzerland). The supernatants
were stored at –70°C until use.
Sodium dodecyl sulfate polyacrilamide gel electrophoresis (SDS-PAGE) and Western
blotting were performed according to standard procedures [19-21]. 100 µg of protein extracts
were separated on a 7.5% polyacrylamide gel. Then the gel was transferred to a
polyvinylidene difluoride membrane (Millipore, Switzerland). The membrane was blocked
for 1 hour at room temperature with 5% nonfat dry milk in phosphate buffered saline (PBS)
and incubated with the specific antibodies. Staining with Ponceau red before blocking
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assessed that equal quantities of proteins were loaded on each line. The membrane was then
incubated over-night at 4°C with anti-oatp1 (1:1 000), anti-oatp2 (1:5 000), anti-oatp4
(1:2 000) or anti-mrp2 (1:2 000) antibody in PBS containing 5% nonfat dry milk. The
membrane was washed four times with PBS-0.2% Tween-20 and incubated for 1 hour with an
alkaline phosphatase-conjugated goat anti-rabbit IgG antibody at 1:5 000 (Stressgen, Victoria,
Canada). Then the membrane was washed four times with PBS-Tween buffer. Development
was performed using an Immune-Star chemiluminescent protein-detection system (Bio-Rad)
according to the manufacturer’s instructions. Molecular weight markers and controls were
included in each experiment. 
7.2.4 Uptake of Gd-BOPTA by hepatocytes in suspension
Suspensions containing 5·107 freshly isolated hepatocytes were introduced in centrifuge
tubes of 15 ml (figure 7.1) and gently mixed with 10 ml of ice cold incubation solution which
had the same composition than the perfusion solution used for the bioreactor experiments
(chapter 5), namely 76.0 mM NaCl, 5.37 mM KCl, 0.63 mM Na2HPO4, 0.44 mM KH2PO4,
17.9 mM NaHCO3, 2.00 mM CaCl2, 0.41 mM MgSO4, 40.0 mM HEPES Na, 5.55 mM
glucose, 99420 U/l Penicillin G, 77700 U/l streptomycin sulfate, 280 U/l insulin and 0.5%
BSA, pH 7.2. The tubes were then centrifuged (50 g, 2 min, 4°C) and supernatant was
removed. Cell suspensions were prepared by suspending the cell pellet in 100 ml of
incubation solution supplemented with 0.2 mM of Gd-BOPTA or Gd-DTPA. Hepatocyte
suspensions were incubated (37°C, shaking, 5% CO2 in air atmosphere) in an incubator
(EG 110IR, Société Juan, Saint Herblain, France) for 60 minutes. Control experiments were
performed under the same experimental conditions but without contrast agent in the
incubation solution. Cell viability was checked every 30 minutes by trypan blue exclusion.
After incubation, hepatocytes were centrifuged, the supernatant was removed, and the cell
pellets were washed twice with ice cold incubation solution free of contrast agent. The cell
pellets were kept at -80°C till analysis by inductively coupled plasma atomic emission
spectrometry (ICP-AES) to determine their levels of gadolinium (Gd3+). The intracellular
Chapter 7 168
concentration of Gd3+ was calculated from this value considering that the cell pellets
contained 5·107 hepatocytes having a mean volume of 8181 m3 [22-24].
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Figure 7.1: Preparation of the hepatocyte suspensions. The hepatocytes were incubated 60 minutes
(37°C, 5% CO2) in incubation solution containing either 0.2 mM Gd-DTPA, 0.2 mM Gd-BOPTA or
no contrast agent.
7.2.5 Transport of contrast agents in hepatocytes within a MRI compatible bioreactor
The whole procedure for the preparation of the hepatocyte HFB was described in detail in
chapter 5. Briefly, a suspension containing 1·109 freshly isolated hepatocytes obtained after
the isolation processes of two livers was centrifuged (50 g, 2 min, 4°C) and the cell pellet was
mixed with ice-cold modified University of Wisconsin solution. The resulting cell suspension
was inoculated in a HFB (Minikros Sampler M15E 260 01N, Spectrum, Rancho Dominguez,
CA, USA) and the bioreactor was preserved at 4°C till MRI experiment. 
For the MRI experiment, the hepatocyte HFB was set in the wrist coil and perfused with a
37°C oxygenated perfusion solution with or without contrast agent at a flow rate of
100 ml/min. Experiments were carried out with contrast agent concentrations of 0.05, 0.1, 0.2
and 0.4 mM. Inhibition experiments were performed by perfusing the HFB first with a
solution containing 0.1 mM Gd-BOPTA alone and then with a solution containing 0.1 mM
Gd-BOPTA and 0.1 mM BSP. The experiment was repeated with 0.4 mM solutions of
Gd-BOPTA and BSP. The viability of hepatocytes was greater than 85% after 4 hours of
experiment as assessed by the release of lactate dehydrogenase (LDH) and aspartate
aminotransferase (AST) in the perfusate and by determining the oxygen consumption of
hepatocytes. 
Results were based on the signal intensity (SI) of the 4th cross section of the HFB during
dynamic sequences, as already described in chapter 5. The SI-time curves obtained were
submitted to a compartmental pharmacokinetic analysis after normalization with reference
vials and correction for the baseline. 
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Figure 7.2: Scheme of hepatocytes extraction and lysis with a solution of Triton-X 100 0.1% after the
MRI experiment. Supernatants were put together, weighted and measured by ICP-AES for the
determination of the Gd 3+ content.
After the MRI experiments, the hepatocytes were extracted from the bioreactor and lysed
with a solution of Triton X-100 0.1% as illustrated in figure 7.2. Three consecutive
extractions of the HFB were made. The extracts were centrifugated, the supernatants
collected, and the cell pellets further lysed with Triton X-100. All supernatants were put
together, weighted and analyzed by ICP-AES to determine their levels of gadolinium (Gd3+).
The intracellular concentration of Gd3+ was calculated from this value considering that the
HFB contained 1·109 hepatocytes having a mean volume of 8181 m3 [22-24].
7.2.6 Development of a compartmental pharmacokinetic model to describe the MRI data
SI-time curves normalized with reference vials and corrected for the baseline were
submitted to compartmental analysis using the software NONMEM (Version V, University of
California, San Francisco, USA). 
A compartmental model uses compartments to describe the different parts of the organism.
Compartment 1 is frequently called the central compartment because drug is administered into
and distributed from it. The drug distributes between this central compartment and peripheral
compartments composed of tissues into which distribution is slower. Figure 7.3 illustrates a
two-compartment model where elimination occurs only from the central compartment and
where the drug distributes into a peripheral compartment. A two-compartment model can
adequately describe a biexponential curve of drug increase or decay. Movements of drug
between the two compartments can be characterized by transfer rate constants, where k12
denotes the rate constant associated with passage from compartment 1 into compartment 2,
and k21 is the rate constant associated with the reverse process. The rate constant k10 is
associated with loss from compartment 1 by metabolism and/or excretion. 
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Figure 7.3: Schematic representation of a two-compartment open model. Drug is administered and
eliminated from compartment 1 (central compartment) and distributes between compartment 1 and 2
(peripheral compartment). The rate constants for the processes are indicated.
In a two-compartment model, the concentration-versus-time curve of a drug during
infusion is described by equation 7.1, whereas equation 7.2 describes the curve during the
washing phase, after having stopped drug administration [25]. 
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where K0 is the infusion rate, T is the duration of infusion, V is the volume of the central
compartment,  and  are rate constants defined by equations 7.3 and 7.4. 
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The half-life t1/2(k) of a process characterized by a rate constant k is calculated using
equation 7.5.
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Implementation of the model in NONMEM proceeded through the use of the ADVAN3
and TRANS1 subroutines. Observations were assumed to reflect the sum of predictions in the
central and peripheral compartments plus an additive error term, according to the following
equation:
Cobserved = Cpredicted, central + Cpredicted, peripheral +  [Equation 7.6]
where  is the residual error normally distributed with mean 0 and constant variance 	2.
Alternatively, an exponential error model identical to a constant CV model was
considered:
Cobserved = (Cpredicted, central + Cpredicted, peripheral) · exp() [Equation 7.7]
Primary parameters to be estimated were k10, k12, k21, V and 	2. Secondary parameters (i.e.
calculated on the basis of primary parameters) were ,  and the corresponding half-lives t1/2
and t1/2. NONMEM provided information about precision of the estimates through standard
errors and correlation matrix of parameter estimates. Goodness of fit was assessed through
analysis of residuals and graphical techniques. 
In the present case, the concentration was replaced by the signal intensity and the volume
of distribution reflected a proportionality constant relating the signal to the infusion rate. The
baseline SI at the time point immediately preceding SI increase was determined visually and
manually to be the starting value of the perfusion with contrast agent for pharmacokinetic data
analysis and the SI at the time point immediately preceding SI decrease was determined
visually and manually to be the end of the perfusion of contrast agent and the starting value of
the washing phase. 
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7.3 Results and discussion
7.3.1 Determination of the expression of hepatic transporters by Western blotting
The transport of the hepatobiliary contrast agents Gd-BOPTA and Gd-EOB-DTPA into rat
hepatocytes is not yet fully elucidated. Some authors suggest a transport through passive
diffusion [2], while others believe that Gd-BOPTA is transported by the specific organic
anion transporting polypeptide OATP1/oatp1 (capital letters refer to the human protein)  [3].
On the other hand, the excretion of Gd-BOPTA and Gd-EOB-DTPA into the bile is known to
occur via the multidrug resistance-associated protein MRP2/mrp2 at the canalicular side of
the hepatocyte [5-7,26]. Taking these observations into account, we studied the expression of
the transporters of the oatp family and mrp2 in isolated rat hepatocytes. We checked that these
transporters were not altered during the isolation procedure of the liver, and as a consequence
that isolated rat hepatocytes can be used as a cellular model to study the transport of
Gd-BOPTA. 
Figure 7.4 shows the Western blot with the expression of the hepatic transporters oatp1,
oatp2, oatp4 and mrp2 in isolated hepatocytes obtained with three different rats (lanes 1-3)
and in a control liver extract (C).  
The hepatic transporter oatp1 had the same expression in freshly isolated hepatocytes and
in a control liver extract, oatp2 seemed to be lower in isolated hepatocytes and oatp4 was no
longer expressed in hepatocytes after the isolation procedure (figure 7.4). Mrp2 also seemed
to have a similar expression in isolated hepatocytes than in the entire liver, although the
expression in the isolated hepatocytes coming from rat 3 seemed to be lower. 
It is important to check the presence of transporters in the isolated hepatocytes, as they can
be lost during the isolation process [27,28]. Indeed, beside the direct aggressive effect of
collagenase on hepatocyte membranes, membrane polarity is altered. Microscopic observation
of freshly isolated hepatocytes reveals a spherical shape of the cells with a uniform
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membrane, such that one can no longer recognize the different poles of the membrane present
in vivo, where the hepatocyte membrane is in contact with three different compartments,
namely the perisinusoidal space (37% of the membrane area), the biliary capillaries (13%),
and the neighboring hepatocytes (50%) [24]. Isolated cells in suspension are no more
surrounded by different compartments, but only by the culture solution. Nevertheless, freshly
isolated hepatocytes were found to be more suitable to evaluate the uptake of ligands by
multispecific anion transporter systems than primary hepatocyte cultures that maintain
membrane polarity [29]. 
C 1 2 3
oatp1
oatp2
oatp4
mrp2
Figure 7.4: Western blot showing the expression of oatp1, oatp2, oatp4 and mrp2 proteins in isolated
rat hepatocytes coming from 3 rat livers (lanes 1-3) compared to a control liver extract (C).
To sum up, one can say that the expression of the transporters oatp1, oapt2 and mrp2 was
slightly or not changed during the isolation procedure of the liver, in contrast to oatp4. Hence,
these results suggest that freshly isolated hepatocytes can be used as a cellular model to study
the transport of drugs which imply the presence of oatp1, oapt2 and mrp2, although a Western
blot only tells whether the transporters are expressed, not whether they are functional.
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Therefore the functionality should be investigated in additional experiments, for instance with
specific substrates.
7.3.2 Uptake of Gd-BOPTA by hepatocytes in suspension
The intracellular concentration of gadolinium (Gd3+) in hepatocytes incubated 60 minutes
with Gd-BOPTA 0.2 mM was 32.6  4.6 M, i.e. 16.3  2.3% of the concentration in the
incubation solution (figure 7.5). A much lower concentration of Gd3+, namely 4.9  0.3 M,
was observed after incubation with 0.2 mM Gd-DTPA, the extracellular contrast agent. This
amount represented 2.4  0.2% of the initial concentration in the incubation solution. There
was no Gd3+ detectable in control hepatocytes incubated in solution free of contrast agent. 
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Figure 7.5: Intracellular content of contrast agent in hepatocytes incubated 60 minutes with 0.2 mM
Gd-BOPTA, 0.2 mM Gd-DTPA or without contrast agent (n = 3).
The intracellular concentration of Gd3+ measured after incubation with Gd-DTPA may be
due to contrast agent sticking to the cell surface, indicating that two washing cycles were not
sufficient to eliminate all traces after incubation. Actually, it is known that Gd-DTPA is not
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taken up by hepatocytes, explaining why it is classified among the extracellular contrast
agents. Thorsternsen et al.  [30] found that freshly isolated rat hepatocytes in suspension
approximately took up 0.8% of the total extracellular Gd-DTPA .
These results clearly demonstrate that freshly isolated hepatocytes in suspension were able
to take up the hepatobiliary contrast agent Gd-BOPTA. Actually, hepatocytes incubated in
0.2 mM solutions took up about 16% of the total extracellular concentration. These
observations indicate that the uptake transport of Gd-BOPTA was not only present but also
functional and that freshly isolated hepatocytes could be further used as a cellular model for
the uptake study of Gd-BOPTA. 
7.3.3 Perfusion of a MRI compatible hepatocyte bioreactor with contrast agents:
pharmacokinetic analysis of the MRI data and transport studies  
7.3.3.1 Development of a compartmental pharmacokinetic model to describe the MRI data
Unlike with most of the conventional software used for pharmacokinetic analysis, with
NONMEM it is possible to define the compartment which is monitored as being the sum of
all compartments present, i.e. the central and the peripheral compartments. Actually, the
particularity of the results obtained by MRI is that the SI measured is the mean of the element
imaged (in the present case a cross section of the HFB); hence, it includes the SI coming from
all compartments present. This situation is different from the one found in conventional
pharmacokinetics where the sampling is made in the central compartment (generally blood). 
The pharmacokinetic analysis was first done on the curves obtained with the hepatobiliary
contrast agent Gd-BOPTA with a proportional constant CV error model according to
equation 7.7. Although appropriate for Gd-BOPTA, this error model was found to be
unsuitable to treat the curves obtained with the extracellular contrast agent Gd-DTPA,
because some of the points were equal or close to 0 and the SI fluctuations were similar over
the whole curve, i.e. for the higher values of SI as well as for the SI values near 0. As the
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additive error model (equation 7.6) best fitted the Gd-DTPA curves and also suited for the
analysis of the curves obtained with Gd-BOPTA, it was further used for all the modeling. 
Figure 7.7 shows an example of SI-time curves of Gd-BOPTA and Gd-DTPA after
normalization with reference vials and correction for the baseline together with the predicted
curves resulting from pharmacokinetic analysis. One can see that the predicted curve for the
whole system fitted very well the experimental data for the two contrast agents investigated.
The SI-time curves of Gd-BOPTA were fitted successfully with a two-compartment model
and these of Gd-DTPA with a one-compartment model. Indeed, during the perfusion with
Gd-BOPTA (figure 7.7a), the SI increased rapidly at the beginning of the perfusion and then
increased more slowly. During the initiation of the washing step, SI decreased rapidly to a
value different from the one before the perfusion. Beyond that point, SI remained stable or
decreased very slightly but without returning to the baseline. These observations were
described correctly by a two-compartment model. During the perfusion with Gd-DTPA
(figure 7.7b), the SI increased and rapidly reached a steady-state. During washing, the inverse
process occurred and the SI returned to the same value as before the perfusion with
Gd-DTPA. These observations fitted well with a one-compartment model. We also tried to
apply a two-compartment model to the data of Gd-DTPA, but the resulting estimation error
on k12 and k21 was more than 100% and the correlation matrix of estimates showed that these
parameters were correlated, indicating that the two-compartment model was too complex to
describe the data. 
The graphs of residuals show that they were well distributed around 0. However, higher
residuals were observed at times corresponding to the beginning and end of the perfusion with
the contrast agent (about 30 minutes for Gd-BOPTA and 15 minutes for Gd-DTPA). This
indicates that the visual determination of the beginning and end of the perfusion might not be
an adequate technique. For Gd-DTPA, an additional remark has to be done concerning the last
points. Actually, as the software does not allow negative values, all the negative values were
changed to 0, which explains the slightly positive residuals of the last points of the Gd-DTPA
curve.
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In addition to the fitting of the observations coming from the whole system, the two-
compartment model enables to estimate the SI due to Gd-BOPTA in the central and peripheral
compartment. The evolution of the SI in the central compartment is similar to the one
observed with Gd-DTPA. SI rapidly reached steady-state during the perfusion of Gd-BOPTA
and quickly returned to baseline during washing. On the other hand, in the peripheral
compartment SI rose regularly and less intensely during the perfusion and did not or only
slightly diminish over the period of washing. The comparison between the one-compartment
model describing the behavior of the extracellular contrast agent Gd-DTPA and the two-
compartment model describing the one of the hepatobiliary contrast agent Gd-BOPTA
suggests that the peripheral compartment of Gd-BOPTA may represent the hepatocytes in
which Gd-BOPTA distributed. Considering the evolution of the SI in the peripheral
compartment, i.e. in the hepatocytes, one can see that Gd-BOPTA entered hepatocytes
regularly over the period of perfusion but did not exit at the same rate. In fact, Gd-BOPTA
stayed in the hepatocytes or was only slightly released back in the central compartment during
washing. Moreover, when considering the composition of the HFB itself, one remarks that it
consists of two compartments, the intracapillary space (ICS) and the extracapillary space
(ECS). Nevertheless, the filling process of the HFB with Gd-DTPA followed a one-
compartment model, which signifies that fiber filling with Gd-DTPA and its diffusion through
the fibers in the ECS were not distinguishable processes. This was already observed during
the choice of the HFB in chapter 5.
In most cases, the pharmacokinetic models described observations very well, but there
were some exceptions. Figure 7.8 illustrates a case where k21 had to be fixed to 0 to fit the
experimental data and a case where the model was less adapted to the experimental
observations. In both cases, the fluctuation of the SI was reflected in the distribution of
residuals. In the example of Gd-BOPTA 0.2 mM (figure 7.8 a), the model was not good when
we allowed the software to choose the k21 value freely. Fixing of k21 to 0 improved
considerably the quality of the estimate. The k21 value was in fact not fixed strictly to 0
because the software does not accept 0, but to 1.00E-06. In the example of Gd-BOPTA
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0.4 mM (figure 7.8b), the estimated curve did not strictly fit the observations, especially for
the first points, where the SI of the experimental points rose more rapidly than the estimate. 
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Figure 7.7: SI-time curves of Gd-BOPTA and Gd-DTPA after normalization with reference vials and correction for the baseline together with the predicted
curves resulting from the pharmacokinetic analysis with a two-, respectively one-compartment model. CP = observations in the whole system,
PRED = predictions in the whole system, Y1 = predictions in the central compartment, Y2 = predictions in the peripheral compartment, RES = residuals.
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Figure 7.8: SI-time curves of Gd-BOPTA after normalization with reference vials and correction for the baseline together with the predicted curves resulting
from the pharmacokinetic analysis with a two-compartment model. Two particular examples are illustrated: a) k12 had to be fixed to 0 to fit the experimental
data, b) the model was not well adapted to the data. CP = observations in the whole system, PRED = predictions in the whole system, Y1 = predictions in the
central compartment, Y2 = predictions in the peripheral compartment, RES = residals.
Table 7.1: Results of the pharmacokinetic analysis of the SI-time curves of Gd-BOPTA with a two-compartment model, and Gd-DTPA with a one-
compartment model, after normalization with reference vials and correction for the baseline. 
Gd-BOPTA
concentration
[mM]
k10
[min-1]
SEE
[min-1]
k12
[min-1]
SEE
[min-1]
k21
[min-1]
SEE
[min-1]

[SI]

[min-1]

[min-1]
t1/2 ()
[min]
t1/2 ()
[min]
0.05 4.24E-01
3.89E-01
2.43E-02
4.12E-02
1.02E-02
1.04E-02
1.25E-03
4.58E-03
5.41E-04
2.75E-02
4.27E-03
1.70E-02
2.21E-01
3.39E-01
4.34E-01
4.01E-01
5.28E-04
2.68E-02
1.60E+00
1.73E+00
1.31E+03
2.59E+01
0.1 5.60E-01
3.44E-01
1.33E-01
1.14E-02
7.02E-03
1.58E-02
8.63E-04
1.44E-03
1.00E-06
3.27E-02
k21 fixed
3.30E-03
3.02E-01
1.80E-01
5.67E-01
3.61E-01
9.88E-07
3.11E-02
1.22E+00
1.92E+00
7.02E+05
2.23E+01
0.2 4.20E-01
4.79E-01
1.49E-02
1.80E-02
8.45E-03
9.59E-03
9.85E-04
1.01E-03
1.06E-02
1.28E-02
4.04E-03
3.57E-03
4.53E-01
5.14E-01
4.28E-01
4.89E-01
1.04E-02
1.26E-02
1.62E+00
1.42E+00
6.69E+01
5.52E+01
0.4 3.02E-01
4.21E-01
2.95E-02
3.30E-02
8.89E-03
9.02E-03
1.90E-03
3.02E-03
1.90E-02
3.00E-02
7.97E-03
1.47E-02
2.49E+00
1.23E+00
3.11E-01
4.31E-01
1.84E-02
2.94E-02
2.23E+00
1.61E+00
3.76E+01
2.36E+01
mean
SD
4.17E-01
7.90E-02
9.92E-03
2.60E-03
1.66E-02
1.28E-02
4.28E-01
7.75E-02
1.62E-02
1.24E-02
1.67E+00
3.06E-01
8.79E+04
2.48E+05
Gd-DTPA
concentration
[mM]
k10
[min-1]
SEE
[min-1]

[SI]
t1/2 (k10)
[min]
0.05 4.21E-01 2.10E-02 2.66E-01 1.65E+00
0.1 5.28E-01
2.75E-01
3.26E-02
6.47E-03
2.99E-01
3.30E-01
1.31E+00
2.52E+00
0.2 3.87E-01
5.20E-01
1.19E-02
1.66E-02
6.54E-01
6.18E-01
1.79E+00
1.33E+00
0.4 3.70E-01 1.32E-02 1.12E+00 1.87E+00
mean
SD
4.17E-01
9.61E-02
1.75E+00
4.45E-01
SEE: standard error of estimate, SD: standard deviation, : standard deviation of the residual error according to equation 7.6
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Several comments can be made on the results contained in table 7.1. First, the precision of
k21 was low for some Gd-BOPTA experiments, showing that estimating this parameter was
difficult and suggesting that it might have been adequate to fix it to 0, as done with the first
experiment at 0.1 mM. Second, the between-experiment variability was large for k21
(1.66E-02  1.28E-02 min-1), because of very low values in some experiments. In particular
fixing k21 to 1E-06 in one experiment led to an increase in the standard deviation of both k21
and . Although k21 (1.66E-02  1.28E-02 min-1) was in general higher than k12
(9.92E-03  2.60E-03 min-1), the amount of Gd-BOPTA transferred from the central to the
peripheral compartment was much higher than the inverse transfer because the concentration
of Gd-BOPTA in the central compartment was much higher than the one in the peripheral
compartment. This phenomenon was visible on figures 7.7 and 7.8 where the SI in the
peripheral compartment increased over the time of perfusion and only slightly decreased
during washing. 
Another important point is that there was no difference between the rate constants obtained
with different concentrations of Gd-BOPTA. The same remark can be made with Gd-DTPA.
Hence, we calculated mean values and standard deviations of all rate constants across all
concentrations. The k10 were identical for Gd-BOPTA (4.17E-01  0.79E-01 min-1) and
Gd-DTPA (4.17E-01  0.96E-01 min-1). In theory, they were expected to be identical. Indeed,
k10 represented the elimination of the contrast agent from the HFB (central compartment) by
the simple washing with a solution free of contrast agent and Gd-BOPTA was not
metabolized by hepatocytes but excreted unchanged. The fact that k10 were found to be
identical indicates that the complex model developed to describe the Gd-BOPTA
experimental curves was of good quality. In table 7.1, the t 1/2 (k10) was aligned with the t 1/2 ().
Actually, when changing from a two- to a one-compartment model and setting k12 = k21 = 0 in
equations 7.3 and 7.4, the result is that  = k10 and  = 0. The t 1/2 () were similar for
Gd-BOPTA (1.67  0.31 min) and Gd-DTPA (1.75  0.45 min), showing that the alpha phase
of Gd-BOPTA reflected especially the diffusion of the contrast agent in the HFB. Hence, the
scheme of figure 7.3 could be adapted to our hepatocyte HFB as seen in figure 7.9.
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Figure 7.9: Schematic representation of the hepatocyte hollow fiber bioreactor as a two-compartment
open model. Contrast agents are administered and eliminated from compartment 1, i.e. the HFB.
Gd-BOPTA distributes between compartment 1 and 2, i.e. it enters the hepatocytes, in contrast to the
extracellular Gd-DTPA. The rate constants for the processes are indicated, full lines refer to
Gd-BOPTA and dashed lines to Gd-DTPA. 
In summary, the compartmental models developed permitted to describe well our
experimental data. Nevertheless, several suggestions are made to overcome some weaknesses
of this modeling procedure. The first problem encountered was linked to the visual and
manual determination of the baseline. Actually, as seen in figure 7.6 and as already discussed
in chapter 5, the initial SI had a positive value. The curves were first normalized according to
reference vials and corrected to 0, in order to be comparable to each other. This manual
approximation could induce errors of estimation. A solution to this problem would be the
introduction of an additional parameter in the model which would estimate the baseline. A
second problem came from the visual and manual determination of the start and end point of
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the perfusion which was reflected by high residuals at the times corresponding to the
beginning and end of the perfusion. This problem could be solved by the introduction of a
parameter which would estimate a lag-time for the beginning of the perfusion and a parameter
to estimate its end. The influence of the lag-time on the estimation of concentration-time
curves has been studied [31]. Finally, a third problem was linked to the background noise
characterized by an oscillatory behavior which increased with the concentration of contrast
agent. These fluctuations of SI induced high residual errors and could distort estimations. To
solve this problem seems to be more difficult as the origin of these oscillations should be
known in order to be able to suppress them.
Most of the data on the pharmacokinetics and tissue distribution of MRI contrast agents
have been obtained by dosage of their content in biological samples such as plasma, urine and
bile [32]. Nevertheless, some recent pharmacokinetic studies have been based on dynamic
contrast enhanced T1-weighted MRI (DCE-MRI) data. Actually, DCE-MRI has recently
emerged as a promising method notably for diagnosis, prognosis and therapy monitoring of
cancer [33,34] or for the assessment of blood brain-barrier permeability [35]. The review by
Taylor and Reddick [36] gives a good overview of the progresses made in the field of
pharmacokinetic MRI. A considerable variation in both the methods of data acquisition and
analysis exists between the different research groups. The majority of clinical investigations
do not analyze MRI data using a pharmacokinetic model, but rather extract a variety of
empirical parameters. These semi-quantitative analyses usually calculate the magnitude or the
rate of SI change after injection of contrast agent. Some authors correlated these empirical
values with histological diagnosis with relative success. Pharmacokinetic MRI determinations
have two advantages over empirical determinations: they can be compared between groups of
investigators and patients, and they can yield insight into physiological parameters (e.g.
vascular permeability). To convert empirical data to more robust pharmacokinetic parameters,
two major steps have to be done. The first step is to convert the dynamic MR SI curve, SI(t),
into a concentration curve, C(t). Knowledge of the contrast agent concentration is required to
extract as much relevant physiological information as possible from the kinetic data. This
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complicates analysis of DCE-MRI data because only the SI is generally measured, and that
may not be easily related to the concentration of contrast agent in tissue as already discussed
in chapters 3 and 6. The second step is to model the relation of the concentration in the tissue
to the concentration-time curve in the central compartment in order to gain insight into the
physiological process of exchange of contrast agent between the different compartments. A
variety of parameters have been estimated; often the same quantity appears with different
names or symbols in different reports, so that a comparison of work from different research
groups is almost impossible. Tofts et al.  [37] described a standard set of names and symbols
related to the estimate of kinetic parameters and proposed to use them as international
standards. It was not possible for us to know whether it was trivial or not to use a software
which permitted to fix the monitored compartment as being the sum of all compartments
present, as done in the present study, since this information was not mentioned in available
papers related to MRI pharmacokinetics. 
7.3.3.2 Transport studies of Gd-BOPTA with hepatocytes contained in a HFB
To elucidate the transport mechanism of Gd-BOPTA into hepatocytes, the uptake of
different concentrations (0.05 - 0.4 mM) of Gd-BOPTA was studied by MRI with the newly
developed hepatocyte HFB. After a pharmacokinetic analysis of the perfusion experiments,
we plotted the value of the SI in the peripheral compartment at the end of the 30 minutes
perfusion with Gd-BOPTA, attributable to the amount of Gd3+ inside the hepatocytes, against
the concentration of Gd-BOPTA perfused (figure 7.10).
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Figure 7.10: Signal intensity in the peripheral compartment, i.e. in the hepatocytes, after 30 minutes
of perfusion of the hepatocyte HFB with a solution containing Gd-BOPTA at concentrations ranging
from 0.05 to 0.4 mM.
Figure 7.10 shows that the SI due to the Gd3+ contained in the hepatocytes after 30 minutes
of perfusion with different concentrations of Gd-BOPTA was not linearly correlated to the
concentration of Gd-BOPTA perfused. The approximate curve which ran through the points
typically described a saturable process. These observations tend to support a receptor-
mediated mechanism rather than an uptake mechanism by free diffusion. 
After experiments where two solutions of Gd-BOPTA were perfused consecutively in the
same hepatocyte HFB, cells were extracted from the HFB, lysed and the residual quantity of
Gd3+ in the bioreactor was determined by ICP-AES. The study of the relation between the
total residual SI and the residual intracellular concentration of Gd3+ in the HFB showed that
1 unity of SI corresponded to 15.9  2.1 M of Gd3+ (n = 4) for cumulative concentrations of
Gd-BOPTA in the solution perfused up to 0.4 mM. We made an approximation of the
intracellular content of Gd3+ after the perfusion of a solution containing 0.2 mM Gd-BOPTA.
The mean of the two points obtained with Gd-BOPTA 0.2 mM was 2.95 SI (figure 7.10),
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which could be transformed in an intracellular concentration of Gd3+ equal to 46.9  6.2 M,
i.e. 23.5  3.1% of the concentration in the perfusion solution. On the other hand, the
intracellular content of Gd3+ after the incubation of the freshly isolated hepatocytes in
suspensions for 60 minutes with Gd-BOPTA 0.2 mM was 32.6  4.6 M, i.e. 16.3  2.3% of
the concentration in the incubation solution (§7.3.2). Although the calculation of the
intracellular content of Gd3+ in the HFB was approximate and resulted from a 30 minutes
perfusion (compared to 60 minutes for the incubation), the two values were in the same order
of magnitude. 
Despite these observations, the SI of the peripheral compartment after 30 minutes of
perfusion with Gd-BOPTA could not be transformed in an exact intracellular concentration of
Gd3+. Actually, the intracellular amount of Gd3+, reflected by the SI in the peripheral
compartment, was the consequence of successive perfusions with different concentrations of
Gd-BOPTA. And as already discussed in chapter 6, conversion of SI to concentration of
contrast agent is not possible yet because the relation between the intracellular concentration
of Gd3+ and the resulting SI is still not known. 
The possible inhibition of the uptake of Gd-BOPTA by BSP was assessed by perfusing the
HFB first with a solution containing 0.1 mM Gd-BOPTA alone and then with a solution
containing 0.1 mM Gd-BOPTA and 0.1 mM BSP. The same experiment was repeated with
concentrations of Gd-BOPTA and BSP of 0.4 mM (figure 7.11). Although SI were slightly
lower during the perfusion with Gd-BOPTA + BSP, this difference was not significant
considering the fluctuations of SI. The same was observed with the perfusion of Gd-BOPTA
+ BSP at a concentration of 0.1 mM. Despite their preliminary character (we tested only two
concentrations one time), the results reported here seem to indicate that there was no
inhibition of the transport of Gd-BOPTA into hepatocytes by BSP. 
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Figure 7.11: Evolution of normalized MR signal intensity with time in a hollow fiber bioreactor
containing 4·107 hepatocytes/ml. The bioreactor was perfused with a solution containing 0.4 mM
Gd-BOPTA for 30 minutes, with a solution exempt of contrast agent for 15 minutes, with a solution
containing 0.4 mM Gd-BOPTA + 0.4 mM BSP for 30 minutes, and then with a solution exempt of
Chapter 7 192
contrast agent for 15 minutes. SI were normalized according to the SI of reference vials and corrected
to zero. Although the perfusions were consecutive, they were superposed for a better comparison.
Similar experiments of inhibition were performed with perfused rat livers and it was found
that an equimolar concentration of BSP totally inhibited the hepatocyte uptake of Gd-BOPTA
at concentrations of 0.5 mM [38]. These results are in contradiction with our observations.
Such contradictory observations are also found in the literature: De Haën et al.  [4] observed a
partial inhibition of the Gd-BOPTA uptake by BSP in rats, while Pascolo et al.  [2] found that
the free diffusion of Gd-BOPTA was not inhibited by BSP in rat sinusoidal membrane
vesicles. These findings could indicate that a modification of the transport system occurs
during the isolation of the hepatocytes and the sinusoidal membrane vesicles which renders
the transport of Gd-BOPTA no longer sensitive to the inhibition of BSP. Indeed, this could be
the consequence of the rather aggressive isolation procedure or of the loss of the membrane
polarity, as already discussed in paragraph 7.3.1.
The excretion of Gd-BOPTA is known to occur via the active transporter mrp2 [5-7].
Although mrp2 was expressed in freshly isolated hepatocytes as shown on Western blots
(figure 7.4), the SI due to Gd-BOPTA in the peripheral compartment, meant to represent the
hepatocytes, only slightly decreased over 30 minutes washing (figure 7.7a). Several
hypotheses can be proposed to explain these observations. The slow excretion observed in
vitro can be of the same magnitude as in vivo, where the excretion of Gd-BOPTA by mrp2
into the bile is known to be a rate-limiting step [7], or it can be slower, due for instance to a) a
change of the transporter during the hepatocyte isolation, b) an unfavorable energetic state of
the cells, or c) binding of Gd-BOPTA anywhere in the hepatocytes. Moreover, these results
do not allow to make comments on the possible reversibility of the uptake transport
mechanisms as it cannot be excluded that the slow release of Gd-BOPTA occurred through
this mechanism. 
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7.4 Conclusion
The goal of this work was to study the transport of the hepatobiliary MRI contrast agent
Gd-BOPTA in freshly isolated rat hepatocytes. First, the expression of the transporters known
or suspected to be involved in the transport of Gd-BOPTA in isolated hepatocytes, i.e. oatp1,
oatp2, oatp4 and mrp2, was verified. Western blotting indicated that all of them, except oatp4,
were expressed similarly in isolated hepatocytes and in a control sample of an entire liver.
Then, the uptake of Gd-BOPTA by freshly isolated hepatocytes in suspension was evaluated
by ICP-AES to check the functionality of the uptake mechanisms. After 1 hour of incubation
with Gd-BOPTA 0.2 mM, the intracellular content of Gd3+ represented 16% of the
concentration of Gd-BOPTA in the incubation solution. The results of these two experiments
ensured that freshly isolated hepatocytes offer a suitable cellular model for the investigation
of Gd-BOPTA uptake.
We pursued the study of the uptake mechanisms of Gd-BOPTA by MRI with our newly
developed MRI compatible hepatocyte HFB. This cellular model was shown to reproducibly
differentiate the behavior of the intracellular contrast agent Gd-BOPTA and the extracellular
contrast agent Gd-DTPA, while ensuring a functional stability and an intact cellular
morphology. Concentrations of Gd-BOPTA ranging from 0.05 to 0.4 mM were perfused
through the HFB and the resulting SI-time curves were submitted to compartmental
pharmacokinetic modeling. The software NONMEM was used for this purpose as it permitted
to take into account the particularity of the MRI data, i.e. it allowed to consider the
compartment of measure as being the sum of all the compartments present (the central and the
peripheral compartments), in contrast to most of the usual pharmacokinetic software.
Gd-BOPTA curves were fitted successfully with a two-compartment model while a one-
compartment model described well the ones with Gd-DTPA. The estimated parameters (k10,
k12, k21) were the same for all concentrations of Gd-BOPTA perfused through the HFB. The
means of the elimination rate constants k10 were identical for Gd-BOPTA
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(4.17E-01  0.79E-01) and Gd-DTPA (4.17E-01  0.96E-01). Considering that Gd-BOPTA
underwent no biotransformation and that the HFB were identical, the elimination rate
constants k10 were theoretically the same. The fact that estimates were indeed identical thus
indicated that the proposed model adequately described the system under study. Expressing
the data in terms of compartmental models and associated parameters permitted a better
interpretation of the data. Actually, the additional compartment present with Gd-BOPTA, as
compared to Gd-DTPA, could be associated to the hepatocytes, into which Gd-BOPTA
distributed. The relation between the SI in the peripheral compartment, i.e. the hepatocytes,
after 30 minutes of perfusion and the concentration of Gd-BOPTA perfused was nonlinear.
This indicated that the uptake of Gd-BOPTA seemed to follow a saturable mechanism, which
is in agreement with a carrier mediated transport. 
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Chapter 8
General conclusion and perspectives
Magnetic resonance imaging (MRI) plays an important role in the diagnosis of several
hepatic diseases. The use of contrast agents, and in particular hepatobiliary contrast agents
such as Gd-BOPTA, allows to improve the detection of such diseases. Actually, hepatobiliary
contrast agents are able to enter hepatocytes by a mechanism which is not yet fully elucidated
and are partially excreted into the bile. The aim of this work was thus to develop a MRI
compatible in vitro model to study the transport of hepatobiliary contrast agents into
hepatocytes. 
The cellular device chosen consisted of a hollow fiber bioreactor (HFB), a structure
particularly well suited for our expectations. First, its plastic composition made it MRI
compatible. Second, it was included in a dynamic system which has the advantage that
hepatocytes contained in the HFB were continually fed with a thermoregulated solution
containing oxygen and nutrients which allowed to use high cellular densities without loss of
viability. Finally, the dynamic aspect of the culture system permitted to change the solutions
perfused in the HFB and thus to study different conditions during a single experiment.
The HFB perfusion system was also built in order to be compatible with the magnetic field,
i.e. all the elements situated inside the magnet were made of plastic or glass, while the
elements containing metal were set in a room adjacent to the magnet. The sensible choice of
the heating system, oxygenation, HFB device, flow rate and hepatocyte density in the HFB
assured optimal experimental conditions. The preservation at 4°C of the hepatocytes in the
University of Wisconsin solution permitted to keep them viable and functional during the
period of time between their isolation and the MRI experiment. A good viability was also
obtained during the MRI experiments as assessed by oxygen consumption and release of
intracellular enzymes. 
Chapter 8 198
First, we demonstrated that the hepatocyte HFB is able to distinguish in a reproducible
manner between the hepatobiliary contrast agent Gd-BOPTA and the extracellular contrast
agent Gd-DTPA. The results were expressed as the variation of the mean signal intensity (SI)
of a cross-section of the HFB with time. Although the SI was linearly correlated with the
concentration of contrast agent, SI-time curves obtained with the hepatocyte HFB were not
converted to concentration-time curves, mainly because the relaxivity of Gd-BOPTA is not
identical in the intracellular fluid and in the perfusion solution. The SI-time curves were
submitted to compartmental pharmacokinetic analysis. The curves of Gd-DTPA and
Gd-BOPTA were fitted successfully with a one- respectively two-compartment model, where
the peripheral compartment is meant to represent the hepatocytes in which Gd-BOPTA
distributed. In a second step, the effect of the concentration of Gd-BOPTA on its uptake into
hepatocytes was studied to elucidate the transport mechanism involved. The results showed
that Gd-BOPTA seemed to be taken up into hepatocytes by a saturable mechanism indicating
that the transport of Gd-BOPTA was mediated by a specific transporter rather than by free
diffusion.
Additional experiments should be carried out to confirm this hypothesis, such as the
inhibition of the transport of Gd-BOPTA with specific substances. Another interesting
approach would be to replace the hepatocytes in the HFB by oocytes transfected with cRNA
encoding for different transporters to study the selectivity of Gd-BOPTA transport into the
cells. Our newly developed hepatocyte HFB could be further used to study other hepatobiliary
contrast agents to get a better understanding of their uptake and excretion mechanisms in
hepatocytes. Healthy rat hepatocytes in the HFB could be replaced by healthy human
hepatocytes or by diseased rat or human hepatocytes to see how or if the transport
mechanisms of hepatobiliary contrast agents are disturbed. Finally, the pharmacokinetic
compartment model developed should be applied to other MRI data. As it would be more
appropriate to process concentration-time curves rather than SI-time curves, further studies
are needed convert SI into contrast agent concentration.
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In summary, we developed a useful tool to study the hepatic transport of hepatobiliary
contrast agents directly by MRI. The challenge for future work is now to extend its use to
allow the extrapolation of the findings to humans and to use the assessment of the transport of
MRI hepatobiliary contrast agents as a means to diagnose liver diseases. 
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Development of a hepatocyte hollow fiber bioreactor for the study
of contrast agents by magnetic resonance imaging
Magnetic resonance imaging (MRI) is a powerful tool of medical diagnosis notably
because of the remarkably good resolution of its images. Contrast agents, in particular
gadolinium (Gd3+) chelates, allow to further improve the detection of diseases. One can
distinguish between extracellular gadolinium chelates such as Gd-DTPA, and hepatobiliary
gadolinium chelates such as Gd-BOPTA. The latter are able to enter hepatocytes from which
they are partially excreted into the bile. Due to these properties, hepatobiliary contrast agents
are particularly interesting for the MRI of the liver. It is conceivable that a diseased liver has a
modified transport of hepatobiliary contrast agents in hepatocytes which would be reflected in
a change of the signal intensity. However, these mechanisms and their possible modifications
due to hepatic diseases are not completely understood.
The aim of this thesis was to develop an in vitro model to study the transport of
hepatobiliary contrast agents in hepatocytes directly by MRI. A dynamic system including a
hollow fiber bioreactor (HFB) containing a high density of freshly isolated rat hepatocytes
was built in order to be compatible with the magnetic field, which implied in particular the
absence of metal in the elements placed in the magnet. Despite this technical difficulty, a
sensible choice of the HFB, the constituents of the perfusion system and the experimental
conditions permitted to maintain good cellular viability and to distinguish in a reproducible
manner between Gd-BOPTA and Gd-DTPA. The data obtained, expressed as signal intensity
(SI) versus time, were analyzed with a compartmental pharmacokinetic model. The SI-time
curves of Gd-DTPA and Gd-BOPTA were fitted successfully with a one- respectively two-
compartment model, where the peripheral compartment is meant to represent the hepatocytes
into which Gd-BOPTA distributed. The results obtained showed that Gd-BOPTA seemed to
be taken up into hepatocytes by a saturable mechanism, indicating the presence of a specific
transporter. 
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The HFB developed here offers an interesting tool to study the transport mechanisms of
hepatobiliary contrast agents. A better understanding of these mechanisms could allow to use
the kinetics of hepatobiliary contrast agents as an efficient diagnostic method of hepatic
diseases.
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Développement d'un bioréacteur à réseaux capillaires contenant
des hépatocytes pour l'étude d'agents de contraste par imagerie
par résonance magnétique
L'imagerie par résonance magnétique (IRM) est un outil diagnostique très puissant
notamment grâce à la remarquable précision de ses images. L'IRM peut faire appel à des
agents de contraste, les plus utilisés étant ceux à base de gadolinium (Gd3+). On distingue les
agents extracellulaires comme le Gd-DTPA, des agents hépatobiliaires comme le Gd-BOPTA
qui sont capables d'entrer spécifiquement dans les hépatocytes et qui sont ensuite
partiellement excrétés dans la bile. Cette propriété les rend particulièrement intéressants pour
l'imagerie du foie, où une atteinte peut se manifester par un changement dans l'intensité du
signal IRM dû à une modification du transport du produit de contraste dans les hépatocytes.
Or ces mécanismes de transport et leurs modifications possibles en cas de maladie ne sont
toujours pas entièrement élucidés à l'heure actuelle. 
Le but de cette thèse était donc de mettre au point un modèle in vitro permettant d'étudier
directement par IRM le transport des agents de contraste hépatobiliaires dans les hépatocytes.
Un système dynamique comprenant un bioréacteur à réseaux capillaires contenant une haute
densité d'hépatocytes de rat fraîchement isolés a été construit de façon à être compatible avec
le champ magnétique, ce qui impliquait surtout l'absence de métal dans les éléments se
trouvant dans l'aimant. Malgré cette difficulté technique, le choix judicieux du bioréacteur,
des constituants du système de perfusion et des conditions expérimentales a permis de
maintenir une bonne viabilité cellulaire et de pouvoir distinguer de façon reproductible les
comportements du Gd-BOPTA et du Gd-DTPA. Les données obtenues, exprimées en
intensité de signal en fonction du temps, ont été analysées par un modèle pharmacocinétique
compartimental. Les données du Gd-DTPA et du Gd-BOPTA ont pu être modélisées avec
succès par un modèle mono- respectivement bi-compartimental, où le compartiment
périphérique supplémentaire dans le deuxième cas est sensé représenter les hépatocytes dans
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lesquels le Gd-BOPTA est capable de pénétrer. Les résultats ont montré que le Gd-BOPTA
semble entrer dans les hépatocytes selon un mécanisme saturable indiquant la présence d'un
transporteur spécifique. 
Le bioréacteur développé représente un outil intéressant pour l'étude des mécanismes de
transport cellulaire des agents de contraste hépatobiliaires. Une meilleure connaissance de ces
mécanismes pourrait permettre d'utiliser par la suite la cinétique des agents de contraste
hépatobiliaires comme méthode de diagnostic de maladies hépatiques.
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Les produits de contraste pour l'imagerie par résonance magnétique (IRM) sont utilisés
pour améliorer la différentiation entre les divers tissus imagés. Les agents de contraste les
plus utilisés sont ceux à base de gadolinium (Gd3+). On distingue les agents extracellulaires,
comme le Gd-DTPA, des agents hépatobiliaires, comme le Gd-BOPTA, qui sont capables
d'entrer spécifiquement dans les cellules hépatiques (hépatocytes) et qui sont ensuite
partiellement excrétés dans la bile. Les mécanismes de transport des agents hépatobiliaires
dans les hépatocytes ainsi que la façon dont ces mécanismes de transport sont modifiés en cas
de maladie hépatique ne sont pas entièrement élucidés à l'heure actuelle. 
Le but de cette thèse était donc de mettre au point une méthode de culture cellulaire
permettant d'étudier le transport des agents de contraste hépatobiliaires dans les hépatocytes.
Nous avons construit un bioréacteur contenant des hépatocytes de rat fraîchement isolés de
manière à ce qu'il soit compatible avec le champ magnétique, ceci afin de pouvoir faire les
mesures directement avec l'appareil d'IRM utilisé pour les patients (voir la figure ci-dessous).
Les résultats obtenus ont montré que le Gd-BOPTA semble entrer dans les hépatocytes selon
un mécanisme saturable indiquant la présence d'un transporteur spécifique. 
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Bioréacteur contenant
des hépatocytes
Tunnel formé 
d’un aimant 
Lit d’examen 
Dans le futur, l'utilisation du bioréacteur pourrait être étendue à l'étude d'autres agents de
contraste pour IRM. On pourrait également introduire d'autres cellules dans le bioréacteur,
comme par exemple des hépatocytes de rat malades, ou des hépatocytes humains, sains ou
non. Ceci permettrait de disposer de suffisamment de données pour envisager une
extrapolation des résultats à l'homme afin d'utiliser le transport des agents de contraste
hépatobiliaires comme outil de diagnostic de maladies hépatiques.
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Abbreviations 
The following abbreviations are currently used throughout the document:
- A -
AEBSF: 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride
ALF: acute liver failure
ALT: alanine aminotransferase
AST: aspartate aminotransferase
- B -
BAL: bioartificial liver
BBB: blood-brain barrier
BSA: bovine serum albumin
BSP: bromosulfophtalein
BSS: balanced salt solution
- C -
CT: computed tomography
- D -
DCE-MRI: dynamic contrast enhanced T1-weighted MRI
DMSO: dimethylsulfoxide
- E -
E-64: N-(trans-epoxysuccinyl)-L-leucine 4-guanidinobutylamide
7-EC: 7-ethoxycoumarin
ECS: extracapillary space of the hollow fiber bioreactor
EDTA: ethylenedinitrilo tetraacetic acid
EGTA: ethyleneglycol-O,O'-bis(2-aminoethyl)-N,N,N',N'-tetraacetic acid
EHBR: Eisai hyperbilirubinaemic rat
- F -
FA: flip angle
FCS: fetal calf serum
FOV: field of view
FSA: fiber surface area of the HFB
- G -
GGT: -glutamyl transpeptidase
GLDH: glutamate dehydrogenase
GPT: glutamic pyruvic transaminase
GRE: gradient echo
GSH: glutahthione
- H -
HF: hollow fiber
HFB: hollow fiber bioreactor
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7-HC: 7-hydroxycoumarin
- I -
ICP-AES: inductively coupled plasma atomic emission spectrometry
ICS: intracapillary space of the hollow fiber bioreactor
IR: inversion recovery
- L -
LDH: lactate dehydrogenase
- M -
MRI: magnetic resonance imaging
MRP: multidrug resistance-associated protein
- N -
NMR: nuclear magnetic resonance
- O -
OATP: organic anion transporting polypeptide
- P -
PEG: polyethyleneglycol
PET: positron emission tomography
- R -
RES: reticuloendothelial system
RF: radiofrequency
ROI: region of interest
- S -
SE: spin echo
SI: signal intensity
SR: total or partial saturation recovery
- T -
T1: longitudinal relaxation time
T2: transversal relaxation time
TE: echo delay time
TI: inversion time
TMZ: trimetazidine
TR: repetition time
- U -
US: ultrasound
UW solution: University of Wisconsin solution
